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ABSTRACT 
 
RIMA HAJJO: In Silico Strategies to Study Polypharmacology of G-Protein-Coupled 
Receptors 
(Under the direction of Alexander Tropsha) 
 
The development of drugs that simultaneously target multiple receptors in a rational way 
(i.e., ‗magic shotguns‘) is regarded as a promising approach for drug discovery to treat 
complex, multi-factorial and multi-pathogenic diseases. My major goal is to develop and 
employ different computational approaches towards the rational design of drugs with 
selective polypharmacology towards guanine nucleotide-binding protein (G-protein)-coupled 
receptors (GPCRs) to treat central nervous system diseases. Our methodologies rely on the 
advances in chemocentric informatics and chemogenomics to generate experimentally 
testable hypotheses that are derived by fusing independent lines of evidence. We posit that 
such hypothesis fusion approach allows us to improve the overall success rates of in silico 
lead identification efforts. We have developed an integrated computational approach that 
combines Quantitative Structure-Activity Relationships (QSAR) modeling, model-based 
virtual screening (VS), gene expression analysis and mining of the biological literature for 
drug discovery.  
The dissertation research described herein is focused on: (1) The development of robust 
data-driven Quantitative Structure-Activity Relationship (QSAR) models of single target 
GPCR datasets that will amount to the compendium of GPCR predictors: the GPCR 
QSARome; (2) The development of robust data-driven QSAR models for families of GPCRs 
iv 
 
and other trans-membrane molecular targets (i.e., sigma receptors) and the application of 
models as virtual screening tools for the quick prioritization of compounds for biological 
testing across receptor families; (3) The development of novel integrative chemocentric 
informatics approaches to predict receptor-mediated clinical effects of chemicals. Results 
indicated that our computational efforts to establish a compendium of computational 
predictors and devise an integrative chemocentric informatics approach to study 
polypharmacology in silico will eventually lead to useful and reliable tools aimed at 
identifying and enriching chemical libraries with compounds that have the desired activities 
for more than one molecular target of interest.  
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CHAPTER 1 
INTRODUCTION 
 
Drugs Acting at Multiple Targets and Selective Polypharmacology as an Important 
Drug Discovery Approach 
 Over the past decade, there has been a decline in the number of new drugs reaching 
the market and being used as effective therapeutics.  Many reasons have been suggested to 
explain this decline in drug development productivity (Bakker et al. 1999, Cascante et al. 
2002, Hood & Perlmutter 2004, van der Greef & McBurney 2005). This led to the suggestion 
that there may be real issues with the core assumptions that framed drug discovery 
approaches in the past two decades (Hopkins 2008). One of the key goals of the rational drug 
design has been the discovery of very selective ligands acting via individual molecular 
targets.  In fact, a highly selective ligand for a given target does not always result in clinically 
efficacious drug because of the redundancy in our biological systems (Frantz 2005, Mencher 
& Wang 2005). Therefore, this one-molecule, one-target approach, which has led to the 
discovery of many blockbuster drugs and will probably remain popular for many years, 
might not be suitable for treating complex multifactorial diseases such as neuropsychiatric 
and neurodegenerative diseases. 
2 
 
Polypharmacology (Frantz 2005, Hampton 2004, Keith et al. 2005, Mencher & Wang 
2005, Roth & Kroeze 2006, Wermuth 2004) or the selective promiscuous modulation of 
several molecular targets has been proposed as a promising approach for drug discovery to 
treat complex diseases. Recent studies provided a substantial evidence that compound 
promiscuity is the main reason for the great efficacy of a significant number of approved 
drugs (Hampton 2004, Hopkins et al. 2006, Keith et al. 2005, Mencher & Wang 2005, Roth 
et al. 2004). The growing  understanding of the complexity of biological networks and the 
robustness and redundancy of biological systems challenges the current approaches of single 
target drug discovery including in silico approaches (Hopkins 2007, Hopkins 2008, Roth et 
al. 2000, Roth & Kroeze 2006). Nowadays, medicinal chemists are becoming more interested 
in identifying polypharmacological drugs (i.e., ‗magic shotguns‘) (Armbruster & Roth 2005, 
Roth et al. 2004) that can bind moderately to several targets in a disease-protein network and 
affect the overall outcome significantly (Hopkins et al. 2006, Hopkins 2009, Roth et al. 
2004).  
 Thus, the main goal of polypharmacology is to identify a compound with a desired 
biological profile across multiple targets whose combined modulation will perturb a disease 
state (Hopkins 2008).  The history of drug development of antipsychotics is a clear example 
of the migration from single target approach centered on dopamine D2 to a multiple target 
strategy involving D2 blockade and the recruitment of a wide array of other receptor 
activities. The recent generation of antipsychotics which are called ―atypical‖, approved by 
the U.S Food and Drug Administration (FDA) for use in the treatment of schizophrenia, 
acute mania, bipolar mania, psychotic agitation, bipolar maintenance, and other indications, 
3 
 
have interactions with dopaminergic, serotonergic, histaminergic, cholinergic and adrenergic 
receptors (Roth et al. 2004).  
 However, this approach faces many challenges such as the need to process, 
understand, and utilize the available information about drug interactions with multiple 
biological targets. Currently, most of the successful polypharmacological drugs on the 
market have been discovered by serendipity (Roth et al. 2004).  Currently, there is no 
systematic strategy to design and optimize multi-target drugs in traditional drug discovery 
approaches.  Thus, the integration of in silico methods, combined with ligand biological 
profiles against protein assays and gene expression arrays, can provide researchers with a 
novel toolbox to assess polypharmacology (Cavalli et al. 2008).  
G Protein-Coupled Receptors as Molecular Targets to Study Polypharmacology 
G Protein-Coupled Receptors (GPCRs) are promising targets for the discovery of 
novel drugs. They constitute the largest family of membrane proteins that mediate most 
cellular responses to hormones and neurotransmitters and are also responsible for vision, 
olfaction and taste (Rosenbaum et al. 2009). The entire family of currently known and 
verified human GPCRs includes at least 799 unique full-length members (Gloriam et al. 
2007). GPCRs are involved in a multitude of biological responses in all organs and systems 
including the central and peripheral nervous systems. In the latter, particularly important 
functions include neurotransmitter release, cell-to-cell communication, modulation of 
learning and memory, response to psycho-active substances, regulation of neuronal growth 
and differentiation and of glial responses. However, ligands for GPCRs comprise structurally 
very different compounds and often the ligands interact with more than one GPCR, i.e., they 
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are promiscuous. Thus, this group of receptors was chosen to study polypharmacology and to 
fulfill the research aims of my thesis projects. 
 GPCRs present a wide range of opportunities as therapeutic targets in areas including 
cancer, cardiac dysfunction, diabetes, central nervous system disorders, obesity, 
inflammation, and pain. Consequently, GPCRs are major components of pipelines in small 
and large pharmaceutical companies, and many drug discovery projects in academia and 
industry focus exclusively on these receptors. But the path to novel GPCR-targeted 
medicines is not routine. Most GPCR-modulating drugs on the market weren‘t initially 
targeted to a specific protein but were developed on the basis of functional activity observed 
in an assay. That they activated or inhibited a GPCR specifically was only later discovered. 
Post- Human Genome Project, however, targets are the starting points for most drug 
discovery endeavors. And there is still much to be learned about how GPCRs work and how 
they can be selectively modulated.  
Quantitative Structure Activity Relationships Modeling 
QSAR studies rely heavily upon statistics to derive models that relate the biological 
activity of a series of compounds to one or more molecular properties that can be easily 
measured or calculated. Modern QSAR approaches are characterized by the use of multiple 
descriptors of chemical structure combined with the application of both linear and non-linear 
optimization approaches, and a strong emphasis on rigorous model validation to afford robust 
and predictive QSAR models. The goal of QSAR modeling is to establish a trend in the 
descriptor values, which parallels the trend in biological activity. All QSAR approaches 
imply, directly or indirectly, a simple similarity principle, which for a long time has provided 
a foundation for the experimental medicinal chemistry: compounds with similar structures 
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are expected to have similar biological activities.  However the definition of similarity is not 
always simple as it depends on descriptors, variable selection, and similarity functions. 
 The differences in various QSAR methodologies can be understood in terms of the 
types of target property values, descriptors, and optimization algorithms used to relate 
descriptors to the target properties and generate statistically significant models.  Target 
properties can generally be of three types: continuous (i.e., real values covering certain range, 
e.g., IC50 values, or binding constants), categorical related (i.e., classes of target properties 
covering certain range of values, e.g., active and inactive compounds, frequently encoded 
numerically for the purpose of the subsequent analysis as one (for active) or zero (for 
inactive), and categorical unrelated (i.e., classes of target properties that do not relate to each 
other in any continuum, e.g., compounds that belong to different pharmacological classes, or 
compounds that are classified as drugs vs. non-drugs).    The corresponding methods of data 
analysis are referred to as classification or continuous property QSAR. The examples of 
leading QSAR approaches, their applications, and developing trends in the field can be found 
in recent reviews (Fan et al. 2001, Girones et al. 2000, Randic & Basak 2000). 
In silico Receptoromics to Study Polypharmacology 
 One way to identify polypharmacological chemical compounds is to virtually screen 
all potential molecular targets of interest for interactions with these chemicals (Roth 2005). 
Here in, we suggest that one approach to enable virtual screening of the receptorome would 
be to generate a compendium of computational predictors (e.g., QSAR models or structure 
based models). Subsequently, these models can be used for the virtual screening of chemical 
libraries to identify new ligands for the different molecular targets and predict 
polypharmacological matrices for these all chemicals included in these databases. Ultimately, 
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all models can be consolidated in a database of models that can be used for parallel virtual 
screening of chemical compounds, including current medications, for their abilities to 
interact with all known members of the receptorome.  
In silico screening approaches are routinely employed nowadays in academic, 
governmental and commercial sectors and they have become largely applied in drug 
discovery (Armbruster & Roth 2005, Bajorath 2002, Bajorath 2005, Becker 2004, Becker et 
al. 2004, Evers & Klebe 2004, Kitchen et al. 2004, Klabunde et al. 2009). Research 
conducted in our group has demonstrated that the generation of QSAR models and 
subsequent model-based virtual screening of chemical libraries has led to the identification of 
chemically diverse molecules with high success rates in experimental validation tests (Hsieh 
et al. 2008, Oloff et al. 2005, Peterson et al. 2009, Shen et al. 2002, Shen et al. 2004, Tang et 
al. 2009, Tropsha 2006, Tropsha & Pearlman 2000, Tropsha & Wang 2006). This approach 
to drug discovery comprises the following steps: (1) defining the target(s) of interest, (2) 
extracting relevant structure activity data from the biological literature and specialized 
databases, (3) dataset curation, (4) compound representation by suitable chemical descriptors, 
(5) model generation and validation, (6) the application of validated QSAR models for virtual 
screening (VS) of chemical databases to predict binders and, if possible agonists and 
antagonists. Often, the interpretation of chemical descriptors found significant for the success 
of QSAR models can reveal important structural requirements for ligand binding and 
activity. For the most part, this approach has been applied to datasets of compounds tested in 
individual assays characterizing their interaction with a single molecular target. 
Theoretically, QSAR models explore information restricted to the experimental 
knowledge of chemical structures and biological activities of ligands. Hence, this approach is 
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especially important when the X-ray crystal structures for the biological targets of interest 
(e.g., most GPCRs and trans-membrane proteins) are unavailable.  By applying QSAR 
modeling approach to a large number of datasets, we can accumulate a compendium of 
QSAR models representing a variety of different biological targets, and subsequently 
establish a virtual receptorome system to screen molecules simultaneously against an array of 
available models.  Ultimately, we can use these models to obtain a list of common matching 
hits among several receptor families and could link the hits to all predicted biological targets, 
thereby enabling an in silico identification of biological networks (i.e., virtual networks 
formed from the ‗predicted‘ chemical-molecular target activity profiles across a multitude of 
molecular targets) which will possibly be influenced by these compounds (concept explained 
in Fig. 1.1). This approach can also identify selective compounds for each receptor family 
after excluding common hits. An example of a similar approach to broad in silico profiling of 
compound libraries is given by the method PASS (Brady & Stouten 2000), which currently 
allows in silico screening against a large panel of target proteins. However, the datasets 
behind PASS models are not publicly available, which makes it difficult to employ and 
validate alternative techniques to the same datasets. 
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Figure 1.1. Concept of QSAR-based in silico receptoromics enabling a virtual network 
pharmacology approach. 
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 Lately, different computational groups have attempted to predict 
polypharmacological effects of chemical molecules (Freyhult et al. 2005, Lapinsh et al. 2002, 
Becker et al. 2004).  As an example on one of the most recent efforts, one group at Indiana 
University used PubChem activity data available at for multiple assays to develop a network 
representation of the assay collection and then applied a bipartite mapping between this 
network and various biological networks (Chen et al. 2009). They claimed that their method 
of mapping to a drug-target network permitted the prioritization of new selective compounds, 
while mapping to other biological networks enabled them to observe interesting target pairs 
and their associated compounds in the context of biological systems. 
It is likely that our studies and these other efforts described above will eventually 
result in useful and reliable tools aimed at enriching chemical libraries in compounds that 
have affinities for more than a single molecular target. We think that a combination of these 
methods will be more powerful than a single method alone as our expertise in the 
computational field has indicated time after time. 
Chemocentric Informatics  
Target-oriented drug discovery has become one of the most popular modern drug 
discovery approaches (Connor et al. 2010, Nicholson et al. 2004, Petak et al. 2010, 
Raamsdonk et al. 2001, Yang et al. 2010). Target-oriented approaches rely on established 
functional associations between activation or inhibition of a molecular target and a disease. 
Modern genomics approaches including gene expression profiling, genotyping, genome-wide 
association, and mutagenesis studies continue to serve as useful sources of novel hypotheses 
linking genes (proteins) and diseases and providing novel putative targets for drug discovery.  
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Recently, functional genomics approaches have been increasingly augmented by 
chemical genomics (Brenner 2004, Darvas et al. 2004, Nislow & Giaever 2003, Salemme 
2003, Zheng & Chan 2002b, Zheng & Chan 2002a), i.e., large scale screening of chemical 
compound libraries in multiple biological assays (Campbell et al. 2010, Hamadeh et al. 2010, 
Kiessling & Splain 2010, Ogorevc et al. 2010, Wagner & Clemons 2009). Chemical 
genomics studies yield data indicating that both physical and functional interactions exist 
between chemicals and their biological targets. Such data (either obtained in chemical 
genomics centers or collected and curated from published literature) is deposited in many 
public and private databases such as the NIMH Psychoactive Drug Screening Program 
(PDSP) (PDSP 2009), PubChem (PubChem 2009), ChEMBL (ChEMBL 2010), WOMBAT 
(Olah et al. 2007) and others (see Oprea and Tropsha (Oprea & Tropsha 2006) for a recent 
review).   
Various in silico techniques have been exploited for analyzing target-specific 
biological assay data. A recent publication by Kortagere and Ekins (Kortagere & Ekins 2010) 
could serves as a good summary of most common target-oriented computational drug 
discovery approaches including: (1) structure based virtual screening (docking and scoring) 
using either experimentally characterized (with X-ray or NMR) or predicted by homology 
modeling structure of the target protein, (2) chemical similarity searching using known active 
compounds as queries, (3) pharmacophore based modeling and virtual screening, (4) 
quantitative structure activity relationship (QSAR) modeling, and (5) network or pathway 
analysis.  
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‘Omics’ Data Types and Repositories 
Data resulting from large-scale gene or protein expression or metabolite profiling 
(often collectively referred to as 'omics' approaches) (Burgun & Bodenreider 2008, Kandpal 
et al. 2009, Polychronakos 2008, Vangala & Tonelli 2007) can be explored not only for 
specific target identification but also in the context of systems pharmacology to identify 
networks of genes (or proteins) that may collectively define a disease phenotype. For 
example, ‗omics‘ data can be used to ask what genes or proteins, or post-translationally 
modified states of proteins are over- (or under-) expressed in patients suffering from a 
particular disease.  These types of data can be found in a number of public repositories such 
as the Gene Expression Omnibus (GEO) (Edgar et al. 2002, Barrett & Edgar 2006), 
GEOmetadb (Zhu et al. 2008b), the Human Metabolome Database (HMDB) (Wishart 2007, 
Wishart et al. 2009), Kinase SARfari (Kinase SARfari 2010), the Connectivity Map (cmap) 
(Lamb et al. 2006), the Comparative Toxicogenomics Database (CTD) (Davis et al. 2009), 
STITCH (Kuhn et al. 2009, Kuhn et al. 2008), GenBank (Burks et al. 1991, Burks et al. 
1990), and others.   
Insights into disease pathology and underlying mechanisms can be revealed by the 
disease ‗gene signature‘, i.e., those genes whose expression varies consistently between 
patients and healthy individuals (controls) (Palfreyman et al. 2002). Gene-expression 
profiling has been often applied to elucidate the mechanisms underlying the roles of 
biological pathway in a disease (DeRisi et al. 1997, Lamb et al. 2003), reveal arcane subtypes 
of a disease (Golub et al. 1999, Perou et al. 2000), and predict cancer prognosis (Pomeroy et 
al. 2002, van, V et al. 2002). At the same time, the treatment of cultured human cells with 
chemical compounds that target a disease can produce a drug related ‗gene signature‘, i.e., 
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differential expression profile of genes in response to the chemical (Altar et al. 2009, Ogden 
et al. 2004, Palfreyman et al. 2002, Le-Niculescu et al. 2007). Recently, a group of scientists 
at the Broad Institute have established the Connectivity Map (cmap) database (see Fig. 1.2 
for concept) to catalog the biological responses of a large number of diverse chemicals in 
terms of their gene expression profiles (Lamb et al. 2006). It has been shown that examining 
the correlations between gene expression profiles characteristic of a disease and those 
modulated by drugs may lead to novel hypotheses linking chemicals to either etiology or 
treatments for a disease (Garman et al. 2008, Golub et al. 1999, Hassane et al. 2008, 
Hieronymus et al. 2006, Lamb et al. 2006, Riedel et al. 2008, Setlur et al. 2008, Zimmer et al. 
2008, Zimmer et al. 2010).  
The cmap database provides an unusual but intriguing example of what we shall call a 
chemocentric ‗omics‘ database and methodology for generating independent and novel drug 
discovery hypotheses.  Indeed, there exists a wealth of information buried in the biological 
literature and numerous specialized chemical databases (ChEMBL 2010,  2004, PDSP 2009, 
PubChem 2009, Olah et al. 2007) linking chemical compounds and biological data (such as 
targets, genes, experimental biological screening results; cf. Baker and Hemminger (Baker & 
Hemminger 2010).  The chemocentric exploration of these sources, either individually or in 
parallel opens up vast possibilities for formulating novel drug discovery hypotheses 
concerning the predicted biological or pharmacological activity of investigational chemical 
compounds or known drugs. The integration and cross-validation of such independent 
structural hypotheses can increase their level of confidence and can be referred to as 
structural hypothesis fusion.  
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Figure 1.2.  The connectivity map concept. Functional relationships between a drug 
(yellow), a gene (green) and a disease (pink) constitute the nodes in this map. Adopted from 
Lamb, J. Nature, 7, 54-60. 
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The Multidimensional Chemocentric Space 
In order to design novel chemocentric informatics approaches to tackle the problems 
of conventional drug discovery projects, we should first understand the chemocentric space 
and how to divide this space into smaller subspaces that could be dealt with separately. The 
chemocentric space is a complex space defined by multiple interconnected dimensions. This 
is schematically represented in Fig.1.3, where molecules, proteins, genes, pathways, and 
diseases are some of the different dimensions represented within the chemocentric space. 
Different types of experimental data, deposited in a multitude of databases, allow for 
connecting pairs of dimensions in this representation. For example, pharmacological data on 
the binding affinities of chemicals to particular proteins allow the mapping of the molecule-
protein space (see Fig.1.3), one of the two-dimensional subspaces defining this 
multidimensional chemocentric space.  
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Figure 1.3. Chemocentric informatics multidimensional space with examples on online 
databases populated with relevant data concerning the two dimensions forming each 
subspace. Dashed red lines show examples of connecting other dimensions and forming new 
subspaces that are not clearly drawn here. 
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Hypothesis Fusion 
Data Fusion is the process of combining multiple data in order to produce new 
information that improves the performance of a system (i.e., in silico model or predictor). 
Data can come from one or many sources. Sources may be similar, or dissimilar. Data fusion 
may be useful for several objectives such as detection, recognition, identification, tracking, 
change detection, decision making, etc. Similarly, hypothesis fusion is the process of fusing 
different hypotheses derived independently from different data types. In all cases, efficient 
fusion schemes may have significant advantages such as: (1) improved confidence in 
decisions due to the use of complementary information, (2) improved performance to 
countermeasures (e.g., outliers in QSAR studies) and (3) Improved performance in adverse 
experimental conditions. This fusion approach was first developed for applications in signal 
processing (Klien 1999) and later on was applied in VS efforts to enable better decisions to 
which small number of molecules should go further for biological testing (Sukumar et al. 
2008, Whittle et al. 2006a, Whittle et al. 2006b).  
Herein, we used hypothesis fusion to cross-examine structural hypotheses that have 
been generated from different sets of data and using different machine learning algorithms 
and then applied for virtual screening of chemical libraries with those hypotheses derived 
from biological network mining efforts. Finally, we accepted accept common hits only based 
on chemical structure identity. 
Overview of Chapter 2: Materials and Methods  
In Chapter 2 we discussed the major computational approaches applied in our studies 
including: (1) QSAR model development, (2) QSAR-based VS, (3) Comparison studies with 
simple similarity searches to evaluate the performance of our QSAR methods, (4) Devising a 
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novel chemocentric informatics approach to study polypharmacology, and (5) Independent 
structural hypothesis fusion. 
Overview of Chapter 3: In silico Receptoromics 
Studies described in this chapter were designed to improve the rigor of QSAR 
modeling techniques to analyze GPCR datasets including the computational data modeling as 
well as novel approaches to tackle difficult problems in modern QSAR modeling such as 
dealing with unbalanced datasets, and applying different validation methods (e.g., consensus 
prediction, applicability domain, consensus predictions thresholds, and external sets) to 
improve the predictive power of models. Models were generated for many GPCRs with a 
special focus on a few receptors that are highly implicated in drug design efforts for 
neuropsychiatric and neurodegenerative diseases. Anti-target GPCRs (e.g., 5-HT2B receptors) 
were given special emphasis as well and will be discussed separately as a model QSAR study 
in Chapter 4.   
The growing  understanding within molecular pharmacology of the complexity of 
biological networks and the robustness and redundancy of biological systems, however, 
challenges the current approaches of single target drug discovery including in silico 
approaches (Hopkins 2007, Hopkins 2008, Roth et al. 2000, Roth & Kroeze 2006). 
Nowadays, medicinal chemists are becoming more interested in identifying 
polypharmacological drugs that can bind moderately to several targets in a disease-protein 
network and affect the overall outcome significantly (Hopkins et al. 2006, Hopkins 2009, 
Roth et al. 2004). Herein, we suggest for the first time receptor-family-based QSAR models 
as computationally inexpensive tools for the quick prioritization of polypharmacological hits 
for further experimental testing against a large panel of receptors. Additionally, the generated 
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receptor family-based models will be highly valuable due to both their biological relevance 
and statistical significance.  
Family based models seem promising tools to statically increase the rigor of the 
generated QSAR models for the following reasons: (1) increased size of datasets, (2) 
increased diversity of datasets, (3) improved applicability domains of the models, (4) 
suitability of the dataset for applying MTL to uncover hidden cross-family relationships and 
family specific chemical features. As a consequence, it is very likely that these models will 
increase the potential of QSAR models to indentify novel leads that are difficult to uncover 
otherwise. 
Overview of Chapter 4: The Development, Validation, and Use of Quantitative 
Structure Activity Relationship Models of 5-Hydroxytryptamine (2B) Receptor Ligands 
to Identify Novel Receptor Binders and Putative Valvulopathic Compounds among 
Common Drugs 
 In this study, we have applied a combinatorial QSAR approach to a dataset of 
800 compounds experimentally annotated as 5-Hydroxytryptamine (2B) (5-HT2B) 
receptor agonists, antagonists and inactives resulting in statistically validated and 
externally predictive models. We will discuss this study in details as an example on our 
QSAR performed herein.  Specifically, we used three different classification methods: k 
nearest neighbor (kNN), classification based on association (CBA), and distance 
weighted discrimination (DWD) and four different descriptor types (Dragon, MolconnZ, 
MOE and subgraphs) to generate classification QSAR models to discriminate between 5-
HT2B actives (agonists and antagonists) from inactives. Predictive models with 
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classification accuracies as high as 0.80 for actives vs. inactives, as estimated on external 
validation sets, were obtained.  
Classification models for actives vs. inactives were further validated by predicting 
an external validation set obtained after we completed the modeling studies. The high 
accuracy of prediction for the second external validation set proved that our models were 
indeed rigorous. Therefore, we posited that our studies afforded a robust computational 
tool to predict potential 5-HT2B activity and consequently prioritize hits for testing in 
functional 5-HT2B assays to predict valvulopathic side effects of drugs and drug 
candidates that act as 5-HT2B agonists. We suggested that this computational predictor 
could be used to eliminate high risk compounds at the early stages of the drug 
development process. To illustrate this point, we have used this predictor retrospectively 
to evaluate the valvulopathic potential of two drugs withdrawn from the U.S. market for 
this reason, i.e., fenfluramine and dextrofenfluramine. Both drugs were not included in 
our modeling set and both were indeed predicted with high confidence as actives for 
binding to 5-HT2B receptors.  
Encouraged by our model validation results, we have applied these models for 
virtual screening of the 59000 compounds in WDI database. Our classification strategies 
identified 122 potential 5-HT2B ligands. Ten structurally diverse VS hits were 
experimentally tested at PDSP. Nine compounds were experimentally confirmed as 5-
HT2B ligands thereby demonstrating a very high success rate of 90%.  
The predictor developed in this report is similar in its potential use to other 
predictors of drug liability such as carcinogenicity and mutagenicity that are widely used 
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in pharmaceutical industry. For instance, the TOPKAT program available in the 
Discovery Studio (Discovery Studio 2008), is a QSAR-based system that generates and 
validates accurate, rapid assessments of various types of chemical toxicity solely from a 
chemical's molecular structure. In contrast, our predictor is a unique specialized tool for 
the prediction of 5-HT2B activity and therefore prioritizing compounds for functional 
testing against 5-HT2B receptors to assess their valvulopathic potential. Therefore, this 
predictor can be used, along with other computational chemical health risk assessment 
tools, to evaluate compounds‘ safety at early stages of the drug development. It can be 
used as well to verify that all drugs available on the market are free from possibly fatal 
valvulopathic risk. This predictor is publicly available at the ChemBench server 
established in the Laboratory for Molecular Modeling (chembench.mml.unc.edu).   
Overview of Chapter 5:  An Integrative Chemocentric Informatics Approach to Drug 
Discovery Based on Structural Hypothesis Fusion 
Herein, we describe a novel integrative chemocentric informatics approach to drug 
discovery that combines structural hypotheses generated from independent analysis of both 
traditional target-specific assay data and those resulting from large scale genomics and 
chemical genomics studies.  Herein, we have focused on the Alzheimer‘s disease as one of 
the most debilitating neurodegenerative diseases with complex etiology and 
polypharmacology.  We have considered and cross-examined two independent but 
complimentary approaches to the discovery of novel putative anti-Alzheimer‘s drugs. First, 
we have employed a traditional target-oriented cheminformatics approach to discovering 
anti-Alzheimer‘s agents. We have built QSAR models of ligands binding to 5-
hydroxytryptamine-6 receptor (5-HT6R), a potential target for the cognitive enhancement in 
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Alzheimer‘s disease (Geldenhuys & Van der Schyf 2009); it has been shown that 5-HT6R 
antagonists can improve memory and cognition in animal models of impaired cognition 
(Holenz et al. 2006). We have then used models developed with the rigorous predictive 
QSAR modeling workflow established and implemented in our laboratory (Tropsha 2010) 
for virtual screening (VS) of the World Drug Index database (WDI) (Daylight 2004) and 
DrugBank (Wishart et al. 2006, Wishart et al. 2008) to identify putative cognition enhancing 
agents with potential utility as anti-Alzheimer‘s agents as compounds predicted to interact 
with 5-HT6R. Second, we have explored (chemo)genomic data available from the cmap 
project (Lamb et al. 2006) to link chemical compounds and the Alzheimer‘s disease without 
making explicit hypotheses about target-specific mechanisms of action, i.e., treating 
Alzheimer‘s disease as a complex polypharmacological disease.  
We then cross-examined and combined common hits regarded as structural 
hypotheses resulting from both approaches (i.e., hypothesis fusion) towards common 
integrated higher-confidence hypotheses supported by two independent lines of 
computationally-based evidence.  Thirteen common hits were tested in 5-HT6R binding 
assays at the NIMH Psychoactive Drug Screening Program (PDSP) and ten were confirmed 
experimentally as having activity. Unexpectedly, we found that the confirmed actives 
included several selective estrogen receptor modulators (SERMs) suggesting that they may 
be potential 5-HT6R actives as we as cognitive enhancing agents in Alzheimer‘s disease. 
Indeed, we have identified clinical evidence in biomedical literature in support of this 
hypothesis.  We believe that approaches discussed in this study can be applied to a large 
variety of systems to identify novel drug-target-disease associations. 
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Overview of Chapter 6: Conclusions and Future Studies 
We think it is likely that our computational efforts described herein and other efforts 
by different groups to study polypharmacology in silico will eventually result in useful and 
reliable tools aimed at enriching chemical libraries in compounds that have affinities for 
more than a single desired molecular target. We think that a combination of these methods 
will be more powerful than a single method alone as our expertise in the computational field 
has indicated time after time. However, our studies revealed some limitations of the current 
available methods that could be improved dramatically in the near future with the availability 
of more specialized databases, better disease signatures, and full matrices of tested chemical-
molecular target interactions.  
  
  
CHAPTER 2 
MATERIALS AND METHODS 
Databases and Datasets 
PDSP Ki-DB. PDSP Ki-DB (PDSP 2009) (http://pdsp.med.unc.edu/pdsp.php) 
includes published binding affinities (Ki) of drugs and chemical compounds for receptors, 
neurotransmitter transporters, ion channels, and enzymes. It currently lists more than 47000 
Ki values for more than 700 molecular targets. Ki-DB represents a curated, fully searchable 
database of both published data and data internally-derived from the NIMH-PDSP.  The 
experimental data for Alzheimer‘s disease related target 5-HT6R were extracted from the 
PDSP Ki-DB available in the public domain. The complete 5-HT6R dataset included binding 
affinity data for 250 compounds 
World Drug Index. The world drug index (WDI) (Daylight 2004) is an authoritative 
database for marketed and developmental drugs providing information about internationally 
recognized drug names, synonyms, trade names, trivial names, trial preparation codes, 
compound structures, and activity data. Herein, we used WDI for QSAR-based VS to 
identify putative 5HT6R ligands.  
DrugBank. DrugBank (Wishart et al. 2008) (http://www.drugbank.ca) is a unique 
bioinformatics and cheminformatics resource that combines detailed drug data (i.e., 
chemical, pharmacological, and pharmaceutical) with comprehensive drug target information 
(i.e., sequence, structure, and pathway). Currently, the database contains nearly 4800 drug 
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entries. Herein, we used DrugBank for virtual screening using QSAR models to 
identify putative 5-HT6R ligands among known drugs  
PubChem. PubChem (PubChem 2009) (http://pubchem.ncbi.nlm.nih.gov/) is a public 
repository of chemical structures and their activities obtained from a variety of biological 
assays. The PubChem compound repository presently contains more than 25 million unique 
structures with biological property information provided for many of the compounds. Herein, 
we used PubChem obtain all chemical structures for our datasets in SDF file format. 
Connectivity Map. The connectivity map  (cmap) (Lamb et al. 2006, Lamb 2007) 
(http://www.broadinstitute.org/cmap/) is a unique database for using genomics in drug 
discovery framework. It provides researchers with a systematic solution for the discovery of 
the functional connections between drugs, genes, and diseases. The database (cmap build 02) 
currently houses 7056 genome-wide expression profiles representing 6100 individual 
treatment instances with 1309 bioactive small molecules (i.e., drugs and other biologically 
active compounds). All gene expression profiles included in the cmap were derived from 
treating cultured human cells (MCF7, PC3, HL60, SKMEL5, HepG2, SHSY5Y) with 
chemical compounds.   
 ChemoText. ChemoText (Baker & Hemminger 2010)  is an in-house repository of 
chemical entities, and activity terms (indicating biological effects) extracted from annotations 
provided in Medline records. This resource has different applications in drug discovery 
projects. First, we can use ChemoText in a discovery-mode to formulate independent 
hypotheses about chemical-disease associations according to Swanson‘s ABC rule (Swanson 
1990). Secondly, we can use it as an information retrieval tool to gather relevant data about 
chemical-protein (or gene)-disease connections derived from biomedical literature. In this 
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study, we used ChemoText to retrieve all available biological information about the final 
computational hits predicted by our integrative approach. This analysis helped us in assessing 
the novelty of the produced hypotheses and in validating some of them. 
 STITCH. STITCH (Kuhn et al. 2008, Kuhn et al. 2009) (http://stitch.embl.de/) is a 
tool for searching chemical and protein interaction networks. It integrates information from 
metabolic pathways, crystal structures, binding experiments, and drug-target relationships. 
Inferred information from phenotypic effects, text mining, and chemical structure similarity 
is used to predict relations between chemicals. The database contains interaction information 
for over 68000 chemicals, including 2200 drugs, and connects them to 1.5 million genes 
across 373 genomes. In this study we used STITCH  to analyze chemical-protein networks 
for some computational hits predicted by our QSAR-based VS or the  integrative approach to 
be discussed later. 
NetAffx. NetAffx (Cheng et al. 2004, Liu et al. 2003) (http://www.affymetrix.com) 
gene ontology mining tool is a web-based, interactive tool that permits traversal of the gene 
ontology graph in the context of microarray data. It accepts a list of Affymetrix probe sets 
and renders a gene ontology graph as a heat map colored according to significance 
measurements. It also details and annotates probe sets on Affymetrix GeneChip microarrays. 
In this study we used NetAffx to populate our disease gene signatures with Affymetrix 
U133A probe sets.  
Dataset curation 
 Data curation is a mandatory step in data analysis that must be performed before 
proceeding with any modeling project. Several case studies have been reported by our lab 
where chemical curation of the original ―raw‖ dataset/database resulted in a significant 
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improvement of the outcome of the modeling study (especially, QSAR analysis). The 
different steps that will be used for cleaning chemical records in datasets and databases 
include: the removal of a fraction of data that cannot be appropriately handled by 
conventional cheminformatics techniques such as inorganic compounds, counter-ions and 
mixtures; structure validation; ring aromatization; normalization of specific chemo-types; 
curation of tautomeric forms; addition or deletion of hydrogen atoms; and the deletion of 
duplicates (see Fig. 2.1) (Fourches et al. 2010).  
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Figure 2.1. General workflow of chemical dataset curation developed in our lab (Fourches et 
al. 2010). 
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 For the purposes of this work, all datasets will be curated as follows:  First, all 
molecules will be ―washed‖ using both the Wash Molecules application in MOE (MOE 
2008) (v.2007.09) and ChemAxon Standardizer included in the ChemAxon JChem package 
(JChem 2009). The MOE Wash application normalizes chemical structures by carrying out a 
number of operations including 2D depiction layout, hydrogen correction, salt and solvent 
removal, chirality and bond type normalization, tautomer generation, adjustment and 
enumeration of protonation states. Second, duplicate chemical structures will be removed 
using the Sort and Remove Duplicates functionalities in MOE: keeping one chemical 
structure only if both activities in both cases are the same and removing both if activities 
were different. Activities might differ due to different stereochemistry that is not considered 
in our modeling studies where we only use 2D descriptors that cannot differentiate between 
stereoisomers. Finally, a careful manual inspection step should not be neglected as a last step 
in data curation. Some of the common errors identified during the manual cleaning procedure 
may include: wrong structures, incomplete normalization of chemical bonds, some duplicates 
may still be present despite the use of automated software to remove them, wrong charges, 
presence of explicit hydrogens in a hydrogen depleted structures, incorrect bonds, etc. 
  
29 
 
Computational Methods 
We used the combinatorial QSAR approach using different sets of molecular 
descriptors and applying several machine learning methods to establish the correlation 
between structural descriptors and biological activities. We also devised a novel 
chemocentric informatics approach the course of these studies. 
Combinatorial QSAR Approach 
To achieve QSAR models of the highest internal, and most importantly, external 
accuracy, we apply a combi-QSAR approach (de Cerqueira et al. 2006, Kovatcheva et al. 
2004), which explores all possible combinations of various descriptor types and 
optimization methods along with external model validation.  All modeling attempts are 
conducted according to our predictive QSAR modeling workflow (Fig. 2.2) (Tropsha 
2010). For purposes of this research, descriptors types mentioned earlier and different 
QSAR methods will be explored. We envision QSAR as a highly experimental area of 
statistical data modeling where it is impossible to decide a priori as to which particular 
QSAR modeling method will prove most successful.  Each combination of descriptor sets 
and optimization techniques is likely to capture certain unique aspects of the structure-
activity relationship.  Since our ultimate goal is to use the resulting models as reliable 
activity (property) predictors, combi-QSAR will increase our chances for success.  
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Figure 2.2. Flowchart of predictive QSAR modeling framework based on validated QSAR 
models. 
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Molecular Descriptors 
Molecular descriptors are numerical values that characterize properties of molecules. 
They vary in complexity of encoded information and in computation time. For purposes of 
this research we will be using the so called 2D molecular descriptors due to their relative 
simplicity of calculation, lack of dependence on conformation, and demonstrated ability to 
compete, if not outperform, 3D descriptors in chemical similarity and QSAR studies. Herein, 
five sets of 2D molecular descriptors will be used: 2D Dragon (Dragon 2007), MolConnZ 
(MZ) (MolconnZ 2006), Molecular Operating Environment (MOE) (MOE 2008), subgraph 
descriptors (SG) (Khashan et al. 2005) developed in this laboratory and MACCS structural 
keys (MDL Ltd 1992). Each type of these descriptors will be used separately with different 
machine learning methods in the context of our combi-QSAR strategy. 
DRAGON Descriptors. The Dragon Professional version 5.4 software (Dragon 
2007) was used to calculate 2D descriptors. These included topological descriptors, 
constitutional descriptors, walk and path counts, connectivity indices, information 
indices, 2D autocorrelations, edge adjacency indices, Burden eigenvalues, topological 
charge indices, eigenvalue-based indices, functional group counts, atom-centered 
fragments and molecular properties. The initial descriptor set was reduced by eliminating 
the constant and near-constant variables using built-in functions within the software. The 
pairwise correlations for all descriptors were examined and one of the two descriptors 
with the correlation coefficient R
2
 of 0.95 or higher was excluded. The calculation 
procedures for these descriptors, with related literature references, are reported by 
Todeschini and Consonni (Todeschini & Consonni 2000). Finally, the remaining 
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descriptors were normalized by range-scaling so that their values were distributed within 
the interval 0-1.  
MolConnZ Descriptors. The MolConnZ (MZ) software (MolconnZ 2006) 
available from EduSoft affords the computation of a wide range of topological indices of 
molecular structure. These indices include, but are not limited to, the following 
descriptors: valence, path, cluster, path/cluster and chain molecular connectivity indices 
(Kier & Hall 1976, Kier & Hall 1986, Randic 1975), kappa molecular shape indices (Kier 
1985, Kier 1987), topological (Hall & Kier 1990) and electrotopological state indices 
(Hall et al. 1991a, Hall et al. 1991b, Kellogg et al. 1996, Kier & Hall 1999), differential 
connectivity indices (Kier & Hall 1986, Kier & Hall 1991), graph‘s radius and diameter 
(Petitjean 1992), Wiener (Wiener 1947) and Platt (Platt 1947) indices, Shannon (Shannon 
& Weaver 1949) and Bonchev-Trinajstić (Bonchev et al. 1981) information indices, 
counts of different vertices, counts of paths and edges between different types of vertices 
(http://www.edusoft-lc.com/molconn/manuals/400). Descriptors with zero values or zero 
variance were removed; the remaining descriptors were normalized by range-scaling so 
that their values were distributed within the interval [0-1].  
MOE Descriptors. MOE 2007.09 software (MOE 2008) was used to generate 2D 
MOE descriptors. These included physical properties, subdivided surface areas, atom and 
bond counts, Kier and Hall connectivity (Kier & Hall 1976, Kier & Hall 1986, Randic 
1975) and kappa shape indices (Kier 1985, Kier 1987), adjacency and distance matrix 
descriptors (Balaban 1979, Balaban 1982, Petitjean 1992, Wiener 1947), pharmacophore 
feature descriptors, and partial charge descriptors (MOE 2008). Descriptors with zero 
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values or zero variance were removed; the remaining descriptors were normalized by 
range-scaling so that their values were distributed within the interval [0-1].  
Subgraph Descriptors (SG). Frequent subgraph mining of chemical structures is 
a novel approach to generating fragment descriptors that was developed recently in our 
group (Khashan et al. 2005). SG descriptors are derived from each dataset, i.e., not pre-
defined which gives the advantage of finding important chemical fragments that may 
have not been defined a priori by other fragment descriptor generating methods. The 
fragments are derived based on recurring substructures found in at least a subset of 
molecules (defined by a support value ) in the dataset. These recurring substructures can 
implicate chemical features responsible for compounds‘ biological activities.  
First, chemical structures were converted into labeled, undirected graph 
representations where nodes were labeled by atom types and edges corresponded to 
chemical bonds. Fast frequent subgraph mining (FFSM) algorithm (Huan et al. 2003) was 
then used to find common frequent subgraphs for a given support value (σ), which is one 
of the variables defined by the user that determines the size of the set of subgraphs 
generated using FFSM. Obviously, the larger is the value of the support, the smaller is the 
number of subgraphs descriptors. As the support value decreases, the number of 
subgraphs increases dramatically. Redundant subgraphs were identified and removed 
leaving only the so called ―closed subgraphs‖. A subgraph SGi is closed in a database if 
there exists no supergraph SGj such that SGi ⊆ SGj and σSGi = σSGj.  However, subgraph 
SGi would not be deleted if it also occurs by itself (not as part of the SGj) in the graph 
database. Removing redundant subgraphs (fragments) reduces the number of subgraphs 
descriptors drastically and therefore makes the subsequent calculations more efficient. 
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The frequency of individual ‗closed subgraphs‘ in each molecule of the dataset is 
calculated and used as the descriptor value for each molecule.  
MACCS Structural Keys. 166 MACCS (MDL Ltd 1992) structural keys 
implemented in MOE 2007.09 software (MOE 2008) were used for purposes of simple 
similarity searching using an in-house written script and applying Tanimoto coefficients 
for similarity measures. 
Machine Learning Methods 
Different machine learning algorithms will be used to correlate chemical descriptors 
with the corresponding biological activities. Correlation algorithms including kNN (Zheng & 
Tropsha 2000), super vector machine (SVM) (Cortes & Vapnik 1995), classification based 
on association (CBA) (Liu et al. 2001), distance weighted discrimination (DWD) (Marron et 
al. 2007), MOE (MOE 2008) binary QSAR, and MOE decision tress will be used in this 
research in combination with the descriptor types mentioned earlier. There is no single 
machine learning method that can claim to be uniformly superior to any other. Hence, the 
implementation of combi-QSAR (Kovatcheva et al. 2004, de Cerqueira et al. 2006) (i.e. 
ensemble machine learning), a set of modeling techniques (different molecular descriptors 
and different correlation algorithms) whose individual decisions are combined in some way 
(typically by weighted or un-weighted voting) will be employed to improve the performance 
of the overall modeling system and the success rates of in silico lead identification. 
 k Nearest Neighbors QSAR.  The k nearest neighbors (kNN) QSAR method 
(Zheng & Tropsha 2000) is based on the k nearest neighbors principle and the variable 
selection procedure. It employs the leave-one-out (LOO) cross-validation (CV) procedure 
and a simulated-annealing algorithm (Kirkpatrick et al. 1983, Metropolis et al. 1953) to 
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optimize variable selection. The procedure starts with the random selection of a 
predefined number of descriptors from all descriptors. If the number of nearest neighbors 
k is higher than one, the estimated activities ŷi of compounds excluded by the LOO 
procedure are calculated using the following formula: 
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where yj is the activity of the j-th compound. Weights wij are defined as: 
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and dij is Euclidean distances between compound i and its j-th nearest neighbor. 
However, if the number of nearest neighbors k is equal to one, then the estimated activity 
ŷi of the compound will be equal to the activity of this one nearest neighbor. 
The kNN classification algorithm employs an LOO cross-validation procedure on the 
training set and a simulated annealing algorithm in order to select subsets of descriptors, 
which lead to the highest LOO cross-validation correct classification rate (CCR). The 
procedure starts with the random selection of a predefined subset of descriptors from all 
descriptors. If the number of nearest neighbors k is higher than one, estimated activities ŷi of 
compounds excluded by LOO procedure are calculated using the following formula: 
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where yj is the binary activity of the j-th nearest neighbor. Weights wij are defined in Eq. (2), 
where dij is the Euclidean distance between compound i and its j-th nearest neighbor. If k=1, 
then ii yyˆ .       
The predicted values are then rounded to the closest integer. After each run, CCR and 
other statistical parameters are calculated as follows: 
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Then, a predefined small number of descriptors are randomly replaced by other descriptors 
from the original pool, and a new CCR value is obtained. If CCR (new) > CCR (old), the 
new set of descriptors is accepted; otherwise, if CCR (new) ≤ CCR (old), the new set of 
descriptors is accepted with probability p = exp ((CCR (new) - CCR (old))/T), or rejected 
with probability (1-p), where T represents the simulated annealing temperature parameter. 
During this process, T is decreasing until a predefined threshold. Thus, the optimal (highest) 
CCR is achieved (Zheng & Tropsha 2000, Xiao et al. 2004). For the prediction, the final set 
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of selected descriptors is used, and expressions (2) and (3) with rounding the predicted 
activity to the closest integer are applied to predict activities of test set compounds. 
Prediction is unreliable, if a representative point of a compound is ―too far‖ from the k 
nearest neighbors representing training set compounds with known activities. To limit the 
model‘s applicability domain, we apply a distance cutoff value between a compound under 
prediction and its nearest neighbors of the training set.  
Support Vector Machines. The description of the original support vector machines 
(SVM) algorithm could be found in many publications (Cortes & Vapnik 1995, Chang & Lin 
2001). Briefly, molecular descriptors are first mapped onto a high dimensional feature space 
using various kernel functions. Then, SVM finds a separating hyperplane with the maximal 
margin in this high dimensional space in order to separate compounds with different 
activities. Models built with this machine learning technique allow the prediction of a target 
property using a set of descriptors solely calculated from the structure of a given compound. 
In this study, we used the WinSVM program developed in our group (freely available for 
academic laboratories upon request) implementing the open-source libSVM package 
(http://www.csie.ntu.edu.tw/~cjlin/libsvm/) (Chang & Lin 2001). The WinSVM program 
provides users with a convenient graphical interface to prepare input data; to split datasets 
into training and test sets; to set up parameters for SVM grid calculations, including iterative 
and simultaneous grid optimization of SVM parameters; to launch and follow calculation 
progress in a powerful graphical interface; to select models with the best prediction accuracy 
on both training and internal test sets; and to apply them to the external evaluation set as an 
ensemble consensus model. The program also allows one to visualize molecular structures 
and various plots, making the use of SVM easier and more appropriate for QSAR modeling 
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in order to obtain robust and predictive models and apply them to virtual libraries.   
Classification Based on Association. Classification based on association (CBA) 
method integrates both classification rule mining (Breiman et al. 1984, Quinlan 1992), 
which aims to discover a small set of rules in the database that forms an accurate 
classifier, and association rule mining (Agrawal & Srikant 1994), which finds all the 
rules existing in the database that satisfy some minimum support and minimum 
confidence constraints. For association rule mining, the target of discovery is not pre-
determined, while for classification rule mining there is one and only one predetermined 
target. The integration is done by focusing on mining a special subset of association rules, 
called class association rules (CARs). An efficient algorithm is also used for building a 
classifier based on the set of discovered CARs.  
The CBA algorithm (Liu et al. 1998, Liu et al. 1999) consists of two parts, a rule 
generator, which is based on the a priori algorithm for finding association rules, and a 
classifier builder. The candidate rule generator is similar to the a priori one. The 
difference is that CBA updates the support value in each step while the a priori algorithm 
only updates this value once. This allows us to compute the confidence of the ruleitem. A 
ruleitem is of the form: <condset, y> where condset is a set of items, y Y is a class 
label. The support count of the condset (called condsupCount) is the number of cases in 
the dataset (D) that contain the condset.  
Next, a classifier is built from CARs. To produce the best classifier out of the 
whole set of rules would involve evaluating all the possible subsets of it on the training 
data and selecting the subset with the right rule sequence that gives the least number of 
errors. There are 2m such subsets, where m is the number of rules. It is a heuristic 
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algorithm.  Given two rules, ri and rj, ri precedes rj if (1) the confidence of ri is greater 
than that of rj, or (2) their confidences are the same, but the support of ri is greater than 
that of rj, or (3) both the confidences and the supports of ri and rj are the same, but ri is 
generated earlier than rj. If R is a set of generated rules (i.e. CARs) and D the training 
data, the basic idea of the algorithm is to choose a set of high precedence rules in R to 
cover D. The classifier follows this format: <r1, r2, …, rn, default_class>, where ri  R. In 
classifying an unseen case, the first rule that satisfies the case will classify it. If there is 
no rule that applies to the case, it takes on the default class. 
The descriptors used with CBA need to be discrete in nature (Liu et al. 1998) as is 
the case with SG descriptors but not Dragon, MolConnZ or MOE. Hence, this method 
was only used with SG descriptors using CBA (v2.1) software (Liu et al. 2001).  
Distance Weighted Discrimination. Distance weighted discrimination (DWD) 
was initially proposed by Marron and Todd (Marron et al. 2007) with the goal of 
improving the performance of SVM (Cristiainini & Shawe-Taylor 2000, Vapnik 1995) in 
high dimensional low sample size (HDLSS) contexts. The main idea is to improve upon 
the criterion used for ―separation of classes‖ in SVM. SVM has data piling problems 
along the margin, because it is maximizing the minimum distance to the separating plane, 
and there are many data points that achieve the minimum. A natural improvement is to 
replace the minimum distance by a criterion that allows all the data to have an influence 
on the result. DWD does this by maximizing the sum of the inverse distances. This 
results in directions that are less adversely affected by spurious sampling artifacts. The 
major contribution of this new discrimination method is that it avoids the data piling 
problem, to give the anticipated improved generality. Like SVM, DWD is based on 
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computationally intensive optimization; however, while SVM uses well known quadratic 
programming algorithms, DWD uses interior-point methods for so-called Second-Order 
Cone Programming (SOCP) problems (Alizadeh & Goldfarb 2003). Detailed discussion 
of these issues may be found in Marron and Todd (Marron et al. 2007), which is available 
with the supporting information at https://genome.unc.edu/pubsup/dwd/. All DWD 
computations were performed using the DWD software (Marron 2002) written in Matlab 
(Mathworks 2010) and kindly provided by Dr. Marron.  
Balancing Datasets Using Similarity Searching 
Some of the classification datasets we are dealing with are highly imbalanced, i.e. one 
of the classes (e.g., non-binders) is much larger or smaller than the other class (binders). 
However, highly imbalanced datasets might affect the predictive performance of QSAR 
models negatively. Therefore, only a subset of the larger class of approximately the same size 
of the smaller class will be used for model building with some modeling techniques like k-
nearest neighbors (kNN) that are highly sensitive to imbalanced datasets. This subset will be 
selected to include compounds from the larger class that are most similar to the compounds 
in the smaller class.  
Model Selection and Validation 
 Following our predictive QSAR modeling workflow (Tropsha 2010) (cf.  Fig. 2.2), all 
QSAR models generated to build regression models for binding affinities or to classify 
binders vs. non-binders were validated by predicting both test and external validation sets and 
applying different validation criteria.  
 Dataset Division for Model Building and Validation. All QSAR models generated 
in this research will be validated by predicting external validation sets generated by: (1) 
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Randomly extracting 20% of the dataset using an in-house script, or (2) Extracting 5 different 
external validation sets using external 5-fold cross validation (CV) (Hawkins et al. 2003, 
Kohavi 1995). Datasets employed in QSAR studies were first randomly divided into a 
modeling set and an external validation set (evs). Another level of internal validation was 
achieved by dividing the modeling set into multiple chemically diverse training and test sets 
using the Sphere Exclusion algorithm implemented in our laboratory (Golbraikh & Tropsha 
2002b). These routines are always employed as a part of our predictive QSAR modeling 
workflow to emphasize the fact that training-set-only modeling is not sufficient to obtain 
reliable models that are externally predictive. It should be mentioned that only models that 
are highly predictive on the test sets will be retained for the consensus prediction of the 
external validation sets. Finally, only those models that are shown to be highly predictive on 
both external sets will be used in consensus fashion for virtual screening of external 
compound libraries. 
Model Acceptability Criteria for Rigorous Predictor Development. Several 
publications by our group have recommended a set of statistical criteria which must be 
satisfied by a predictive model (Golbraikh & Tropsha 2002b, Golbraikh & Tropsha 
2002a, Golbraikh et al. 2003, Tropsha 2006, Tropsha & Golbraikh 2007, Tropsha 2010). 
For continuous QSAR, criteria that we will follow in developing activity/property 
predictors are as follows: (i) correlation coefficient R between the predicted and observed 
activities; (ii) coefficients of determination (predicted versus observed activities R, and 
observed versus predicted activities 
2
0'R  for regressions through the origin); (iii) slopes k 
and k' of regression lines through the origin. We consider a QSAR model predictive, if 
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the following conditions are satisfied  (i) q
2
>0.6; (ii) R
2
>0.6; (iii) 
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0 RR  where q2 is 
the cross-validated correlation coefficient calculated for the training set, but all other 
criteria are calculated for the test set.  
For classification and category QSAR, a 2 × 2 confusion matrix can be defined (see 
Table 3) in the case when compounds belong to two classes (e.g., active and inactive 
compounds), where N(1) and N(0) are the number of  compounds in the data set that belongs 
to classes (1) and (0) respectively. TP, TN, FP, and FN are the number of true positives, true 
negatives, false positives, and false negatives, respectively. The following classification 
accuracy characteristics associated with confusion matrices are widely used in QSAR 
studies: sensitivity (SE=TP/N(1)), specificity (SP=TN/N(0)), and enrichment E = 
TP*N/[(TP+FP)*N(1)]. In this study, we have employed normalized confusion matrices. A 
normalized confusion matrix can be obtained from the non-normalized one by dividing the 
first column by N(1) and the second column by N(0). Normalized enrichment is defined in 
the same way as E but is calculated using a normalized confusion matrix: En = 
2TP*N(0)/[TP*N(0)+FP*N(1)]. En takes values within the interval of [0, 2] (Golbraikh et al. 
2002, Kovatcheva et al. 2004). The prediction accuracy (correct classification rate, CCRtrain) 
is calculated as in Equation 2.5.  
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Table 2.1. Confusion matrix for binary classification models. 
  Observed class 
(1) 
Observed class 
(0) 
Total 
Predicted 
class (1) 
TP FP TP+FN 
Predicted 
class (0) 
FN TN FN+TN 
Total N(1) = TP+FN N(0) = FP+TN N=TP+FP+FN+TN 
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 Robustness of QSAR Models. Y-randomization test is a widely used validation 
technique to ensure the robustness of a QSAR model (Wold & Eriksson 1995). This test will 
be used to evaluate all generated QSAR models in our research efforts. Applying this test 
includes (i) randomly shuffling the dependent-variable vector, Y-vector (class labels or actual 
activity values) of training sets  and (ii) rebuilding models with the randomized activities (or 
class labels) of the training set. All calculations are repeated several times using the original 
independent-variable matrix. It is expected that the resulting QSAR classification models, 
built with randomized activities for the training set, should generally have low CCRs for 
training, test, and external validation sets. It is likely that sometimes, though infrequently, 
high CCR values may be obtained due to a chance correlation or structural redundancy of the 
training set. However, if some QSAR classification models obtained in the Y-randomization 
test have relatively high CCR it implies that an acceptable QSAR classification model cannot 
be obtained for the given dataset by the particular modeling method used. Y-randomization 
test will be applied to all datasets considered in this research, and the test will be repeated 
five times in each case. 
Virtual Screening 
 Our main goal from model building studies is the prediction of the target properties of 
the compounds in chemical libraries allowing for their immediate prioritization for 
subsequent experimental validation. Therefore, we are seeking to develop and deliver highly 
efficient yet accurate QSAR-based virtual screening and scoring protocols that will 
significantly increase the experimentally validated hit rate of virtual screening. Robust and 
externally predictive QSAR models generated for selected GPCRs were used for VS of 
chemical databases to predict new ligands for these targets. The predicted ligands could 
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become important biological probes or drug candidates. The final compendium of models 
could be potentially useful for predicting biological profiles and side effects of drugs. Our 
search methodologies will be based on chemical similarity estimated in two different ways: 
(1) global similarity based on all descriptors calculated for the modeling set and acts as a 
primary filter that will assure a some level of similarity of the predicted compounds to the 
modeling set, (2) model-based similarity where the predicted compounds possess the 
chemical features (descriptors) that have been chosen by the QSAR model after the variable 
selection process. Model-based similarity implies that few chemical features in the chemical 
structure in fact control the modeled biological property. 
  Applicability Domain. Formally, a QSAR model can predict the target property for 
any compound for which chemical descriptors can be calculated. However, if it is highly 
dissimilar from all compounds of the modeling set, reliable prediction of its activity is 
unlikely to be reached. The concept of applicability domain AD, previously implemented and 
widely used in our laboratory (Zhu et al. 2008a, Zhang et al. 2008a, Tropsha 2003), was 
applied to avoid unreliable prediction. In this study, we defined AD as a distance threshold 
DT between a compound under prediction and its closest nearest neighbors of the training set. 
It was calculated as follows: 
   ZyDT                 (Eq. 2.9) 
where, y  is the mean Euclidean distance between each compound and its k-nearest neighbors 
in the model space of the training set (i.e., k is the parameter optimized during QSAR model 
generation, and the distances are calculated using descriptors selected by the optimized 
model only), σ is the standard deviation of these Euclidean distances, and Z is an arbitrary 
parameter. We set the default value of this parameter Z at 0.5, which formally places the 
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allowed distance threshold at the mean plus one-half of the standard deviation. We also 
defined the AD in the entire descriptor space, i.e., global AD. In this case, the same formula 
(9) is used, k=1, Z=0.5, and Euclidean distances were calculated using all descriptors. Thus, 
if the distances of the external compound from its k nearest neighbors (see above) in the 
training set within either the entire descriptor space or the selected descriptor space exceeded 
these thresholds, no prediction was made.  
 Consensus Prediction. Our experience suggests that consensus prediction of the 
target property for external compounds, i.e., when the compound activity is calculated by 
averaging values predicted by all individual models that satisfy our acceptability criteria, 
always provides the most stable and accurate solution (de Cerqueira et al. 2006, Zhu et al. 
2008a, Kovatcheva et al. 2004). The assumption being that averaging predicted activities of a 
compound over multiple predictive models cancels out the errors of prediction.  In this 
research we will be averaging the predictions for each compound by majority voting for 
QSAR models, using all models passing the validation criteria (CCRtrain, CCRtest and CCRex 
≥ 0.70 for classification models and q2 and R2 ≥ 0.70 for continuous models). In order to 
determine the confidence in the obtained predictions we need to define a consensus score 
(CS) for each of the predicted hits first. The consensus score can be defined as the average 
predicted value of the target property by all models used for prediction. In this research we 
investigated the performance of different consensus scores when prioritizing hits for 
experimental testing.  
Integrative Chemocentric Informatics Approach  
We have devised an integrative workflow focused on the discovery of new drug 
candidates and finding new uses for existing drugs by fusing predictions generated from 
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different data types and methods. Currently, the workflow (will be discussed in details in 
Chapter 5 as a new integrative methodology based on hypothesis fusion devised herein) 
incorporates three major components: (1) a module for QSAR-based VS of chemical libraries 
to identify new ligands for target proteins, (2) a network-mining module to identify small 
molecule therapeutics for specific diseases without necessarily knowing the underlying 
target-specific mechanism; this module explicitly relies on cmap(Lamb et al. 2006, Lamb 
2007), an external online database (www.broadinstitute.org/cmap/) that links the effects of 
different drugs and diseases using gene expression profiles, and (3) ChemoText (Baker & 
Hemminger 2010), an in-house repository of relationships between chemicals, diseases, 
proteins, and biological processes. The first two modules have been employed extensively for 
studies reported herein. This new approach will be discussed in details in chapter 5. 
Experimental Method 
Radioligand Binding Assays. This screen was performed by the National Institute of 
Mental Health Psychoactive Drug Screening Program (PDSP). Radioligands were purchased 
by PDSP from Perkin-Elmer or GE Healthcare. Competition binding assays were performed 
using transfected or stably expressing cell membrane preparations as previously described 
(Roth et al. 2002, Shapiro et al. 2003) and are available online (http://pdsp.med.unc.edu). All 
experimental details are available online (http://pdsp.med.unc.edu/UNC-
CH%20Protocol%20Book.pdf). 
 Chemistry. Chemical compounds predicted as hits from the virtual screening were 
obtained from commercial suppliers according to their availability. All compounds were 
ordered to have ≥ 95% purity. Additionally, all compounds were subjected to purity 
assessment using LC/MS by the Center for Integrative Chemical Biology and Drug 
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Discovery at UNC-Chapel Hill. LC/MS spectra of all compounds were acquired from an 
Agilent 6110 Series system with UV detector set to 220 nm.  Samples were injected (5 uL) 
onto an Agilent Eclipse Plus 4.6 x 50 mm, 1.8 uM, C18 column at room temperature. A 
linear gradient from 10% to 100% B (MeOH + 0.1% Acetic Acid) in 5.0 min was followed 
by pumping 100% B for another 2 minutes with A being H2O + 0.1% acetic acid.  The flow 
rate was 1.0 mL/min.   
  
  
CHAPTER 3 
IN SILICO RECEPTOROMICS: QSAR MODELING OF RECEPTOR SUBTYPES 
AND FAMILIES, MODEL APPLICATION FOR VIRTUAL SCREENING, AND 
EXPERIMENTAL VALIDATION OF COMPUTATIONAL HITS 
Introduction 
In silico screening approaches are routinely employed nowadays in academic, 
governmental and commercial sectors and they have become broadly applied techniques in 
drug discovery (Armbruster & Roth 2005, Bajorath 2002, Bajorath 2005, Becker 2004, 
Becker et al. 2004, Evers & Klebe 2004, Kitchen et al. 2004, Klabunde et al. 2009). Research 
conducted in our group demonstrated that the generation of Quantitative Structure Activity 
Relationship (QSAR) models and subsequent model-based virtual screening of chemical 
libraries has led to the identification of chemically diverse molecules with high success rates 
in experimental validation tests (Hsieh et al. 2008, Oloff et al. 2005, Peterson et al. 2009, 
Shen et al. 2002, Shen et al. 2004, Tang et al. 2009, Tropsha 2006, Tropsha & Pearlman 
2000, Tropsha & Wang 2006). This approach to drug discovery comprises the following 
steps: (1) defining the target(s) of interest, (2) extracting relevant structure activity data from 
the biological literature and specialized databases, (3) dataset curation, (4) compound 
representation by suitable chemical descriptors, (5) model generation and validation, (6) the 
application of validated QSAR models for mining chemical databases to predict binders and, 
if possible agonists and antagonists. Often, the interpretation of chemical descriptors found 
significant for the success of QSAR models can reveal important structural requirements for 
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ligand binding and activity. For the most part, this approach has been applied to datasets of 
compounds tested in individual assays characterizing their interaction with a single molecular 
target. 
The growing  understanding within molecular pharmacology of the complexity of 
biological networks and the robustness and redundancy of biological systems challenges the 
current approaches of single target drug discovery including in silico approaches (Hopkins 
2007, Hopkins 2008, Roth et al. 2000, Roth & Kroeze 2006). Nowadays, medicinal chemists 
are becoming more interested in identifying polypharmacological drugs that can bind 
moderately to several targets in a disease-protein network and affect the overall outcome 
significantly (Hopkins et al. 2006, Hopkins 2009, Roth et al. 2004). Herein, we suggest 
receptor-family-based QSAR models as computationally inexpensive tools for the quick 
prioritization of polypharmacological hits for further experimental testing against a large 
panel of receptors.  
Theoretically, QSAR models explore information restricted to the experimental 
knowledge of chemical structures and biological activities of ligands. Hence, this approach is 
especially important when the X-ray crystal structures for the biological targets of interest 
(e.g., most GPCRs and trans-membrane proteins) are unavailable.  By applying QSAR 
modeling approach to a large number of datasets, we can accumulate a compendium of 
QSAR models representing a variety of different biological targets, and subsequently 
establish a virtual receptorome system to screen molecules simultaneously against an array of 
available models.  Ultimately, we can use these models to obtain a list of common matching 
hits among several receptor families and could link the hits to all predicted biological targets, 
thereby enabling an in silico identification of biological networks that will possibly be 
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influenced by these compounds (concept explained in Fig. 1.1). This approach can also 
identify selective compounds for each receptor family after excluding common hits. An 
example of a similar approach to broad in silico profiling of compound libraries is given by 
the method PASS (Brady & Stouten 2000), which currently allows in silico screening against 
a large panel of target proteins. However, the datasets behind PASS models are not publicly 
available, which makes it difficult to employ and validate alternative techniques to the same 
datasets. 
In this research, we have focused on G-protein Coupled Receptors (GPCRs) and 
related trans-membrane proteins (i.e., Sigma receptors) as promising targets for the drug 
discovery projects targeting polypharmacology. GPCRs constitute the largest family of 
membrane proteins that mediate most cellular responses to hormones and neurotransmitters 
and are also responsible for vision, olfaction and taste (Rosenbaum et al. 2009). The total 
number of currently known and verified human GPCRs consists of at least 799 unique full-
length members (Gloriam et al. 2007). GPCRs have been involved in a multitude of 
biological responses in all organs and systems including the central and peripheral nervous 
systems. In the latter, particularly important functions include neurotransmitter release, cell-
to-cell communication, modulation of learning and memory, response to psycho-active 
substances, regulation of neuronal growth and differentiation and of glial responses.  
However, ligands for GPCRs comprise structurally very diverse compounds and often 
the ligands interact with more than one GPCR, i.e., they are promiscuous. Furthermore, most 
highly effective polypharmacological compounds (e.g., clozapine) are highly promiscuous as 
well and consequently, they often have serious side effects. Although polypharmacology is 
desired for treating many diseases, highly promiscuous compounds are sometimes very toxic. 
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Therefore, we should be investigating new approaches to identify moderately promiscuous 
compounds that have decent binding affinities to few highly desired receptors that belong to 
the same family or different families of receptors. For example, a compound that acts as a 5-
HT2C agonist, 5-HT6 and H3 antagonist might be a good anti-obesity lead/drug. However, 
such compound would be a major health hazard if it activates 5-HT2B receptor subtype since 
the latter activity often leads to undesired cardiovascular effects (Huang et al. 2009, Setola & 
Roth 2005, Setola & Roth 2008). Thus, predicting ligand‘s binding to serotonin and 
histamine families of receptors is very crucial for activity, while binding to other receptor 
families of receptors (or receptor subtypes) would make the drug less safe.   
In this regard, family based models where a compound is regarded as active if it 
interacts with at least one member of the family, and inactive if it shows no (or poor) binding 
affinity against all members of the family, can be useful tools to predict selective 
polypharmacological profiles where promising compounds can be identified and 
experimentally validated for both efficacy and safety, and then may be, modified to achieve 
better activity profiles against the desired pharmacologic targets. Moreover, the use of family 
specific datasets will increase the statistical rigor of the generated QSAR models for the 
following reasons: (1) increased size of datasets, (2) increased chemical diversity of datasets, 
(3) larger applicability domains of the models.  
In this study, we have developed QSAR classification models for ligands interacting 
with several receptor subtypes and families of GPCRs and other trans-membrane proteins as 
part of an ongoing project in our lab; the GPCR QSARome project. The modeled receptor 
families included 5-Hydroxytryptamine (5-HT), adrenergic alpha, dopaminergic, histamine, 
muscarinic, and sigma receptors achieving external classification accuracies as high as 95 %.  
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All models were subjected to rigorous internal and external validation. The results confirmed 
the high external prediction accuracy of our computational models, which led us to conclude 
that these models can be used reliably to screen chemical databases to identify putative 
binders across receptor families. Thus, the models were used for virtual screening (VS) of 
two commercially available databases: the World Drug Index (WDI) (Daylight 2004) and 
DrugBank (Wishart et al. 2006, Wishart et al. 2008). Eleven VS hits from the WDI were 
subjected to parallel binding assays against a panel of trans-membrane protein targets. Nine 
compounds were found to bind to at least one receptor subtype among the predicted families 
with binding affinities between 0.6 - 9000 nM. Thus, these models will be highly valuable to 
assess the potential of chemicals to bind several families of GPCRs in an effort to predict 
interesting polypharmacological profiles. 
Materials and Methods 
Databases and Datasets 
Four databases described in details in chapter 2 were used for purposes of the work 
presented herein, namely: PDSP Ki-DB, WDI, DrugBank, and PubChem. The experimental 
data for receptor family datasets (i.e., for 5-HT, adrenergic alpha, dopamine, histamine, 
muscarinic and sigma receptors) were extracted from the PDSP Ki-DB available in the public 
domain. We used WDI and DrugBank chemical databases for QSAR-based VS to identify 
putative ligands for the studied receptor families, while we used PubChem obtain all 
chemical structures for our datasets in SDF file format. 
Preprocessing of the Datasets 
We used a workflow for chemical data curation that was developed in our lab and 
published recently (Fourches et al. 2010) and described in details in Chapter 2. We assigned 
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the ‗activity‘ class for each compound based on its Ki value(s) obtained from the PDSP and 
according to PDSP specifications as reported at the PDSP website (http://pdsp.med.unc.edu/). 
Compounds with Ki values less than 10 µM were considered binders and assigned to class 1, 
whereas compounds with Ki values more than or equal to 10 µM were considered non-
binders and assigned to class 0.  
Binders to 5-HT family consisted of compounds that bind to any of the following 
receptors: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, or 5-
HT7. Binders to the adrenergic alpha receptors consisted of compounds that bind any of the 
following receptor subtypes: alpha1A, alpha1B, alpha 2A, alpha 2B, or alpha 2C. Binders to 
the dopamine family consisted of compounds that bind any of the following receptor 
subtypes: D1, D2, D3, D4 or D5. Binders to the histamine family consisted of compounds that 
bind any of the following receptor subtypes: Binders to the muscarinic family consisted of 
compounds that bind any of the following receptor subtypes: M1, M2, M3, M4, or M5. Binders 
to the sigma family consisted of compounds that can bind either sigma 1 or sigma 2 (or both) 
receptors. 
Dataset Division for Model Building and Validation  
Previously, we and other groups demonstrated that, generally, there is no correlation 
between the statistical parameters of QSAR models for the training set, such as leave-one-out 
(LOO) cross-validation R
2
(q
2
), and the correlation coefficient R
2
 between predicted and 
observed activities of the test set. This statement is also true for classification QSAR models: 
high classification accuracy for the training and the test set usually do not correlate with each 
other. Thus, acceptable statistics for the training set only is insufficient to assume that the 
model also has high external predictive power and QSAR models should be rigorously 
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validated using external validation sets of compounds which were not used to train the 
models (Golbraikh & Tropsha 2002a). Following our predictive QSAR modeling workflow 
(Tropsha 2010) all QSAR models generated to classify binders vs. non-binders across the 
studied receptor families were validated by predicting both test and external validation sets. 
Each dataset was randomly split into 5 different subsets of nearly equal size to allow for 
external 5-fold cross validation (CV) (Hawkins et al. 2003, Kohavi 1995). In this protocol, 
each subset including 20% of the original dataset was systematically employed as the 
external validation set while the remaining 80% of the compounds constituted the modeling 
set.  
Another level of internal validation was achieved by comparing model performance 
for training and test sets. Herein, all modeling sets (each including 80% of the original 
dataset) were additionally divided multiple times into chemically-diverse training and test 
sets using the Sphere Exclusion program developed in-house and described elsewhere 
(Golbraikh & Tropsha 2002b). The Sphere Exclusion algorithm divides the modeling set into 
multiple pairs of training and test sets to guarantee that at least in the entire descriptor space, 
(i) all representative points of the test set are close to at least one representative point of the 
training set, i.e. test set compounds are within the applicability domain defined by the 
training set; (ii) given the relative sizes of the training and test sets, the highest portion of the 
representative points of the training set are close to representative points of the test set; (iii) 
and the training set is a representative subset of the entire modeling set, i.e., there is no subset 
in the modeling set  not represented by a similar compound in the training set. Here, the 
modeling sets were divided 28-39 times into training and test sets of different sizes. 
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Multiple QSAR models were developed using these training sets and validated using 
the corresponding test sets. Models with high prediction accuracy assessed by statistical 
criteria (cf. Chapter 2) were used for consensus prediction of external validation set 
compounds: each compound was predicted by all models for which it was within the 
applicability domain (refer to Chapter 2 for details), and the consensus predicted value for 
each compound was rounded to the closest integer (class). The predictivity of the models was 
evaluated by the consensus CCR for the external validation set. The model building and 
validation approach is illustrated schematically in Figure 2.2. 
Computational Methods 
Dragon Descriptors. An ensemble of 929 molecular descriptors was computed using  
the Dragon Professional software (version 5.4) (Dragon 2007) for all compounds (with 
explicit hydrogen atoms) in our datasets.  Descriptors included: 0D-constitutional descriptors 
(atom and group counts), 1D-functional groups, 1D-atom centered fragments, 2D-topological 
descriptors, 2D-walk and path counts, 2D-autocorrelations, 2D-connectivity indices, 2D-
information indices, 2D-topological charge indices, 2D-Eigenvalue-based indices, 2D-
topological descriptors, 2D-edge adjacency indices, 2D-Burden eigenvalues, and various 
molecular properties such as octanol-water partition coefficient. Descriptors with low 
variance (standard deviation lower than 0.0001) or missing values were removed. 
Furthermore, if the correlation coefficient between any two descriptors exceeded 95%, one of 
them was removed. The final set used in this QSAR study included 298 descriptors. These 
descriptors were range-scaled, so that their values were within the interval [0, 1]. Definition 
and calculation procedures for Dragon descriptors and the related references are given in the 
Handbook of Molecular Descriptors (Todeschini & Consonni 2000). 
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Machine Learning Methods. Both kNN classification algorithm and SVM were 
used to generate QSAR models herein. All details about these two methods can be found in 
Chapter 2. 
 
Selection and Validation of QSAR Models 
To evaluate the predictive power of the generated QSAR models, CCR (Equation 2.5) 
values for the training, test, and external evaluation set were calculated. We used sensitivity 
(SE) and specificity (SP) (Equations 2.6 and 2.7) as well. SE and SP reflect the accuracy of 
predicting the compounds of active and inactive classes, respectively. We considered a QSAR 
model to have an acceptable predictive power, if both of the following conditions were 
satisfied:  
(i) CCR for the LOO cross-validation of the training set (i.e., ) was at 
least 65%, and CCR for the test set (i.e., ) was also at least 65%;  
(ii) For both training and test sets, SE and SP (i.e.,  ,  ,  , 
) were at least 60%.  
 Applicability domain  
Formally, a QSAR model can predict the target property for any compound for which 
chemical descriptors can be calculated. However, if it is highly dissimilar from all 
compounds of the modeling set, reliable prediction of its activity is unlikely to be reached. 
The concept of applicability domain (AD), previously implemented and widely used in our 
laboratory (Zhu et al. 2008a, Zhang et al. 2008a, Tropsha 2003), was applied to avoid 
unreliable prediction. In this study, we defined AD as a distance threshold DT between a 
compound under prediction and its closest nearest neighbors of the training set according to 
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Equation 2.9 (cf. Chapter 2). In all these studies we set the default value of this parameter Z 
at 0.5, which formally places the allowed distance threshold at the mean plus one-half of the 
standard deviation. We also defined the AD in the entire descriptor space. In this case, the 
same formula (Eq. 2.9) is used, where Z equals to 0.5, using one nearest neighbor (i.e., k=1), 
and Euclidean distances were calculated using all descriptors. Thus, if the distances of the 
external compound from its k nearest neighbors (see above) in the training set within either 
the entire descriptor space or the selected descriptor space exceeded these thresholds, no 
prediction was made.  
In receptor family modeling efforts, diversifying datasets will generally increase the 
distance cutoff (DT) that is calculated using Equation 2.9, because we are increasing the 
average distance between each compound and its nearest neighbors in the training set. We set 
the default value of this parameter Z at 0.5. In this way the distance of the external compound 
from its nearest neighbors in the training set might become below the threshold and 
consequently we will be able to predict more compounds using our family-based models that 
were initially very distant from the training set compounds (i.e., out of applicability domain). 
Robustness of QSAR models 
Y-randomization (randomization of response) is a widely used approach to validate 
the robustness of QSAR models. It consists of rebuilding the models using randomized 
activities of the training set and subsequent assessment of the model statistics. It is expected 
that models obtained for the training set with randomized activities should have significantly 
lower values of CCR for the training or the test set than the models built using training set 
with real activities, or at least these models should not satisfy some of the validation criteria 
mentioned above. If this condition is not satisfied, models built for this training set with real 
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activities are not reliable and should be discarded. This test was applied to all training sets 
obtained by data splits into training and test sets and it was repeated three times for each 
split. 
Virtual Screening and Consensus Prediction Thresholds 
We screened both the WDI and DrugBank databases to derive a predicted 
polypharmacology matrices for all compounds included in these databases and to identify 
common and unique binders for the six studied receptor families. Dragon descriptors were 
generated for each compound in the databases and normalized based on the maximum and 
minimum values of each descriptor in the modeling set. Each validated kNN-Dragon model 
was then used to predict the activities of compounds that were within AD. The results for 
each individual prediction were combined into a consensus prediction: a consensus score 
(CS) was calculated for each compound that was within the ADs of multiple models. The 
consensus scores employed in this study take into account the total number of models used to 
predict the compound‘s activity class (binder or non-binder), and the number of models that 
predicted the compound to belong to a specific class. Since we define two classes of 
compounds, i.e., class 1 (binders) and class 0 (non-binders), some models may predict a 
compound to belong to class 0 and others may predict it to belong to class 1. As a result, a 
consensus score between 0 and 1 will be obtained for each of the predicted compounds.  
Additionally, Different Consensus Prediction Thresholds (CPTs) were then used to 
improve prediction accuracy. To clarify, each individual model could only make binary 
predictions of compounds as either active (value of 1) or inactive (value of 0). However, 
since we integrated predictions from the ensemble of models (that passed the acceptance 
criteria), we could have a situation when different models disagree in their predictions. Thus, 
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the averaged (consensus) predicted activity for each compound may be in the range between 
0 and 1. Formally, compounds with a predicted activity higher than or equal to 0.5 are 
classified as active and those lower than 0.50 are classified as inactive. Obviously, the closer 
the average predicted value to 1 or 0 is, the higher the concordance among all models is and 
the higher is our confidence in annotating compounds as active or inactive, respectively. 
Thus, two additional thresholds reflecting this concordance among predictions could be 
established as a different type of the model applicability domain: for instance, selecting only 
external compounds with predicted activity above 0.90 or below 0.10 would limit the 
selection of compounds from virtual screening library to a set with higher confidence (but of 
course reduces the total number of compounds in the predicted set). Therefore, CPTs were 
employed in this study to select compounds with high prediction confidence: for instance, 
CPT 0.9/0.1 means: (i) compounds with predicted activity higher than the upper threshold 
(0.9) were classified as actives; (ii) compounds with activity lower than 0.1 were classified as 
inactives; and (iii) compounds with the average predicted activity between the two thresholds 
were not assigned to any class (inconclusive). The inconclusive compounds were not 
included in models‘ prediction accuracy calculation. Two different CPTs were tested in this 
study; CPT1 0.90/0.10 and CPT2 0.50/0.49 to analyze their impacts on models‘ predictivity. 
The percentages of models that were used to make prediction for each compound in 
the virtual screening database were recorded as well. We hypothesize that the higher 
percentage of models that give the same prediction for a compound, the more likely the 
compound actually possesses this predicted activity; the smaller the prediction variance 
across all models, the more confidence we have that the predicted biological activity for this 
compound is accurate. For these reasons, a compound was selected as a hypothetical hit, if 
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and only if (i) it was predicted by at least 50% of the selected models (i.e., it was found 
within the ADs of these models) and (ii) among those models, at least 90% of them predicted 
this compound as active for CPT1 (or at least 50 % of them predicted this compound as 
active for CPT2).  
Experimental Validation in Radiologand Binding Assays 
Final common hit compounds from QSAR-based VS across six receptor families 
were purchased and submitted to PDSP for experimental target validation. The experimental 
details are described in Chapter 2. 
Results and Discussion 
QSAR Modeling for Receptor Subtypes 
kNN-Dragon. kNN-Dragon models (classification and regression models) were 
generated for several receptor subtypes included in Table 3.1. First, a validation set (20% of 
the dataset) was excluded from each datasets randomly. The compounds in the remaining 
modeling set (80% of the original dataset) were divided into multiple training and test sets 
(28-35 divisions) using the Sphere Exclusion method implemented in our laboratory 
(Golbraikh & Tropsha 2002b). Multiple QSAR models were generated independently for all 
training sets and applied to the test sets. We accepted classification models with CCR values 
for both the training and test set greater than 0.70. We also accepted models with q
2 
and R
2
 
values greater than or equal to 0.70. These models were used for the prediction of external 
validation sets. Model statistics (i.e., CCRevs, R
2
) based on external sets are provided in Table 
3.1. Additionally, results of the Y-randomization test confirmed that kNN classification 
models with CCRtrain and CCRtest values above or equal to 0.70 were robust. Additionally, 
regression models with q
2
 and R
2
 above or equal 0.70 were also robust. None of the models 
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with randomized class labels of the training set compounds had CCRrand above 0.54 for any 
dataset, and none of the regression models generated with randomized activities for training 
set activities had R
2
 above 0.50. 
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Table 3.1. QSAR Models for Selected GPCRs 
 
GPCR End Point No. Cps Model Type Accuracy 
5-HT2A  Binder/Non-binder 105/61 Classification CCR=0.94 
5-HT2B  Binder/Non-binder 148/607 Classification CCR=0.74 
5-HT2B  Agonist/Antagonist 33/115 Classification CCR=0.84 
5-HT6  Binder/Non-binder 97/79 Classification CCR=0.92 
5-HT6  Binding affinities 60 Continuous R
2
=0.59 
5-HT7  Binder/Non-binder 72/68 Classification CCR=0.84 
5-HT7  Binding affinities 62 Continuous R
2
=0.60 
Alpha2A  Binding affinities 74 Continuous R
2
=0.67 
Alpha2B  Binding affinities 73 Continuous R
2
=0.62 
Alpha2C  Binding affinities 76 Continuous R
2
=0.65 
D1  Binder/Non-binder 56/44 Classification CCR=0.90 
D2  Binder/Non-binder 56/58 Classification CCR=0.85 
D3  Binder/Non-binder 57/49 Classification CCR=0.88 
D4  Binder/Non-binder 60/51 Classification CCR=0.92 
D5  Binder/Non-binder 51/54 Classification CCR=0.97 
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QSAR Modeling to discriminate Actives vs. Inactives for individual Receptor 
Families  
kNN-Dragon. kNN-Dragon models were generated for the six receptor families 
mentioned earlier. First, a validation set (20% of the dataset) was excluded from each 
datasets randomly. The compounds in the remaining modeling set (80% of the original 
dataset) were divided into multiple training and test sets (24-30 divisions) using the Sphere 
Exclusion method implemented in our laboratory (Golbraikh & Tropsha 2002b). Multiple 
QSAR models were generated independently for all training sets and applied to the test sets. 
We accepted models with CCR values for both the training and test set greater than 0.90. 
These models were used for the prediction of external validation sets. Model statistics based 
on external sets are provided in Table 3.2. Additionally, results of the Y-randomization test 
confirmed that kNN classification models with CCRtrain and CCRtest values above or equal to 
0.70 were robust. None of the models with randomized class labels of the training set 
compounds had CCRrand above 0.54 for any dataset.  
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Table 3.2. Performance of kNN classification methods to classify actives vs. inactives across 
six receptor families based on external validation set statistics. 
Family 
Num. 
 Mod
a
 
Confusion Matrix Statistics for the Models 
N1
 b
 N0
 c
 TP TN FP FN SE SP En1 En0 CCReva
d
 
5-HT 282 17 12 11 11 1 6 0.65 0.92 1.77 1.44 0.78 
Alpha
e
 1126 11 15 9 15 0 2 0.82 1.00 2.00 1.69 0.91 
D
f
 619 12 14 11 13 1 1 0.92 0.93 1.86 1.84 0.92 
H
g
 121 11 11 10 10 1 1 0.91 0.91 1.82 1.82 0.91 
M
h
 297 10 13 8 11 2 2 0.80 0.85 1.68 1.62 0.82 
Sigma 104 8 14 7 12 2 1 0.88 0.86 1.72 1.75 0.87 
a
Num. Mod, number of models with CCRtrain and CCRtest ≥ 0.90 (≥ 0.85 for 5-HT); 
b
N1, 
number of actives; 
c
N0, number of inactives; 
d
CCRevs, correct classification rate of the 
consensus models using the external validation set; 
e
Alpha, adrenergic alpha; 
f
D, dopamine; 
g
H, histamine; 
h
M, muscarinic. 
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SVM-Dragon. Models were built for the six receptor families mentioned earlier. 
First, the dataset was divided into five parts. 80% of the original dataset was used as 
modeling sets and an external set included the remaining 20% of the dataset. The compounds 
in all modeling sets were divided into multiple training and test sets (28-40 divisions) using 
the Sphere Exclusion method (Golbraikh & Tropsha 2002b). Multiple QSAR models were 
generated independently for all training sets and applied to the test sets. We accepted models 
with CCR values for both the training and test set greater than 0.70. Then, we applied the 
accepted models for the prediction of external sets. Model statistics based on external 
validation sets are provided in Tables 3.3-3.8. Additionally, results of the Y-randomization 
test confirmed that kNN classification models with CCRtrain and CCRtest values above or 
equal to 0.70 were robust. None of the models with randomized class labels of the training 
set compounds had CCRrand above 0.50 for any dataset.  
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Table 3.3. Performance of SVM classification methods to classify actives vs. inactives 
across 5-HT receptor family based on external validation set statistics. 
Fold 
Num. 
Mod
a
 
Confusion Matrix Statistics for the Models 
N1
b
 N0
c
 TP TN FP FN SE SP En1 En0 CCRevs
d
 
F1 4 22 7 20 5 2 2 0.91 0.71 1.52 1.77 0.81 
F2 12 16 13 14 11 2 2 0.88 0.85 1.70 1.74 0.86 
F3 75 16 13 15 12 1 1 0.94 0.92 1.85 1.87 0.93 
F4 281 15 13 13 12 1 1 0.87 0.92 1.84 1.87 0.89 
F5 71 16 12 13 12 1 2 0.81 1.00 1.81 1.78 0.91 
Average 0.88 0.88 1.74 1.81 0.88 
a
Num. Mod, number of models with CCRtrain and CCRtest ≥ 0.70; 
b
N1, number of actives; 
c
N0, number of inactives; 
d
CCRevs, correct classification rate of the consensus models using 
the external validation set. 
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Table 3.4. Performance of SVM classification methods to classify actives vs. inactives 
across adrenergic alpha receptor family based on external validation set statistics. 
Fold 
Num. 
Mod
a
 
Confusion Matrix Statistics for the Models 
N1
b
 N0
c
 TP TN FP FN SE SP En1 En0 CCRevs
d
 
F1 463 12 15 12 14 1 0 1.00 0.93 1.88 2.00 0.97 
F2 503 12 14 11 14 0 1 0.92 1.00 2.00 1.85 0.96 
F3 458 10 16 10 13 3 0 1.00 0.81 1.68 2.00 0.91 
F4 445 17 9 17 8 1 0 1.00 0.89 1.80 2.00 0.94 
F5 471 11 15 11 14 1 0 1.00 0.93 1.88 2.00 0.97 
Average 0.98 0.91 1.85 1.97 0.95 
a
Num. Mod, number of models with CCRtrain and CCRtest ≥ 0.70; 
b
N1, number of actives; 
c
N0, number of inactives; 
d
CCRevs, correct classification rate of the consensus models using 
the external validation set. 
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Table 3.5. Performance of SVM classification methods to classify actives vs. inactives 
across dopamine receptor family based on external validation set statistics. 
Fold 
Num. 
Mod
a
 
Confusion Matrix Statistics for the Models 
N1
b
 N0
c
 TP TN FP FN SE SP En1 En0 CCRevs
d
 
F1 336 13 13 12 13 0 1 0.92 1.00 2.00 1.86 0.96 
F2 442 11 15 11 13 2 0 1.00 0.87 1.76 2.00 0.93 
F3 516 12 14 12 14 0 0 1.00 1.00 2.00 2.00 1.00 
F4 407 12 14 10 13 1 2 0.83 0.93 1.84 1.70 0.88 
F5 391 10 16 9 16 0 1 0.90 1.00 2.00 1.82 0.95 
Average 0.93 0.96 1.92 1.87 0.95 
a
Num. Mod, number of models with CCRtrain and CCRtest ≥ 0.70; 
b
N1, number of actives; 
c
N0, number of inactives; 
d
CCRevs, correct classification rate of the consensus models using 
the external validation set. 
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Table 3.6. Performance of SVM classification methods to classify actives vs. inactives 
across histamine receptor family based on external validation set statistics. 
Fold 
Num. 
Mod
a
 
Confusion Matrix Statistics for the Models 
N1
b
 N0
c
 TP TN FP FN SE SP En1 En0 CCRevs
d
 
F1 270 10 13 10 13 0 0 1.00 1.00 2.00 2.00 1.00 
F2 117 13 9 12 9 0 1 0.92 1.00 2.00 1.86 0.96 
F3 131 11 12 9 11 1 2 0.82 0.92 1.82 1.67 0.87 
F4 258 10 12 10 12 0 0 1.00 1.00 2.00 2.00 1.00 
F5 397 14 8 10 7 1 4 0.71 0.88 1.70 1.51 0.79 
Average 0.89 0.96 1.90 1.81 0.92 
a
Num. Mod, number of models with CCRtrain and CCRtest ≥ 0.70; 
b
N1, number of actives; 
c
N0, number of inactives; 
d
CCRevs, correct classification rate of the consensus models using 
the external validation set. 
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Table 3.7. Performance of SVM classification methods to classify actives vs. inactives 
across muscarinic receptor family based on external validation set statistics. 
Fold 
Num. 
Mod
a
 
Confusion Matrix Statistics for the Models 
N1
b
 N0
c
 TP TN FP FN SE SP En1 En0 CCRevs
d
 
F1 205 12 11 10 9 2 2 0.83 0.82 1.64 1.66 0.83 
F2 236 8 15 5 10 5 3 0.63 0.67 1.30 1.28 0.65 
F3 70 6 17 6 15 2 0 1.00 0.88 1.79 2.00 0.94 
F4 332 3 19 3 18 1 0 1.00 0.95 1.90 2.00 0.97 
F5 244 5 17 5 16 1 0 1.00 0.94 1.89 2.00 0.97 
Average 0.89 0.85 1.70 1.79 0.87 
a
Num. Mod, number of models with CCRtrain and CCRtest ≥ 0.70; 
b
N1, number of actives; 
c
N0, number of inactives; 
d
CCRevs, correct classification rate of the consensus models using 
the external validation set. 
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Table 3.8. Performance of SVM classification methods to classify actives vs. inactives 
across Sigma receptor family based on external validation set statistics. 
Fold 
Num. 
Mod
a
 
Confusion Matrix Statistics for the Models 
N1
 b
 N0
 c
 TP TN FP FN SE SP En1 En0 CCRevs
d
 
F1 410 9 14 9 14 0 0 1.00 1.00 2.00 2.00 1.00 
F2 290 9 14 9 13 1 0 1.00 0.93 1.87 2.00 0.96 
F3 362 10 12 9 10 2 1 0.90 0.83 1.69 1.79 0.87 
F4 380 6 16 6 15 1 0 1.00 0.94 1.88 2.00 0.97 
F5 390 10 12 9 12 0 1 0.90 1.00 2.00 1.82 0.95 
Average 0.96 0.94 1.89 1.92 0.95 
a
Num. Mod, number of models with CCRtrain and CCRtest ≥ 0.70; 
b
N1, number of actives; 
c
N0, number of inactives; 
d
CCRevs, correct classification rate of the consensus models using 
the external validation set. 
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Comparison between kNN and SVM Models. The performance of kNN and SVM 
classification models for six receptor families, based on validation set statistics, is 
summarized in Figure 3.1. Both kNN and SVM combined with Dragon descriptors performed 
very well in classifying binders vs. non-binders across six receptor families based on external 
validation set statistics (Tables 3.1-3.8), yielding the highest CCRevs of 0.95 for SVM 
classification models for adrenergic alpha, dopamine and sigma receptor families. Best 
performance for kNN models was for the dopamine receptor family with highest CCRevs of 
0.92 followed by kNN models for the adrenergic alpha and histamine receptor families with 
CCRevs values of 0.91 in both cases.  
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Figure 3.1. Comparison of CCR values for the external validation set (CCRevs) for 
different QSAR models developed to classify binders vs. non-binders across six receptor 
families.  
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Descriptor Analysis 
Mechanistic interpretability is frequently regarded as very important feature of QSAR 
models. We generally argue that only models that have been extensively validated on 
external datasets and identified experimentally-confirmed hits should be subjected to 
interpretation.  Furthermore, very few classes of models, specifically, those based on 
(multiple) linear regression and small number of descriptors can afford a relatively 
straightforward interpretation. The interpretation of multi-parametric statistical models 
developed with non-linear optimization algorithms (as in this study) should be attempted 
with great care because of strong and often poorly understood interplay between descriptors. 
Furthermore, although we could foresee that in some cases medicinal chemists may want to 
modify their candidate compounds to enhance or prevent ligand‘s binding to some receptor 
families of interest, the tools developed in this study are predominantly intended for virtual 
screening of libraries of drug candidates to predict compounds with interesting binding 
profiles and perhaps interesting polypharmacological effects. However, any compound 
designed by chemists could be passed through our models to predict its binding potential 
towards different receptor families.   
It needs to be pointed out that variable selection kNN QSAR optimizes the selection 
of a small number of descriptors to produce an acceptable QSAR model. By default, any 
successful QSAR model captures the correlation between variations in descriptor values and 
those in the target property. Thus, the significant correlation could be achieved with a small 
subset of descriptors. However, some other descriptors may serve as essential determinants 
of the compound pharmacological class but not be included in the model because of their low 
variances across the training set (cf. pharmacophoric groups that by default are the same for 
76 
 
all active compounds). Therefore, if one searches a database with a small number of variables 
selected by QSAR models, a similarity screen of the database using the entire pool of 
descriptors (global similarity) is necessary in addition to model-based activity prediction (i.e., 
so that not to miss any important structural features essential for biological activity).  
We restricted the discussion in this paper to the most frequent descriptors found by all 
acceptable kNN models used for the prediction of external compounds to stress on the fact 
that the process of variable selection employed as part of model optimization has indeed 
converged on a small number of descriptors. From an initial pool of ca. 300 descriptors, only 
a small set of descriptors was selected for the acceptable QSAR models (see Fig. 3.2). 
Clearly, this small set of MFD was different for the different receptor families which is an 
indication that our models were distinct despite the fact that a large portion of the compounds 
contained in the different datasets was similar (i.e., many compounds were promiscuous with 
binding affinities to different receptor families). All details about top twenty MFD selected 
by successful models for all receptor families can be found in Tables 3.9-3.14. 
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Figure 3.2. The heatmap of descriptor frequencies across receptor families analyzed by hierarchical 
clustering of the pairwise similarities in descriptor frequencies using Euclidean distances and 
normalized frequencies of top twenty MFD. The bar-view is a key for coloring according to 
normalized descriptor frequency based on normalized descriptor frequencies where red color 
indicates most frequent descriptors while blue color denotes least frequent or unused descriptors.  
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Table 3.9. Top twenty most frequently used Dragon descriptors in validated kNN-Dragon 
models to classify binders vs. non-binders against the 5-HT receptor family.  
Descriptor Frequency Interpretation Descriptor Category 
N-074 140 R#N / R=N- Atom-centered 
fragments 
C-006 109 CH2RX  Atom-centered 
fragments 
nArOR 102 Number of ethers (aromatic) Functional group counts 
nRNH2 72 Number of primary amines Functional group counts 
C-008 71 CHR2X Atom-centered 
fragments 
nNq 68 Number of quaternary N Functional group counts 
F-084 65 F attached to C1 (sp2) Atom-centered 
fragments 
nRCONR2 55 Number of tertiary amides 
(aliphatic) 
Functional group counts 
JGI3 53 Topological charge index of 
order 3 
Topological charge 
indices 
BELm3  49 Lowest eigenvalue n. 3 of 
Burden matrix 
Burden eigenvalues 
Depressant-
50 
47 Ghose-Viswanadhan-
Wendoloski antidepressant-
like index at 50% 
Molecular properties 
C-028 46 R--CR--X Atom-centered 
fragments 
nOHs 46 Number of secondary 
alcohols 
Functional group counts 
GATS7m 44 Geary autocorrelation - lag 
7/weighted by atomic masses 
2D autocorrelations 
CIC0 44 Complementary information 
content (neighborhood 
symmetry of 0-order) 
Information indices 
H-047 43 H attached to C1(sp3) / 
CO(sp2) 
Atom-centered 
fragments 
C-005 43 CH3X Atom-centered 
fragments 
O-058 42 Corresponds to =O Atom-centered 
fragments 
GATS5e 42 Geary autocorrelation - lag 
5/weighted by atomic 
Sanderson electronegativities 
2D autocorrelations 
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MATS6p 40 Moran autocorrelation - lag 6 
/ weighted by atomic 
polarizabilities 
2D autocorrelations 
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Table 3.10. Top twenty most frequently used Dragon descriptors in validated kNN-Dragon 
models to classify binders vs. non-binders against the adrenergic alpha receptor family.  
Descriptor Frequency Interpretation Descriptor Category 
nN+ 401 Number of positively 
charged N 
Functional group counts 
C-006 358 CH2RX  Atom-centered fragments 
nNq 309 Number of quaternary N Functional group counts 
H-047 257 H attached to C1(sp3) / 
CO(sp2) 
Atom-centered fragments 
T(O..O) 254 Sum of topological distances 
between O..O 
Topological descriptors 
nTB 230 Number of triple bonds Constitutional descriptors 
nDB 217 Number of double bonds Constitutional descriptors 
O-058 215 Corresponds to =O Atom-centered fragments 
nRSR 211 Number of sulfides Functional group counts 
nArNR2 211 Number of tertiary amines Functional group counts 
F-084 205 F attached to C1 (sp2) Atom-centered fragments 
JGI3 191 Topological charge index of 
order 3 
Topological charge 
indices 
nO 175 Number of oxygen atoms Constitutional descriptors 
Depressant-50 173 Ghose-Viswanadhan-
Wendoloski antidepressant-
like index at 50% 
Molecular properties 
BLTF96 166 Verhaar model of fish base-
line toxicity from 
MLOGP(mmol/l) 
Molecular properties 
MLOGP 164 Moriguchi octanol-water 
partition coefficient 
Molecular properties 
MLOGP2 163 Squared Moriguchi octanol-
water partition coefficient 
Molecular properties 
GATS3m 162 Geary autocorrelation - lag 
3/weighted by atomic masses 
2D autocorrelations 
N-071 159 Ar-NAl2 Atom-centered fragments 
ARR 156 Atomic ratio Constitutional descriptors 
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Table 3.11. Top twenty most frequently used Dragon descriptors in validated kNN-Dragon 
models to classify binders vs. non-binders against the dopamine receptor family.  
Descriptor Frequency Interpretation Descriptor Category 
Depressant-50 309 Ghose-Viswanadhan-
Wendoloski antidepressant-
like index at 50% 
Molecular properties 
BELm3 299 Lowest eigenvalue n. 3 of 
Burden matrix 
Burden eigenvalues 
nNq 259 Number of quaternary N Functional group 
counts 
nN+ 247 Number of positively charged 
N 
Functional group 
counts 
nPyrrolidines 246 Number of pyrrolidines Functional group 
counts 
C-006 238 CH2RX  Atom-centered 
fragments 
F-084 221 F attached to C1 (sp2) Atom-centered 
fragments 
O-058 206 Corresponds to =O Atom-centered 
fragments 
nTB 185 Number of triple bonds Constitutional 
descriptors 
C-008 183 CHR2X Atom-centered 
fragments 
H-047 182 H attached to C1(sp3) / 
CO(sp2) 
Atom-centered 
fragments 
TPSA(NO) 172 Topological polar surface area 
using N, O polar contributions 
Molecular properties 
MLOGP2 171 Squared Moriguchi octanol-
water partition coefficient 
Molecular properties 
nArOH 170 Number of ethers (aromatic) Functional group 
counts 
nO 167 Number of oxygen atoms Constitutional 
descriptors 
MATS6e 166 Moran autocorrelation - lag 6 / 
weighted by atomic Sanderson 
electronegativities 
2D autocorrelations 
nIsothiazoles 164 Number of isothiazoles Functional group 
counts 
Hypertens-80 159 Ghose-Viswanadhan-
Wendoloski antihypertensive-
like index at 80% 
Molecular properties 
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T(O..O) 156 Sum of topological distances 
between O..O 
Topological 
descriptors 
nHDon 147 Number of doner atoms for H-
bonds (N and O) 
Functional group 
counts 
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Table 3.12. Top twenty most frequently used Dragon descriptors in validated kNN-Dragon 
models to classify binders vs. non-binders against the histamine receptor family.  
Descriptor Frequency Interpretation Descriptor Category 
nNq 37 Number of quaternary N Functional group 
counts 
Jhetv 31 Balaban-type index from van der 
Waals weighted distance matrix 
Topological 
descriptors 
JGI2 22 Mean topological charge index of 
order 2 
Topological charge 
indices 
IVDE 22 Mean information content on the 
vertex degree equality 
Information indices 
T(N..I) 21 Sum of topological distances 
between N..I. 
Topological 
descriptors 
nPyridines 21 Number of pyridines Functional group 
counts 
MLOGP2 21 Squared Moriguchi octanol-water 
partition coefficient 
Molecular properties 
nTB 20 Number of triple bonds Constitutional 
descriptors 
nN+ 19 Number of positively charged N Functional group 
counts 
S-107 19 R2S / RS-SR Atom-centered 
fragments 
TPSA(NO) 19 Topological polar surface area 
using N, O polar contributions 
Molecular properties 
Hnar 19 Narumi harmonic topological 
index 
Topological 
descriptors 
Hypertens-80 19 Ghose-Viswanadhan-Wendoloski 
antihypertensive-like index at 
80% 
Molecular properties 
MATS6e 18 Moran autocorrelation - lag 6 / 
weighted by atomic Sanderson 
electronegativities 
2D autocorrelations 
GATS7m 18 Geary autocorrelation - lag 
7/weighted by atomic masses 
2D autocorrelations 
F-084 17 F attached to C1 (sp2) Atom-centered 
fragments 
T(N..N) 17 Sum of topological distances 
between N..N. 
Topological 
descriptors 
Mv 17 Mean atomic van der Waals 
volume (scaled on carbon atom) 
Constitutional 
descriptors 
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nRSR 17 Number of sulfides Functional group 
counts 
JGI3 17 Topological charge index of order 
3 
Topological charge 
indices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
Table 3.13. Top twenty most frequently used Dragon descriptors in validated kNN-Dragon 
models to classify binders vs. non-binders against the muscarinic receptor family.  
Descriptor Frequency Interpretation Descriptor Category 
nO 111 Number of oxygen atoms Constitutional 
descriptors 
nArOH 84 Number of ethers (aromatic) Functional group 
counts 
GATS8v 66 Geary autocorrelation - lag 
8/weighted by atomic van der 
Waals volumes 
2D autocorrelations 
nNq 58 Number of quaternary N Functional group 
counts 
C-006 51 CH2RX  Atom-centered 
fragments 
BLTD48 51 Verhaar model of Daphnia base-
line toxicity from MLOGP 
(mmol/l) 
Molecular properties 
nR11 50 Number of 11-memebered rings Constitutional 
descriptors 
nCrs 49 Number of ring secondary C(sp3) Functional group 
counts 
T(O..O) 47 Sum of topological distances 
between O..O 
Topological 
descriptors 
C-008 45 CHR2X Atom-centered 
fragments 
Psychotic-80 44 Ghose-Viswanadhan-Wendoloski 
antipsychotic-like index at 80% 
Molecular properties 
nN(CO)2 44 Number of imides (-thio) Functional group 
counts 
MATS1p 43 Moran autocorrelation - lag 1 / 
weighted by atomic polarizabilities 
2D autocorrelations 
O-062 42 O- (negatively charged) Atom-centered 
fragments 
O-060 41 Al-O-Ar / Ar-O-Ar / R..O..R / R-
O-C=X 
Atom-centered 
fragments 
D/Dr09 40 distance detour ring index of order 
9 
Topological 
descriptors 
GATS4m 40 Geary autocorrelation - lag 
4/weighted by atomic masses 
2D autocorrelations 
nN+ 40 Number of positively charged N Functional group 
counts 
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GATS1v 39 Geary autocorrelation - lag 
1/weighted by atomic van der 
Waals volumes 
2D autocorrelations 
H-047 39 H attached to C1(sp3) / CO(sp2) Atom-centered 
fragments 
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Table 3.14. Top twenty most frequently used Dragon descriptors in validated kNN-Dragon 
models to classify binders vs. non-binders against the sigma receptor family.  
Descriptor Frequency Interpretation Descriptor Category 
Depressant-50 68 Ghose-Viswanadhan-
Wendoloski antidepressant-like 
index at 50% 
Molecular properties 
nO 35 Number of oxygen atoms Constitutional 
descriptors 
C-006 28 CH2RX  Atom-centered 
fragments 
TPSA(NO) 26 Topological polar surface area 
using N, O polar contributions 
Molecular properties 
RBN 23 Number of rotatable bonds Constitutional 
descriptors 
nH 21 Number of hydrogen atoms Constitutional 
descriptors 
C-008 21 CHR2X Atom-centered 
fragments 
C-020 20  =CX2 Atom-centered 
fragments 
BLI 20 Kier benzene-likeliness index Topological descriptors 
nNq 20 Number of quaternary N Functional group 
counts 
F-084 19 F attached to C1 (sp2) Atom-centered 
fragments 
MATS7e 16 Moran autocorrelation - lag 7 / 
weighted by atomic Sanderson 
electronegativities 
2D autocorrelations 
CIC1 16 Complementary information 
content (neighborhood 
symmetry of 1-order) 
Information indices 
MSD 15 Mean square distance index 
(Balaban) 
Topological descriptors 
EEig13d 15 Eigenvalue 13 from edge adj. 
matrix weighted by dipole 
moments 
Edge adjacency indices 
H-052 15 H attached to CO(sp3) with 1X 
attached to next C 
Atom-centered 
fragments 
C-040 14 R-C(=X)-X / R-C#X / X=C=X Atom-centered 
fragments 
GATS5m 14 Geary autocorrelation - lag 
5/weighted by atomic masses 
2D autocorrelations 
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GATS8m 14 Geary autocorrelation - lag 
8/weighted by atomic masses 
2D autocorrelations 
T(F..F) 14 Sum of topological distances 
between F..F. 
Topological descriptors 
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We were also able to identify several common MFD across almost all six receptor 
families. These descriptors included: nN+, the number of positively charged nitrogen atoms 
(functional group counts); C-006, CH2RX (atom centered fragments); nNq, number of 
quaternary nitrogens (functional group counts); T(O..O), sum of topological distances 
between O..O (Topological descriptors); nO, number of oxygen atoms (constitutional 
descriptors); O-058, corresponds to =O (atom centered fragments); MLOGP, Moriguchi 
octanol-water partition coefficient (molecular properties). See Tables 3.9-3.14 for further 
details.  
Virtual Screening and Experimental Validation 
Our primary aim from generating family-based models is to provide a fast, large scale 
system that allows for virtual activity profiling across receptor families to predict 
polypharmacology profiles and consequently establish virtual biological networks. Since our 
models proved to be reasonably accurate based on external validation set statistics, we used 
the best models to mine a large external database of approved and potential drugs for putative 
binders to six receptor families. An important condition that assures reliable predictions by 
the model is the use of AD. Therefore, two types of AD were employed in the virtual 
screening of compound databases. The first is a local AD which is defined for each of the 
individual classification models and using a z threshold of 0.5. The second is a global AD 
that acts as a filter and ensures some level of global similarity between the predicted 
compounds and the compounds in the modeling set. Herein, we kept the latter AD as an 
optional filter because we wanted to explore a larger and more diverse set of compound.  
In an attempt to identify putative binders across all six receptor families (5-HT, 
adrenergic alpha, dopamine, histamine, muscarinic and sigma), validated consensus kNN and 
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SVM models for six different receptor families were used for virtual screening of 59000 and 
4678 molecules within the WDI and DrugBank chemical libraries subsequently. Refer to 
scheme 1 for steps of VS process. 
Eleven structurally diverse hits (1-11, see Table 3.15) were selected from the final 
consensus virtual screening hits of the WDI for further experimental validation taking into 
account both their commercial availability and cost. We also took into account that these 
eleven hits were predicted as binders for almost all receptor families. All eleven hits were 
tested at the PDSP in radioligand binding assays across all receptor subtypes of the six 
receptor families mentioned above. See Table 3.16 for details. 
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Table 3.15. Eleven VS hits selected from WDI Chemical library. 
Cp. 
ID 
Structure/Name PDSP 
ID 
Therapeutic Class/Use 
1 
 
Bephenium 
14816 
 
Anthelmintic 
2 
 
Clidinium 
14817 
 
An anticholinergic drug. 
3 
Clomifene 
13499 
 
SERM 
4 
Fendiline 
 
14821 
 
Calcium channel blocker 
5 
Fluspirilene 
14815 
 
Antipsychotic 
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6 
 
 
Lobeline 
14824 
 
VMAT2 ligand, it also inhibits the 
reuptake of dopamine and 
serotonin, acts as a mixed agonist-
antagonist at nicotinic 
acetylcholine receptors, and an 
antagonist at μ-opioid receptors.[ 
7 
 
LY-294002 
14825 
 
Morpholino derivative of 
quercetin . It is a potent inhibitor 
of phosphoinositide 3-kinase s 
(PI3Ks) 
8 
Prestwick-559 
14814 
 
Drug used in scientific research 
which acts as a moderately 
selective dopamine D3 receptor 
partial agonist. 
9 
Raloxifene 
13505 
 
SERM 
10 
Tamoxifen  
13506 
678 
10572 
SERM 
11 
Toremifene 
16514 
 
SERM 
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Table 3.16.  Experimental validation results for the 11 computational hits predicted to be 
ligands to six families of receptors as a result of QSAR-based mining of the WDI chemical 
screening library (see text for abbreviations). 
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Compound 
5-HT Adrenergic Dopamine 
kNN 
CS 
SVM 
CS 
Exp. kNN 
CS 
SVM 
CS 
Exp. kNN 
CS 
SVM 
CS 
Exp. 
Bephenium 0.94 1.00 NB 0.93 0.96 B 0.87 0.99 B 
Clidinium 0.84 0.88 NB 0.94 0.94 NB 0.71 0.69 NB 
Clomiphene 0.97 0.98 B 0.95 1.00 B 0.96 0.94 B 
Fendiline 0.86 0.95 B 0.93 0.99 B 0.87 0.98 B 
Fluspirilene 0.96 0.98 B 0.99 1.00 B 0.94 0.87 B 
Lobeline 0.73 0.98 B 0.88 1.00 B 0.75 0.94 B 
LY-294002 0.79 1.00 B 0.69 0.99 NB 0.64 0.91 NB 
Prestwick-559 0.97 1.00 B 1.00 1.00 B 0.84 1.00 B 
Raloxifene 0.90 1.00 B 0.90 1.00 B 0.87 0.98 B 
Tamoxifen 0.99 1.00 B 0.95 1.00 B 0.99 1.00 B 
Toremifene 0.99 1.00 B 0.96 1.00 B 0.98 1.00 B 
kNN Accuracy1
a
 
 
82% 
  
82% 
  
82% 
 kNN Accuracy2
b
 
 
86% 
  
88% 
  
100% 
 SVM Accuracy1
c
 
 
82% 
  
82% 
  
82% 
 SVM Accuracy2
d
 
 
90% 
  
82% 
  
91% 
 
Compound 
Histamine Muscarinic Sigma 
kNN 
CS 
SVM 
CS 
Exp. kNN 
CS 
SVM 
CS 
Exp. kNN 
CS 
SVM 
CS 
Exp. 
Bephenium 0.94 0.99 NB 0.48 0.98 NB 0.84 0.99 B 
Clidinium 0.77 0.84 B 0.14 0.82 B 0.72 0.78 B 
Clomiphene 0.92 0.97 B 0.81 0.97 B 0.95 0.96 B 
Fendiline 0.95 0.97 B 0.69 0.98 B 0.85 0.98 B 
Fluspirilene 0.93 0.95 B 0.84 0.94 B 1.00 0.92 B 
Lobeline 0.97 0.97 B 0.46 0.97 B 0.71 0.96 B 
LY-294002 0.64 0.97 NB 0.34 0.96 NB 0.74 0.95 NB 
Prestwick-559 0.97 1.00 B 0.66 1.00 B 1.00 1.00 B 
Raloxifene 0.89 0.99 B 0.52 0.99 B 0.86 0.99 B 
Tamoxifen 0.94 1.00 B 0.75 1.00 NB 0.90 1.00 B 
Toremifene 0.93 1.00 B 0.77 1.00 B 0.95 1.00 B 
kNN Accuracy1 
 
82% 
  
72% 
  
91% 
 kNN Accuracy2 
 
88% 
  
100% 
  
100% 
 SVM Accuracy1 
 
82% 
  
72% 
  
91% 
 SVM Accuracy2 
 
82% 
  
72% 
  
91% 
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a
kNN Accuracy1, accuracy of consensus kNN models at a CPT of 0.51/0.49; 
b
kNN 
Accuracy2, accuracy of consensus kNN models at a CPT of 0.90/0.10; 
c
SVM Accuracy1, 
accuracy of consensus SVM models at a CPT of 0.51/0.49; 
d
SVM Accuracy2, accuracy of 
consensus SVM models at a CPT of 0.90/0.10. 
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Experimental validation results indicated that both kNN and SVM combined with 
Dragon descriptors performed very well on almost all compounds and across all receptor 
family models with predictions accuracies ranging from 82% to 100%. In case of 5-HT 
family models both kNN and SVM achieved overall prediction accuracies of 82% and 86 % 
applying CPTs of 0.51/0.49 and 0.90/0.10 consecutively. Similarly, the prediction accuracy 
of adrenergic alpha models was 82% for both kNN and SVM with a CPT of 0.50/0.49, while 
applying a CPT of 0.90/0.10 increased the accuracy of kNN predictions up to 88% (SVM 
prediction accuracy remained unchanged). Generally, applying a strict CPT of 0.90/0.10 
improved the prediction accuracy of our models especially in case of kNN models. See Table 
14 for comparison between model predictions and experimental validation results for all 
eleven VS hits across the six receptor families. 
Biological Relevance 
In addition to using the models for virtual screening to prioritize hits for further 
experimental validation (see section about virtual screening and experimental validation), we 
predicted a full polyphamacology matrix for 46079 compounds in the WDI database (see Fig. 
3.3). Accumulating such matrices using different computational tools developed by all many 
computational groups and making them publicly available, will shape the future of in silico 
receptoromics; we can compare the binding/activity potential for a compound against a 
specific receptor or receptor family by comparing all predictions for this compound across a 
multitude of computational tools. A consensus prediction generated from all these predictors 
is more likely to hold the accurate answer/prediction. 
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Figure 3.5. The heatmap of kNN CS for 46079 compounds in the WDI across six receptor 
families analyzed by hierarchical clustering of the pairwise similarities in descriptor frequencies using 
Euclidean distances and CSs. The bar-view is a key for coloring according to CS where red color 
indicates CS greater than 0.50 (i.e., binders/actives) while blue color denotes least CS < 0.50 (i.e., 
non-binders/inactives). 
 
 
  
98 
 
Conclusions 
QSAR models are becoming increasingly attractive as robust computational tools for virtual 
screening due to both their computational efficiency and success rates [reviewed in (Tropsha & 
Golbraikh 2007) as well as in a recent monograph (Varnek & Tropsha 2008). In this study, we have 
developed internally validated and externally predictive QSAR models for the classification 
of compounds into binders and non-binders across six different receptor families (5-HT, 
adrenergic alpha, dopaminergic, histamine, muscarinic, and sigma). We have shown that by 
using the kNN and SVM modeling strategies (combined with Dragon descriptors) as well as 
CPTs, it is possible to develop QSAR models with high external prediction accuracy.  
The analysis of most frequent descriptors selected by QSAR models helps interpret 
the binding affinity to different receptor families in terms of chemical features. For example, 
we found that some functional group descriptors were frequently used in accepted kNN-
Dragon models across almost all six receptor families, suggesting they may play a critical 
role in defining binding affinities of organic compounds to biogenic amine GPCRs and sigma 
receptors. These descriptors included: the number of positively charged nitrogen atoms, the 
number of quaternary nitrogens, the sum of topological distances between O..O, the number 
of oxygen atoms (constitutional descriptors); and octanol-water partition coefficients.  
Encouraged by our model validation results, we have applied these models for virtual 
screening of the 59000 compounds in WDI database and 4678 compounds in DrugBank. 
Eleven structurally diverse VS hits were prioritized and experimentally tested at PDSP in 
radioligand binding assays. Nine compounds were found to bind to at least one receptor 
subtype among the predicted families with binding affinities between 0.6 - 9000 nM. Thus, 
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these models will be highly valuable to assess the potential of chemicals to bind several 
families of GPCRs in an effort to predict interesting polypharmacological profiles. 
These predictors will be made publicly available at the ChemBench server established 
in the Laboratory for Molecular Modeling (chembench.mml.unc.edu).   
 
  
CHAPTER 4 
THE DEVELOPMENT, VALIDATION, AND USE OF QUANTITATIVE 
STRUCTURE ACTIVITY RELATIONSHIP MODELS OF 5-
HYDROXYTRYPTAMINE (2B) RECEPTOR LIGANDS TO IDENTIFY NOVEL 
RECEPTOR BINDERS AND PUTATIVE VALVULOPATHIC COMPOUNDS 
AMONG COMMON DRUGS 
Introduction 
During the last decade, several drugs have been shown to cause cardiac valvulopathy 
in humans. The initial discovery of drug-induced valvulopathy occurred when the anorectic 
drug fenfluramine (approved by the FDA in 1973), one of the active ingredients of the 
anorectic drug combination fen-phen, was found to increase the risk of developing two 
potentially serious conditions, pulmonary hypertension and valvular heart disease (VHD), in 
individuals receiving these medications to treat obesity (Connolly et al. 1997). More recently, 
a group at the Mayo Clinic reported VHD in patients taking the anti-Parkinson drug 
pergolide (Pritchett et al. 2002). After the initial 2002 report, other cases of VHD associated 
with pergolide or other dopamine agonists such as cabergoline used as anti-parkinsonian 
drugs were identified (Peralta et al. 2006, Yamamoto et al. 2006, Yamamoto & Uesugi 
2007). In January of 2007, the New England Journal of Medicine published two large 
European studies that independently verified the association of VHD with pergolide and 
carbergoline (Schade et al. 2007, Zanettini et al. 2007). Finally, on March 29, 2007, the Food 
and Drug Administration issued a Public Health Advisory for the voluntary market 
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withdrawal of pergolide. These stunning withdrawals of drugs from the market 
stressed the importance of elucidating the mechanism by which these drugs induce 
valvulopathy and of determining the valvulopathic risk that may be associated with new drug 
candidates or even existing drugs. 
To date, all but two of the VHD-associated drugs are ergoline derivatives 
(dihydroergotamine, methysergide, pergolide and carbergoline) (see Table 1). The two non-
ergoline VHD-associated drugs are fenfluramine (Connolly et al. 1997) and 3,4-
methylenedioxymethamphetamine (MDMA, ecstasy) (Droogmans et al. 2007, Setola et al. 
2003), both of which are amphetamine analogues (see Table 4.1). Thus, it appears that 
compounds from both the ergoline and phenylisopropylamine families can produce VHD 
(Setola & Roth 2008).  
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Table 4.1. Chemical structures of marketed drugs known as 5-HT2B receptor agonists and 
associated with VHD. 
Compound Structure 
Name 
PubChem 
CID 
5-HT2B 
Agonist VHD 
 
Carbergoline  
54746 
Yes Yes 
 
Dihydroergota
mine 10531 
Yes Yes 
 
Fenfluramine 
3337 
Yes Yes 
 
MDA  
1614 
Yes ??
a
 
 
MDMA  
1615 
Yes Yes 
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Methylergonov
ine  
8226 
Yes Yes 
 
Pergolide  
47811 
Yes Yes 
a
Unknown. 
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There is increasing evidence that activation of serotonin 2B receptors (5-HT2B) may 
play a significant role in the pathogenesis of drug-induced valvulopathy (Rothman et al. 
2000, Roth 2007, Berger et al. 2009). For instance, VHD-associated drugs such as 
fenfluramine (Setola & Roth 2005), ergotamine (Setola & Roth 2005), pergolide (Newman-
Tancredi et al. 2002, Setola et al. 2003) and cabergoline, and/or selected active metabolites 
(such as norfenfluramine and methylergonovine) (Setola & Roth 2005), all potently activate 
5-HT2B receptors. Chemically similar medications that do not activate 5-HT2B receptors (e.g., 
lisuride) seemingly do not cause valvular heart disease, further implicating the 5-HT2B 
receptor—but not other receptors that bind ergopeptines/ergolines and phenylisoproylamines 
with high affinity—in the pathogenesis of heart-valve disease (Roth 2007).  
Additionally, valvulopathy-associated drugs have been shown to induce DNA 
synthesis in
 
cultured interstitial cells from human cardiac valves via 5-HT2B receptor 
activation (Setola et al. 2003). It has been suggested that the valvulopathy
 
induced by 5-HT2B 
receptor agonists is caused by the inappropriate mitogenic
 
stimulation of normally quiescent 
valve cells, resulting in
 
an overgrowth valvulopathy (Roth 2007, Setola et al. 2003). 
Although the precise signaling pathways underlying drug-induced valvulopathy remain 
elusive, 5-HT2B receptors are known to activate mitogenic pathways through the
 
phosphorylation of Src kinase and extracellular regulated kinases
 
(ERK), as well as through 
receptor tyrosine kinase transactivation (Nebigil et al. 2000a, Nebigil et al. 2000b), consistent 
with a role in regulating heart valve interstitial cell proliferation.  
The discoveries that 5-HT2B receptors were (1) abundantly expressed in heart valves 
(Fitzgerald et al. 2000), (2) activated by fenfluramine and its metabolite, norfenfluramine 
(Fitzgerald et al. 2000, Rothman et al. 2000), and (3) activated by other valvulopathy-
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inducing drugs (Rothman et al. 2000, Setola et al. 2003) suggested that 5-HT2B receptors 
were involved in the etiology of valvulopathy (Fitzgerald et al. 2000, Rothman et al. 2000). 
Subsequently, several other 5-HT2B agonists were also found to be valvulopathogenic (Setola 
et al. 2003). Since 5-HT2B agonists have the potential of causing valvulopathic side-effects, it 
has been suggested that all pharmaceuticals should be screened for activity at 5-HT2B 
receptors prior to further commercial development (Levy 2006, Roth 2007).  
Similar to experimental high throughput screening (HTS), virtual screening (VS) is 
typically employed as a ‗hit‘ identification tool (Stahura & Bajorath 2004). The experimental 
screening of all molecules against all biological targets is generally cost- and time-
prohibitive. Therefore, pre-selection of compounds by VS that have a reasonable probability 
to act against a given biological target is highly attractive. Typically, VS approaches imply 
the use of structure based methodologies; nevertheless, we have repeatedly advocated for the 
use of ligand based cheminformatics approaches such as QSAR models in virtual screening 
(reviewed in a recent monograph (Varnek & Tropsha 2008)).  
Herein, we report on the development of in silico screening tools for identifying 
compounds with potentially serious valvulopathic side effects. These tools can be employed 
as filters to flag and de-select the potentially harmful compounds at the preclinical stage of 
drug development, thereby potentially avoiding significant economic and human health 
consequences incurred at later stages of drug discovery. To achieve this goal, validated and 
externally predictive, binary QSAR models were generated for 5-HT2B active vs. inactive 
compounds as defined in 5-HT2B functional assays. Similar studies to develop QSAR models 
for 5-HT2B actives vs. inactives were reported recently by Chekmarev et al (Chekmarev et al. 
2008). However, in our investigations we considered a larger dataset that contained the most 
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complete set of all known valvulopathogens reported by Huang et al (Huang et al. 2009) and 
we validated our predictions experimentally in binding assays.  
To obtain the most statistically robust and predictive models, we have employed the 
combinatorial QSAR strategy (de Cerqueira et al. 2006, Kovatcheva et al. 2004) 
implemented as part of our predictive QSAR modeling workflow (reviewed in Tropsha and 
Golbraikh (Tropsha & Golbraikh 2007)). All models were subjected to rigorous internal and 
external validation. The results confirmed the high external prediction accuracy of our 
computational models, which led us to conclude that these models can be used reliably to 
screen chemical databases to identify putative 5-HT2B actives. Screening the WDI database 
using these models led to the identification of 122 possible 5-HT2B actives; 10 of these 
computational hit compounds were experimentally tested in 5-HT2B radioligand binding 
assays at the NIMH Psychoactive Drug Screening Program (PDSP), UNC Chapel Hill 
(http://pdsp.med.unc.edu/). Experiments confirmed that 9 out of 10 compounds were true 
actives implying a hit rate of 90%. These results indicate the reliability of our computational 
models as efficient predictors of compounds‘ affinity towards 5-HT2B receptors. We suggest 
that the computational models developed in this study could be used as drug liability 
predictors similar to commonly used predictors (Mohan et al. 2007, Simon-Hettich et al. 
2006) of other undesired side effects such as carcinogenicity (Benfenati et al. 2009, Ruiz et 
al. 2008, Venkatapathy et al. 2009), mutagenicity (Benfenati et al. 2009, Papa et al. 2008, 
Zhang et al. 2008b), PGP binding (de Cerqueira et al. 2006), or hERG binding (Ekins et al. 
2002, Garg et al. 2008, Seierstad & Agrafiotis 2006, Yoshida & Niwa 2006). Our models can 
be used to flag compounds that are expected to bind to 5-HT2B receptors but they cannot 
distinguish agonists from antagonists.  Nevertheless, as demonstrated in this study, these 
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putative 5-HT2B binders can be tested in functional assays for their potential to activate 5-
HT2B receptors to further assess their valvulopathic potential.   
Materials and Methods 
Dataset 
 The PDSP recently screened roughly 2200 FDA-approved drugs and investigational, 
drug-like molecules against 5-HT2B receptors(Huang et al. 2009). However, this modeling 
study was initiated prior to the completion of the screening of the entire compound library. 
At the time this study began, screening against 5-HT2B receptors had been completed for 800 
compounds. This set became the basis for our model development. After preprocessing of the 
800-compound dataset and deleting duplicates, the final dataset consisted of a class of 146 
‗actives‘, and another class of 608 ‗inactives‘. Detailed PDSP protocols are available online 
(http://pdsp.med.unc.edu/) and in Huang et al (Huang et al. 2009). All chemical structures 
were obtained from PubChem (PubChem 2009) as SDF files. By the time our modeling 
studies were completed, functional data for the remainder of the 2200 compounds (1400 
compounds) had become available. These ‗new‘ data became a source for additional, 
independent validation sets.  
 
Preprocessing of the Dataset 
 For the purposes of this work, the data were curated as follows:  First, all molecules 
were ―washed‖ using the Wash Molecules tool in MOE (MOE 2008) (v.2007.09). Using this 
tool, we processed chemical structures by carrying out several standard operations including 
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2D depiction layout, hydrogen correction, salt and solvent removal, chirality and bond type 
normalization (all details are found in the MOE manual (MOE 2008)). Second, we used 
ChemAxon Standardizer (ChemAxon JChem 2010) to harmonize the representation of 
aromatic rings. Finally, the analysis of the normalized molecular structures resulted in 
detection of 46 duplicate compounds (i.e., different salts or isomeric states). The functional 
data for duplicated compounds were found to be identical, so in each case a single example 
was removed. The curated subset of the original 5-HT2B dataset used in this work contains 
754 unique organic compounds (146 actives and 608 inactives). All details about the dataset 
are available in Supporting Information. 
Dataset Division for Model Building and Validation 
All QSAR models generated in this study to classify actives vs. inactives were 
validated by predicting two external validation sets. Each dataset employed in QSAR studies 
was first randomly divided into a modeling and a validation sets. Additionally, as described 
above, an independent validation set became available after we completed our modeling 
studies. Details about this external set are available in Supporting Information, and in Huang 
et al (Huang et al. 2009).  
Another level of internal validation was achieved by comparing model performance 
for training and test sets. This approach is always employed as a part of our predictive QSAR 
modeling workflow (Tropsha 2010) to emphasize the fact that training-set-only modeling is 
not sufficient to obtain reliable models that are externally predictive (Golbraikh & Tropsha 
2002a). Thus, for each collection of descriptors, the modeling sets were further partitioned 
into multiple chemically diverse training and test sets of different sizes using the Sphere 
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Exclusion method implemented in our laboratory (Golbraikh & Tropsha 2002b). Only 
models that were highly predictive on the test sets were retained for the consensus prediction 
of the external validation sets. Finally, only those models that were shown to be highly 
predictive on both external sets were used in consensus fashion for virtual screening of 
external compound libraries. 
Computational Methods 
A combinatorial QSAR approach (Combi-QSAR) (de Cerqueira et al. 2006, 
Kovatcheva et al. 2004) was used to generate classification models for actives vs. inactives 
(Fig. 4.1). In this study, four types of descriptors were applied in combination with three 
types of statistical methods.  
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Figure 4.1. The workflow for QSAR model building and validation as applied to the 5-HT2B 
dataset (see text for abbreviations). 
 
 
  
111 
 
Molecular Descriptors 
Four sets of molecular descriptors were considered in our modeling studies: Dragon 
(Dragon 2007), MZ (MolconnZ 2006), MOE (MOE 2008), and SG descriptors (Khashan et 
al. 2005) developed in this laboratory. Each type of these descriptors was used separately 
with each of the classification methods in the context of our Combi-QSAR strategy. All 
details about descriptors are mentioned in Chapter 2. 
Balancing the Dataset Using Similarity Searching 
The dataset used for model building was imbalanced, consisting of 146 actives vs. 
608 inactives. Therefore, only a subset of the larger class of inactives of approximately the 
same size as the actives was used in model building unless otherwise indicated. This subset 
was selected to include inactives that were most similar to the actives. Given the vast array of 
available chemical descriptors and the large number of similarity measures, it is always 
difficult to decide a priori which combination of descriptors/similarity metrics to use. This 
problem has been highlighted in several recent publications (Holliday et al. 2002, Sheridan & 
Kearsley 2002). Therefore, similarity searching studies were performed using three types of 
molecular descriptors: fingerprints (FP), Dragon, and MZ, and applying two similarity 
metrics, i.e., Euclidean distance and Tanimoto coefficient (Tc). The similarity cutoff was 
chosen to obtain the most balanced (with roughly equal number of compounds from each 
class) subset of compounds.  
Fingerprints. 166 MACCS (MDL Ltd 1992) structural keys implemented in MOE 
2007.09 software were calculated for all compounds. The similarity searching was performed 
using an in-house written script applying Tanimoto coefficients for similarity measures.  
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Dragon Descriptors. Normalized Dragon descriptors of the original dataset were 
employed to calculate similarities between all compounds in the dataset using Euclidean 
distance as similarity metric; variable similarity thresholds were used to down-sample the 
larger class (inactives). Although many schemes could be considered for down-sampling the 
larger classes, we used the similarity threshold based approach since it restricts the larger 
class to compounds most similar to the smaller class molecules. This approach makes it more 
challenging to develop statistically significant models capable of discriminating smaller class 
compounds from most chemically similar molecules in the larger class. Therefore, it 
increases the robustness of the binary QSAR models.  
MolConnZ Descriptors. Similar procedures to those described above for Dragon 
descriptors were used. 
QSAR Methods 
We used the kNN classification method (Zheng & Tropsha 2000), CBA (Liu et al. 
1998, Liu et al. 1999), and DWD (Marron et al. 2007)  . All details about these methods are 
discussed in Chapter 2. 
Robustness of QSAR Models 
Y-randomization test is a widely used validation technique to ensure the robustness of 
a QSAR model (Wold & Eriksson 1995). This test includes (i) randomly shuffling the 
dependent-variable vector, Y-vector of training sets (class labels in this study) and (ii) 
rebuilding models with the randomized activities (class labels) of the training set. All 
calculations are repeated several times using the original independent-variable matrix. It is 
expected that the resulting QSAR classification models, built with randomized activities for 
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the training set, should generally have low CCRs for training, test, and external validation 
sets. It is likely that sometimes, though infrequently, high CCR values may be obtained due 
to a chance correlation or structural redundancy of the training set. However, if some QSAR 
classification models obtained in the Y-randomization test have relatively high CCR it 
implies that an acceptable QSAR classification model cannot be obtained for the given 
dataset by the particular modeling method. Y-randomization test was applied to all datasets 
considered in this study, and the test was repeated five times in each case. 
Applicability Domains of kNN QSAR Models  
Formally, a QSAR model can predict the target property for any compound for which 
chemical descriptors can be calculated. However, since the training set models are developed 
in kNN QSAR modeling by interpolating activities of the nearest neighbor compounds, a 
special applicability domain (i.e., similarity threshold) should be introduced to avoid making 
predictions for compounds that differ substantially from the training set molecules (Shen et 
al. 2004).  
The similarity was estimated using Euclidean distances in high-dimensional 
descriptors space. Compounds with the smallest distance between them have the highest 
similarity. The distribution of distances (pairwise similarities) of compounds in our training 
set is computed to produce an applicability domain threshold, DT, calculated as in Equation 
2.9. 
In this study two types of applicability domains were employed. First, a global 
applicability domain that ensures some level of global similarity (using all descriptors for 
similarity calculations) between the predicted compounds and the compounds in the 
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modeling set. The second is a local domain which is the applicability domain of each of the 
individual models using only descriptors used for the model building.  
Consensus Prediction 
Our experience suggests that consensus prediction of the target property for external 
compounds, i.e., when the compound activity is calculated by averaging values predicted by 
all individual models that satisfy our acceptability criteria always provides the most stable 
and accurate solution (Zhu et al. 2008a). In general, consensus prediction implies averaging 
the predictions for each compound by majority voting for classification QSAR models, using 
all models passing the validation criteria (e.g., CCRtrain ≥ 0.70 and CCRtest ≥ 0.70). In order to 
determine the confidence in the obtained predictions we need to define a consensus score. 
The consensus scores employed in this study take into account the total number of models 
used to predict the compound‘s activity, and the number of models that predicted the 
compound to belong to a specific class. Since we define two classes of compounds, i.e., class 
1 (actives) and class 0 (inactives), some models may predict a compound to belong to class 0 
and others may predict it to belong to class 1. As a result, a consensus score between 0 and 1 
will be obtained for each of the predicted compounds. As an additional measure of 
confidence (and an additional applicability domain criterion) we only accepted those 
predictions that had an average predicted value (consensus score) above 0.70 (for actives) or 
below 0.30 (for inactives).  
Virtual Screening and Compound Selection for Experimental Validation  
To identify putative actives, validated consensus models generated for 5-HT2B ligands 
were used for virtual screening of ca. 59,000 molecules within the WDI(Daylight 2004) 
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chemical library; the selection of hits was limited by the applicability domains of each 
models. 122 compounds were identified as VS hits (by consensus agreement between all 
accepted models, see Table S1 of Supporting Information for details) and 10 structurally 
diverse and commercially available hits were purchased from different suppliers and tested at 
PDSP in 5-HT2B radioligand binding assays.  
Results and Discussion 
Combinatorial QSAR Modeling of 5-HT2B Actives vs. Inactives 
Balancing the Dataset. The original dataset of 146 actives and 608 inactives was 
first balanced by downsizing the class of inactives. Similarity searching between active and 
inactive compounds using Tc cutoff of 0.7 resulted in 195 inactives (that were similar to at 
least one active compound with Tc above 0.7), which were combined with the 146 actives to 
form the modeling set of 342 compounds. Dragon and MZ descriptors were generated for 
this 342-compound modeling set to be used separately with kNN. However, similarity 
searching using Dragon and MZ descriptors and applying Euclidean distance-based threshold 
resulted in a 304- (146 actives and 158 inactives) and 325-compound (146 actives and 179 
inactives) modeling sets respectively. Thus, slightly different modeling sets were used 
depending on the type of descriptors. 
kNN Classification. kNN method was used with each of the following descriptor 
types: DRAGON, MZ, MOE, and SG descriptors. Models were built for the three datasets 
resulting from the down-sampling of the original dataset. First, a validation set (15-20% of 
the dataset) was excluded from each of the resulting datasets randomly. The compounds in 
the remaining modeling set (85-80% of the original dataset) were divided into multiple 
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training and test sets (28-40 divisions). Multiple QSAR models were generated 
independently for all training sets and applied to the test sets. Generally, we accepted models 
with CCR values for both the training and test set greater than 0.70. kNN combined with 
subgraphs and Dragon descriptors were the two best performing methods based on validation 
set statistics (Table 4.2). kNN-subgraphs (kNN-SG) had a CCRevs = 0.80, while kNN-Dragon 
gave a CCRevs = 0.72.  
Results of the Y-randomization test confirmed that kNN classification models with 
CCRtrain and CCRtest values  0.70 were robust. None of the models with randomized class 
labels of the training set compounds had CCRrand > 0.54 for any dataset.  
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Table 4.2. Performance of kNN classification methods to classify actives vs. inactives based 
on external validation set statistics. 
Model 
Num. 
Mod
a
 
Confusion Matrix Statistics for the Models 
N1
b
 N0
c
 TP TN FP FN SE SP En1 En0 CCRevs
d
 
A
f
 908 26 34 20 23 11 6 0.77 0.68 1.41 1.49 0.72 
B
g
 235 38 36 22 20 16 16 0.58 0.56 1.13 1.14 0.57 
C
h
 619 32 38 17 29 9 15 0.53 0.76 1.38 1.24 0.65 
D
i
 387 30 40 16 29 11 14 0.04 0.73 0.26 1.90 0.63 
E
j
 123 30 40 20 26 14 10 0.67 0.65 1.31 1.32 0.66 
F
k
 93 30 40 23 33 7 7 0.77 0.83 1.63 1.56 0.80 
a
Num. Mod, number of models with CCRtrain and CCRtest ≥ 0.70; 
b
N1, number of actives; 
c
N0, number of inactives; 
d
CCRevs, correct classification rate of the consensus models using 
the external validation set; 
e
CCRrand, correct classification rate of the random models using 
the external validation set; 
f
A, kNN-Dragon; 
g
B, kNN-MZ; 
h
C, kNN-Dragon-FP;
 i
D, kNN-
MZ-FP; 
j
E, kNN-MOE-FP; 
 k
F, kNN-SG. 
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Classification Based on Association. The CBA method was applied to classify the 
dataset using SG descriptors. A dataset of 342 compounds (146 actives and 196 inactives), 
resulting from the downsizing process with FP and Tanimoto distances, was used. The 
dataset was split randomly into training (267 compounds) and validation sets (75 
compounds). A total of 1371 closed frequent subgraphs were generated with FFSM (see 
Methods in Chapter 2) from the training set using a support value of 12% and a maximum 
size limit of the fragments of 7. The training set consisting of 267 compounds (111 actives 
and 156 inactives) was then used to build the classifier in CBA. The classifier gave a CCRtrain 
of 0.79. Then the validation set consisting of 75 compounds (35 actives and 40 inactives) was 
used to assess the robustness of the classifier. The CCRevs was 0.65 which is not as high as 
the CCR value for the training set.  
DWD Modeling. The DWD method was applied to classify the dataset using Dragon 
descriptors. A dataset of 304 compounds (146 actives and 158 inactives), resulting from the 
downsizing process with Dragon descriptors and Euclidean distances, was used. The dataset 
was split randomly into training (244 compounds) and validation sets (60 compounds). A 
total of 387 Dragon descriptors were generated for the training set. The training set 
consisting of 244 compounds (120 actives and 124 inactives) was then used to build the 
DWD model. The DWD model was able to group compounds in this dataset based on their 
biological classes with a CCRevs = 0.70 (TP=18, TN=24, FP=10, FN=8), setting the cutoff at 
―0.15‖. DWD was further used to rank Dragon descriptors according to their importance for 
discriminating the two classes of compounds (actives vs. inactives). DWD uses class label 
information where positive (for actives) and negative (for inactives) signs are assigned to 
each descriptor value to indicate its importance to the corresponding class. The top 20 highly 
119 
 
weighted descriptors (based only on weights‘ values and ignoring the signs) are presented in 
Table 4.3.  
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Table 4.3. Top twenty highly weighted Dragon descriptors by DWD for 5-HT2B actives vs. 
inactives. 
Descriptor  DWD Weight Interpretation 
JGI9 2.07E-01 Mean topological charge index of order 9 
nRNR2 1.99E-01 Number of tertiary amines (aliphatic) 
C-006 1.79E-01 CH2RX 
C-024 1.66E-01 R--CH--R 
T(N..F) 1.52E-01 Sum of topological distances between N..F 
H-047 1.51E-01 H attached to C1 (sp3)/CO (sp2) 
H-049 -1.42E-01 H attached to C3(sp3)/C2(sp2)/C3(sp2)/C3(sp) 
C-027 -1.38E-01 R--CH--X 
JGI10 -1.38E-01 Mean topological charge index of order 10 
GATS7e 1.38E-01 Geary autocorrelation - lag 7 / weighted by atomic 
Sanderson electronegativities 
PCR 1.35E-01 Ratio of multiple path count over path count 
nBnz 1.32E-01 Number of benzene-like rings 
H-051 -1.30E-01 H attached to alpha-C 
GATS8m 1.21E-01 
Geary autocorrelation - lag 8/weighted by atomic 
masses 
C-013 1.16E-01 CRX3 
C-034 -1.14E-01 R--CR..X 
BELe8 1.14E-01 Lowest eigenvalue n. 8 of Burden matrix / weighted by 
atomic Sanderson electronegativities 
JGI5 -1.11E-01 Mean topological charge index of order 5 
nN+ -1.10E-01 Number of positively charged nitrogen 
GATS3p 1.08E-01 Geary autocorrelation - lag 3 / weighted by atomic 
polarizabilities 
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Comparison of Binary QSAR Approaches for Classifying 5-HT2B Actives vs. Inactives 
The performance of different binary QSAR approaches employed as part of 
combinatorial QSAR strategy for 5-HT2B, and based on validation set statistics, is 
summarized in Figure 4.2. kNN-SG, and kNN-Dragon were the best performing methods for 
classifying 5-HT2B actives vs. inactives based on validation set statistics (Table 4.2), yielding 
the highest CCRevs of 0.80 in case of kNN-SG. On the contrary, kNN-MZ was the worst 
performing method with a CCRevs of 0.57 which was very close to random. It was also 
interesting to see that kNN-SG performed much better than CBA-SG with CCRevs = 0.80 in 
the former case and 0.65 in the latter. These results confirm the importance of employing the 
combinatorial QSAR approach to find the most predictive QSAR method/descriptor 
combination for each specific dataset.  
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Figure 4.2. Comparison of CCR values for the external validation set (CCRevs) for different 
QSAR models developed to classify actives vs. inactives. CCRevs values for models built 
with both real (blue) and randomized (red) activities of the training sets are shown (see text 
for abbreviations).  
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Our models also indicated that the nature of the descriptors used has a dramatic effect 
on the performance of the modeling methods. It was clear that MOE and MZ descriptors did 
not perform very well in all tested cases irrespective of the applied modeling techniques. On 
the contrary, Dragon descriptors afforded most significant models with all methods and in all 
tests, for both validation and external sets.  
Model Validation by Predicting Drugs Known to be 5-HT2B Actives and 
Valulopathogens 
Both fenfluramine and dexfenfluramine (known to be 5-HT2B actives and agonists, 
which were not included in our modeling sets) were predicted as 5-HT2B actives using 
consensus models to classify actives vs. inactives. The consensus scores using kNN-Dragon 
were 0.79 for both compounds. Our previous studies suggest that consensus prediction that is 
based on the results obtained by all validated predictive models always provides the most 
stable solution(Zhu et al. 2008a). A 5-HT2B active compound can have consensus scores in 
the interval [0.5-1.0]. The closer value to 1.0 the greater is the confidence in the prediction. 
Therefore, we can claim that both compounds were predicted as actives with statistically 
significant consensus scores.  
These results highlight the predictive power of our validated models that could have 
predicted the possible dangerous side effects of these two drugs by suggesting that they may 
be 5-HT2B actives. This prediction would have suggested that these compounds should be 
tested experimentally in 5-HT2B functional assays and prevented from further development as 
potentially unsafe medicines. This example illustrates the potential use of models developed 
in this study as computational drug safety alerts.  
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Model Validation by Predicting an External Set 
An additional 16-compound set was obtained from PDSP after we finished out 
modeling studies. This external set was used to further assess the robustness and the 
predictive power of our models. All 16 compounds were 5-HT2B actives including 4 agonists 
and 12 antagonists.   
The 16 external compounds were predicted using all consensus models built to 
classify actives vs. inactives. kNN-Dragon was the best performing method on this external 
set with a CCRex of 0.81. Predictions were made by applying local model applicability 
domains with Z = 0.5 (see Applicability Domain of kNN QSAR Models). It was interesting 
to find that kNN-Dragon had CCR ≥ 0.72 with both the validation (CCRevs = 0.72) and the 
external (CCRex = 0.81) sets. However, kNN-SG (the best performing method on validation 
sets) was not as good with the external set (CCRex = 0.65) as it was with the validation set 
(CCRevs = 0.80). CBA-SG gave a CCRex = 0.65, which was consistent with its performance 
with the validation set (CCRevs = 0.65) but less than CCRtrain (0.79). The latter results using 
SG descriptors with kNN and CBA might be due to the limitation that frequent subgraphs are 
derived from the training set compounds; therefore, it is possible that fragments that are 
frequent in the external set are not represented in the frequent subgraphs used for prediction. 
Our current applicability domain filter, which is calculated using the fragments in the training 
set, does not account for this possibility. It is clear that a more stringent applicability domain 
filter could be applied in this case, which uses the distribution of subgraphs counts between 
the training and test set, but this has not been implemented yet within our current method.  
The Importance of Variable Selection  
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Since kNN-Dragon was the best performing method to classify actives vs. inactives 
based on the results for all validation sets, we thought it would be interesting to check the 
performance of kNN using all 387 Dragon descriptors, generated for the actives vs. inactives 
modeling set, without variable selection. The results of this test are shown in Table 4.4. 
Comparison of modeling results for kNN-variable-selection (CCRevs = 0.72) vs. kNN-
without-variable-selection (CCRevs = 0.52) clearly indicates that variable selection is a vital 
part of modeling. Furthermore, the top 20 most frequent descriptors (MFD) selected by kNN 
models (Table 4.5) and top 20 highly weighted descriptors by DWD based only on weights 
and ignoring the sign (Table 4.3) were used independently with the kNN method (with no 
variable selection) to predict actives vs. inactives (Table 4.3). Models built with either the top 
20 DWD-selected Dragon descriptors or MFD from Dragon-kNN and using 1-5 nearest 
neighbors gave CCRevs ~ 0.5 (Table 4.3). These results illustrated again that SA-based 
variable selection procedures implemented in our kNN QSAR method (Zheng & Tropsha 
2000) lead to models with the highest external predictive power as compared to any other 
approach not relying on variable selection for model optimization.  
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Table 4.4. Comparison between different kNN-Dragon QSAR models generated with or 
without variable selection. 
Mod. 
Num. 
Mod
a
 
Confusion Matrix Statistics for the Models 
N1
b
 N0
c
 TP TN FP FN SE SP En1 En0 CCRevs
d
  
Cover
-age
e
 
A
f
 908 26 34 20 23 11 6 0.77 0.68 1.41 1.49 0.72 100% 
B
g
 1 26 34 10 22 10 8 0.38 0.65 1.13 1.36 0.52 83% 
C
h
 1 26 34 14 15 19 9 0.54 0.44 0.98 1.12 0.49 95% 
D
i
 1 26 34 14 15 19 9 0.54 0.44 0.98 1.12 0.49 95% 
a
Num. mod, number of models with CCRtrain and CCRtest ≥ 0.70; 
b
N1, number of actives; 
c
N0, 
number of inactives; 
d
CCRevs, correct classification rate of the consensus models using the 
external validation set; 
e
Coverage, percentage of predicted external compounds; 
f
A, kNN-
Dragon;
 g
B, kNN-Dragon-NVS where kNN model was generated using all 387 Dragon 
descriptors with no variable selection and 1 nearest neighbor (NN); 
h
C, kNN-Dragon-MFD 
where the kNN model was generated with top twenty most frequent Dragon descriptors and 
1NN; 
i
D, kNN-Dragon-DWD where the kNN model was generated with top twenty highly 
weighted Dragon descriptors by DWD and one NN.
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Table 4.5. Top twenty most frequently used Dragon descriptors in validated kNN-Dragon 
models to classify 5-HT2B actives vs. inactives. 
Descriptor  Frequency Interpretation 
nN=C-N< 157 Number of amidine derivatives 
C-027 152 R--CH--X 
MATS5v 151 Moran autocorrelation - lag 5 / weighted by atomic van 
der Waals volumes 
GATS5v 148 Geary autocorrelation - lag 5 / weighted by atomic van 
der Waals volumes 
C-033 146 R--CH..X 
MATS4v 135 Moran autocorrelation - lag 4 / weighted by atomic van 
der Waals volumes 
MLOGP2 135 Squared Moriguchi octanol-water partition coeff. 
(logPˆ2) 
N-074 131 R#N / R=N- 
nR=Cp 130 Number of terminal primary C(sp2) 
MATS4m 128 Moran autocorrelation - lag 4 / weighted by atomic 
masses 
nFuranes 128 Number of furanes 
C-035 125 R--CX..X 
nArNR2 119 Number of tertiary amines (aromatic) 
nPyrroles 119 Number of pyrroles 
nPyridines 118 Number of Pyridines 
nArCO 118 Number of ketones 
nROCON 117 Number of (thio-) carbamates (aliphatic) 
nBeta-Lactams 117 Number of Beta-Lactams 
H-053 114 H attached to CO(sp3) with 2X attached to next C 
C-008 113 CHR2X 
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Mechanistic interpretability is frequently regarded as very important feature of QSAR 
models. We generally argue that only models that have been extensively validated on 
external datasets and identified experimentally-confirmed hits should be subjected to 
interpretation.  Furthermore, very few classes of models, specifically, those based on 
(multiple) linear regression and small number of descriptors can afford a relatively 
straightforward interpretation. The interpretation of multi-parametric statistical models 
developed with non-linear optimization algorithms (as in this study) should be attempted 
with great care because of strong and often poorly understood interplay between descriptors. 
Furthermore, although we could foresee that in some cases medicinal chemists may want to 
modify their candidate compounds to prevent 5HT2B binding, the tools developed in this 
study are predominantly intended for virtual screening of libraries of drug candidates to flag 
and possibly eliminate compounds that are likely to bind 5HT2B receptor, not to design new 
compounds; and any compound designed by chemists could be passed through our models.  
Therefore, we only restricted the discussion in this paper to the most frequent descriptors 
found by all acceptable kNN models and the most highly weighted descriptors selected by 
DWD to stress that the process of variable selection employed as part of model optimization 
has indeed converged on a small number of descriptors. 
Virtual Screening of the World Drug Index Database to Identify Putative 5-HT2B 
Ligands  
Since our models proved to be reasonably accurate based on two external validation 
sets, we used the best models to mine a large external database of approved and potential 
drugs for putative 5-HT2B actives. An important condition that assures reliable predictions by 
the model is the use of AD. Therefore, two types of AD were employed in the virtual 
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screening of compound databases. The first is a global AD that acts as a filter and ensures 
some level of global similarity between the predicted compounds and the compounds in the 
modeling set. The second is a local AD which is defined for each of the individual 
classification models.  
The WDI database of ca. 59000 compounds (approved or investigational drugs) was 
used for virtual screening (Fig. 4.3). This original collection had many duplicates (i.e., many 
salt forms for the same chemical entity). The duplicates were removed using MOE: keeping 
unique structures and deleting duplicates. We also removed all compounds included in our 
modeling and external validation sets. Dragon descriptors were generated for the remaining 
46859 unique compounds in the database; 926 compounds were excluded because Dragon 
was unable to calculate at least one of the descriptors generated for the modeling set. The 
remaining 45933 compounds were then subjected to a global AD filter for the actives vs. 
inactives modeling set using a strict Z cutoff of 0.5 (which formally places the allowed 
pairwise distance threshold at the mean of all pairwise distance distribution for the training 
set plus one-half of the standard deviation). Obviously, increasing the AD would increase the 
number of computational hits identified by virtual screening. However, our experience 
suggests that such increase is typically accompanied by the decrease in prediction accuracy.  
Additionally, we required that the nearest neighbor in the modeling set of a compound from 
the virtual library be an active. The resulting 7286 compounds were then classified into 
actives vs. inactives using DWD-Dragon classifier resulting in 891 actives. Next, all kNN-
Dragon models with CCRtrain and CCRtest ≥ 0.70 were employed in consensus fashion to 
predict these 891 compounds resulting in a selection of the 500 active hits. At this point, SG 
descriptors were generated for these 500 molecules. CBA-SG classifier followed by kNN-SG 
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consensus models were used as final filters for the determination of 122 compounds regarded 
as putative 5-HT2B actives.   
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Figure 4.3. Steps of the virtual screening of the WDI database to identify putative 5-HT2B 
ligands (see text for the abbreviations). 
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Experimental Validation 
Ten structurally diverse hits (1-10, see Table 4.6) were selected from the final 
consensus virtual screening hits for further experimental validation taking into account both 
their commercial availability and cost (see Table 4.6). To our satisfaction, nine compounds 
were confirmed to inhibit 5-HT2B radioligand binding, which implies a hit rate of 90 %. Ki 
values were in the range 0.8 – 3,127 nM, with 4 compounds having Ki values < 100 nM. The 
four highest affinity compounds were: 4 (Ki=33 nM, see Fig. 4 (A)), 7 (Ki=0.8 nM, see Setola 
et al, 2003 (Setola et al. 2003)), 9 (Ki=70 nM, see Fig. 4 (B)), and 10 (Ki=69 nM, see Fig. 4 
(C)). It should be noted that 7, though not included initially in our dataset, was known to be a 
valvulopathic compound and had been tested against 5-HT2B receptors in both binding 
(Ki=0.8 nM) (Setola et al. 2003) and functional assays (pEC50 for 5-HT2B-Mediated calcium 
flux = 7.67) (Huang et al. 2009). In order to determine the activity of the remaining eight 5-
HT2B ligands, all compounds were tested at the PDSP in 5-HT2B functional assays. Results 
indicated that methylergometrine was the only compound among the nine 5-HT2B ligands 
that possessed strong agonist activity.  
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Table 4.6.  Experimental validation results for the 10 computational hits predicted as 5-HT2B 
ligands as a result of QSAR-based mining of the WDI chemical screening library. 
Chemical Structure/ 
Name 
PubChem 
CID 
PDSP 
ID 
Predicted 
5-HT2B Activity 
Experimental 
Ki (nM) 
 
(1) 6-Fluoromelatonin 
43922 14809 Active 2,495.0 
 
(2) Adrenoglomerulotropin 
71028 14807 Active 491.0 
 
(3) CGP-13698 
114709 14806 Active >10,000 
 
(4) DO-897 
3038495 14814 Active 33.1 
 
(5) Fendiline 
 
3336 14821 Active 3,217.0 
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(6) Fluspirilene 
1715104 14815 Active 151.4 
(7) Methylergometrine 
4140 27769 Active 0.8 
 
(8) PIM-35 
195658 14805 Active 1,617.0 
 
(9) PNU-96415E 
9909648 13513 Active 69.6 
 
(10) Raloxifene 
15940170 13505 Active 69.0 
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Figure 4.4. Competition binding at 5-HT2B receptors for (A) 4 (triangle) and SB206553 
(square), (B) 9 (triangle) and SB206553 (square), and (C) 10 (triangle) and chlorpromazine 
(square), versus [3H]LSD. 
 
 
 
A 
 B 
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This low hit rate of 11.1% for identifying validated agonists is in fact not surprising in 
light of Huang et al (Huang et al. 2009) major finding that potent 5-HT2B receptor agonism is 
a relatively rare occurrence among drugs and drug-like compounds. However, to arrive at 
such conclusions, Huang et al screened a composite library containing three publicly 
available collections of FDA-approved and investigational medications and one internally 
compiled library. Of the approximately 2200 compounds screened, 27 5-HT2B receptor 
agonists were identified; thus, the validated hit rate was 1.2%.  
These results illustrate that the validated QSAR workflow, as employed in this paper, 
could be used as a general tool for identifying 5-HT2B ligands by the means of virtual 
screening of chemical libraries using rigorously built QSAR models. As we demonstrated in 
this study, our models identify a relatively small number of VS hits making it feasible to 
employ experimental tools to validate predictions in 5-HT2B binding and functional assays. 
Ten compounds selected from a large external library have been tested experimentally in this 
proof-of-concept study resulting in very high experimentally confirmed hit rate. The list of 
all compounds predicted to be 5-HT2B actives is available in Appendix I. 
To verify the diversity of the experimentally validated hits, we have compared the 
results of QSAR-based virtual screening with simple similarity searches. Similarity 
calculations were done using two different descriptor-metric combinations: (1) MACCS 
structural keys and Tanimoto coefficients (as a standard similarity searching approach, see 
Table 4.7 and Figure 4.5) and (2) Dragon descriptors and Euclidean distances (to compare 
directly with our best performing QSAR models of kNN-Dragon, see Table 4.8 and Figure 
4.6.  The nearest neighbor compounds (based on Tanimoto similarities and MACCS keys) 
from the active compounds in the dataset and the 10 experimentally validated VS hits are 
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reported in Table 4.9. Results of similarity analyses indicated that neither technique would be 
able to efficiently identify the diverse hits obtained with our methods. Hence, our studies 
illustrated the power of combi-QSAR-based VS in prioritizing compounds (which are not 
just close analogs of the modeling set compounds) from screening libraries to achieve high 
success rates when experimentally validated.  
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Table 4.7. Virtual screening recovery results using Tanimoto similarities and 166 MACCS 
keys. 
Tanimoto 
Coefficient 
46406 WDI 
Compounds 
122 VS  
Hits 
10 Tested 
Hits 
≥ 0.9 286 2 2 
≥ 0.8 1341 4 3 
≥ 0.7 7048 13 8 
≥ 0.6 21431 38 9 
≥ 0.5 36719 81 9 
≥ 0.4 44208 115 10 
≥ 0.3 45860 122 10 
≥ 0.2 46220 122 10 
≥ 0.1 46301 122 10 
≥ 0.0 46406 122 10 
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Figure 4.5. The heatmap of the similarity between the 146 5-HT2B actives from the modeling 
set and 46406 WDI compounds. Virtual screening compounds included in WDI were 
analyzed by estimating pairwise structural similarities with modeling set actives using 
Tanimoto coefficients and 166 MACCS structural keys. The bar-view is a key for coloring 
according to similarity/dissimilarity based on Tanimoto coefficients where red color indicates 
most similar compounds while blue color denotes least similar compounds. 
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Table 4.8. Virtual screening recovery results using Euclidean distances and 903 Dragon 
descriptors. 
Euclidean 
Distance 
54933WDI 
Compounds 
122 VS  
Hits 
10 Tested  
Hits 
≤ 0.5 157 0 0 
≤ 1.0 948 3 3 
≤ 1.5 4191 10 6 
≤ 2.0 9835 30 7 
≤ 2.5 16411 54 9 
≤ 3.0 22419 73 10 
≤ 3.5 27200 86 10 
≤ 4.0 31035 96 10 
≤ 4.5 34008 102 10 
≤ 5.0 36340 116 10 
≤ 5.5 38106 119 10 
≤ 6.0 39528 120 10 
≤ 6.5 40714 121 10 
≤ 7.0 41550 122 10 
≤ 10.0 43738 122 10 
≤ 50.0 45692 122 10 
≤ 100 45880 122 10 
≤ 120 45932 122 10 
≤ 130 45933 122 10 
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Figure 4.6. The heatmap of distances between the 146 5-HT2B actives from the modeling set 
and 45933 WDI compounds. Virtual screening compounds included in WDI were analyzed 
by estimating pairwise structural similarities with modeling set actives using Euclidean 
Distances and 903 Dragon descriptors. The bar-view is a key for coloring according to 
similarity/dissimilarity based on Euclidean distances where red color indicates most similar 
compounds while blue color denotes least similar compounds. Additionally, in this figure we 
colored all instances with distances above 20 with blue. 
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Table 4.9.  Nearest neighbor compounds from the active compounds in the dataset and the 
ten experimentally validated VS hits. 
Virtual screening hits 
a
Nearest neighbor from the modeling set 
 
1 
 
PubChem CID  54940 (66 % similarity) 
 
2 
 
PubChem CID  108029 (70 % similarity) 
 
3 
 
PubChem CID  5163 (49 % similarity) 
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4 
 
 
PubChem CID  5684 (88 % similarity) 
 
5 
 
PubChem CID  1001 (71 % similarity) 
 
6 
 
PubChem CID  125085 (90 % similarity) 
 
7 
 
PubChem CID  3250 (98 % similarity) 
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8 
 
PubChem CID  5202 (76 % similarity) 
 
9 
 
PubChem CID  15443 (79 % similarity) 
 
10 
 
PubChem CID  4418 (74 % similarity) 
a
Nearest neighbor from the modeling set compounds based on MACCS structural keys and 
Tanimoto distances.  
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We also think that agonist vs. antagonist models will be highly useful as more data 
about agonist compounds become available. The small number of known 5-HT2B agonists 
made it impossible at this stage to develop statistically significant models that could 
distinguish agonists from antagonists. Thus, the current study was limited to building binder 
vs. non-binder models. We will continue with our efforts to develop quantitative 5-HT2B 
agonist predictors as we accumulate more experimental data. 
 Conclusions  
QSAR models are becoming increasingly attractive as robust computational tools for 
virtual screening due to both their computational efficiency and success rates [reviewed in 
(Tropsha & Golbraikh 2007) as well as in a recent monograph (Varnek & Tropsha 2008)]. In 
this study, we have applied a combinatorial QSAR approach to a dataset of 800 compounds 
experimentally annotated as 5-HT2B receptor agonists, antagonists and inactives resulting in 
statistically validated and externally predictive models. Specifically, we have applied a 
combi-QSAR approach utilizing three different classification methods (kNN, CBA and 
DWD) and four different descriptor types (Dragon, MZ, MOE and SGs) to generate 
classification QSAR models to discriminate between 5-HT2B actives (agonists and 
antagonists) from inactives. Predictive models with classification accuracies as high as 0.80 
for actives vs. inactives, as estimated on external validation sets, were obtained.  
Classification models for actives vs. inactives were further validated by predicting an 
external validation set obtained after we completed the modeling studies. The high accuracy 
of prediction for the second external validation set proved that our models were indeed 
rigorous. Therefore, we posited that our studies afforded a robust computational tool to 
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predict potential 5-HT2B activity and consequently prioritize hits for testing in functional 5-
HT2B assays to predict valvulopathic side effects of drugs and drug candidates that act as 5-
HT2B agonists. We suggested that this computational predictor could be used to eliminate 
high risk compounds at the early stages of the drug development process. To illustrate this 
point, we have used this predictor retrospectively to evaluate the valvulopathic potential of 
two drugs withdrawn from the U.S. market for this reason, i.e., fenfluramine and 
dextrofenfluramine. Both drugs were not included in our modeling set and both were indeed 
predicted with high confidence as actives for binding to 5-HT2B receptors.  
Encouraged by our model validation results, we have applied these models for virtual 
screening of the 59000 compounds in WDI database. Our classification strategies identified 
122 potential 5-HT2B ligands. Ten structurally diverse VS hits were experimentally tested at 
PDSP. Nine compounds were experimentally confirmed as 5-HT2B ligands thereby 
demonstrating a very high success rate of 90%.  
The predictor developed in this report is similar in its potential use to other predictors 
of drug liability such as carcinogenicity and mutagenicity that are widely used in 
pharmaceutical industry. For instance, the TOPKAT program available in the Discovery 
Studio (Discovery Studio 2008), is a QSAR-based system that generates and validates 
accurate, rapid assessments of various types of chemical toxicity solely from a chemical's 
molecular structure. In contrast, our predictor is a unique specialized tool for the prediction 
of 5-HT2B activity and therefore prioritizing compounds for functional testing against 5-HT2B 
receptors to assess their valvulopathic potential. Therefore, this predictor can be used, along 
with other computational chemical health risk assessment tools, to evaluate compounds‘ 
safety at early stages of the drug development. It can be used as well to verify that all drugs 
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available on the market are free from possibly fatal valvulopathic risk. This predictor will be 
made publicly available at the ChemBench server established in the Laboratory for 
Molecular Modeling (chembench.mml.unc.edu).  We will also gladly apply this predictor to 
any compound library that may be of interest to any researcher. 
 
 
  
  
CHAPTER 5 
AN INTEGRATIVE CHEMOCENTRIC INFORMATICS APPROACH TO 
DRUG DISCOVERY BASED ON STRUCTURAL HYPOTHESIS FUSION: 
IDENTIFICATION AND EXPERIMENTAL VALIDATION OF SELECTIVE 
ESTROGEN RECEPTOR MODULATORS AS LIGANDS OF 5-
HYDROXYTRYPTAMINE-6 RECEPTORS 
 
Introduction 
Target-oriented drug discovery has become one of the most popular modern drug 
discovery approaches (Connor et al. 2010, Nicholson et al. 2004, Petak et al. 2010, 
Raamsdonk et al. 2001, Yang et al. 2010). Target-oriented approaches rely on established 
functional associations between activation or inhibition of a molecular target and a disease. 
Modern genomics approaches including gene expression profiling, genotyping, genome-wide 
association, and mutagenesis studies continue to serve as useful sources of novel hypotheses 
linking genes (proteins) and diseases and providing novel putative targets for drug discovery.  
Recently, functional genomics approaches have been increasingly augmented by 
chemical genomics (Brenner 2004, Darvas et al. 2004, Nislow & Giaever 2003, Salemme 
2003, Zheng & Chan 2002b, Zheng & Chan 2002a), i.e., large scale screening of chemical 
compound libraries in multiple biological assays (Campbell et al. 2010, Hamadeh et al. 2010, 
Kiessling & Splain 2010, Ogorevc et al. 2010, Wagner & Clemons 2009). Chemical 
genomics studies yield data indicating that both physical and functional interactions exist 
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between chemicals and their biological targets. Such data (either obtained in chemical 
genomics centers or collected and curated from published literature) is deposited in many 
public and private databases such as the NIMH Psychoactive Drug Screening Program 
(PDSP) (PDSP 2009), PubChem (PubChem 2009), ChEMBL (ChEMBL 2010), WOMBAT 
(Olah et al. 2007) and others (see Oprea and Tropsha (Oprea & Tropsha 2006) for a recent 
review).   
Various in silico techniques have been exploited for analyzing target-specific 
biological assay data. A recent publication by Kortagere and Ekins (Kortagere & Ekins 2010) 
could serves as a good summary of most common target-oriented computational drug 
discovery approaches including: (1) structure based virtual screening (docking and scoring) 
using either experimentally characterized (with X-ray or NMR) or predicted by homology 
modeling structure of the target protein, (2) chemical similarity searching using known active 
compounds as queries, (3) pharmacophore based modeling and virtual screening, (4) 
quantitative structure activity relationship (QSAR) modeling, and (5) network or pathway 
analysis.  
Data resulting from large-scale gene or protein expression or metabolite profiling 
(often collectively referred to as 'omics' approaches (Burgun & Bodenreider 2008, Kandpal et 
al. 2009, Polychronakos 2008, Vangala & Tonelli 2007) can be explored not only for specific 
target identification but also in the context of systems pharmacology to identify networks of 
genes (or proteins) that may collectively define a disease phenotype. For example, ‗omics‘ 
data can be used to ask what genes or proteins, or post-translationally modified states of 
proteins are over- (or under-) expressed in patients suffering from a particular disease.  These 
types of data can be found in a number of public repositories such as the Gene Expression 
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Omnibus (GEO) (Edgar et al. 2002, Barrett & Edgar 2006), GEOmetadb (Zhu et al. 2008b), 
the Human Metabolome Database (HMDB) (Wishart 2007, Wishart et al. 2009), Kinase 
SARfari (Kinase SARfari 2010), the Connectivity Map (cmap) (Lamb et al. 2006), the 
Comparative Toxicogenomics Database (CTD) (Davis et al. 2009), STITCH (Kuhn et al. 
2009, Kuhn et al. 2008), GenBank (Burks et al. 1991, Burks et al. 1990), and others.   
Insights into disease pathology and underlying mechanisms can be revealed by the 
disease ‗gene signature‘, i.e., those genes whose expression varies consistently between 
patients and healthy individuals (controls) (Palfreyman et al. 2002). Gene-expression 
profiling has been often applied to elucidate the mechanisms underlying the roles of 
biological pathway in a disease (DeRisi et al. 1997, Lamb et al. 2003), reveal arcane subtypes 
of a disease (Golub et al. 1999, Perou et al. 2000), and predict cancer prognosis (Pomeroy et 
al. 2002, van, V et al. 2002). At the same time, the treatment of cultured human cells with 
chemical compounds that target a disease can produce a drug related ‗gene signature‘, i.e., 
differential expression profile of genes in response to the chemical (Altar et al. 2009, Ogden 
et al. 2004, Palfreyman et al. 2002, Le-Niculescu et al. 2007). Recently, a group of scientists 
at the Broad Institute have established the Connectivity Map (cmap) database to catalog the 
biological responses of a large number of diverse chemicals in terms of their gene expression 
profiles (Lamb et al. 2006). It has been shown that examining the correlations between gene 
expression profiles characteristic of a disease and those modulated by drugs may lead to 
novel hypotheses linking chemicals to either etiology or treatments for a disease (Garman et 
al. 2008, Golub et al. 1999, Hassane et al. 2008, Hieronymus et al. 2006, Lamb et al. 2006, 
Riedel et al. 2008, Setlur et al. 2008, Zimmer et al. 2008, Zimmer et al. 2010).  
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The cmap database provides an unusual but intriguing example of what we shall call a 
chemocentric ‗omics‘ database and methodology for generating independent and novel drug 
discovery hypotheses.  Indeed, there exists a wealth of information buried in the biological 
literature and numerous specialized chemical databases (ChEMBL 2010, Daylight 2004, 
Olah et al. 2007, PDSP 2009, PubChem 2009) linking chemical compounds and biological 
data (such as targets, genes, experimental biological screening results; cf. Baker and 
Hemminger (Baker & Hemminger 2010).  The chemocentric exploration of these sources, 
either individually or in parallel opens up vast possibilities for formulating novel drug 
discovery hypotheses concerning the predicted biological or pharmacological activity of 
investigational chemical compounds or known drugs. The integration and cross-validation of 
such independent structural hypotheses can increase their level of confidence and can be 
referred to as structural hypothesis fusion.  
Herein, we describe a novel integrative chemocentric informatics approach to drug 
discovery that combines structural hypotheses generated from independent analysis of both 
traditional target-specific assay data and those resulting from large scale genomics and 
chemical genomics studies.  As a proof of concept, we have focused on the Alzheimer‘s 
disease as one of the most debilitating neurodegenerative diseases with complex etiology and 
polypharmacology.  We have considered and cross-examined two independent but 
complimentary approaches to the discovery of novel putative anti-Alzheimer‘s drugs. First, 
we have employed a traditional target-oriented cheminformatics approach to discovering 
anti-Alzheimer‘s agents. We have built QSAR models of ligands binding to 5-
hydroxytryptamine-6 receptor (5-HT6R), a potential target for the cognitive enhancement in 
Alzheimer‘s disease (Geldenhuys & Van der Schyf 2009); it has been shown that 5-HT6R 
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antagonists can improve memory and cognition in animal models of impaired cognition 
(Holenz et al. 2006). We have then used models developed with the rigorous predictive 
QSAR modeling workflow established and implemented in our laboratory (Tropsha 2010) 
for virtual screening (VS) of the WDI (Daylight 2004) and DrugBank (Wishart et al. 2006, 
Wishart et al. 2008) to identify putative cognition enhancing agents with potential utility as 
anti-Alzheimer‘s agents as compounds predicted to interact with 5-HT6R. Second, we have 
explored (chemo)genomic data available from the cmap project (Lamb et al. 2006) to link 
chemical compounds and the Alzheimer‘s disease without making explicit hypotheses about 
target-specific mechanisms of action, i.e., treating Alzheimer‘s disease as a complex 
polypharmacological disease.  
We then cross-examined and combined common hits regarded as structural 
hypotheses resulting from both approaches (i.e., hypothesis fusion) towards common 
integrated higher-confidence hypotheses supported by two independent lines of 
computationally-based evidence.  Thirteen common hits were tested in 5-HT6R binding 
assays at the PDSP and ten were confirmed experimentally as having activity. Unexpectedly, 
we found that the confirmed actives included several selective estrogen receptor modulators 
(SERMs) suggesting that they may be potential anti-Alzheimer‘s drugs as well. Indeed, we 
have identified clinical evidence in biomedical literature in support of this hypothesis.  We 
believe that approaches discussed in this study can be applied to a large variety of systems to 
identify novel drug-target-disease associations. 
Materials and Methods 
Integrative Chemocentric Informatics Approach  
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We have devised an integrative workflow focused on the discovery of new drug 
candidates and finding new uses for existing drugs by fusing predictions generated from 
different data types and methods. Currently, the workflow (Fig. 5.1) incorporates three major 
components: (1) a module for QSAR-based VS of chemical libraries to identify new ligands 
for target proteins, (2) a network-mining module to identify small molecule therapeutics for 
specific diseases without necessarily knowing the underlying target-specific mechanism; this 
module explicitly relies on cmap,
3
 an external online database 
(www.broadinstitute.org/cmap/) that links the effects of different drugs and diseases using 
gene expression profiles, and (3) ChemoText (Baker & Hemminger 2010), an in-house 
repository of relationships between chemicals, diseases, proteins, and biological processes. 
The first two modules have been employed extensively for studies reported herein. 
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Figure 5.1. Study design for the integrative informatics approach for drug discovery 
integrating network mining, text mining of biological literature, the analysis of disease gene 
signatures and efficient cheminformatics techniques, to discover novel drugs with desired 
polypharmacology. 
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We start our study with identifying established disease-target associations (e.g., 5-
HT6R is implicated in Alzheimer‘s disease). Then we mine the biological literature and 
specialized databases to extract structure activity datasets for ligands known to interact with 
the biological target of interest. Activity data could be either binding affinities (Ki values) or 
functional data (IC50 values for agonists and antagonists).  Binding and functional data could 
be either continuous (e.g., Ki and IC50 values) or categorical (e.g., binder vs. non-binder or 
agonist vs. antagonist) in nature. At this stage we use our QSAR-based VS module (see Fig. 
2; predictive QSAR workflow) to generate robust predictive QSAR models for experimental 
structure activity data that can be employed for VS of chemical libraries to derive new 
hypotheses about putative actives (binders, or agonists, or antagonists ). 
Simultaneously, we mine the biological literature for gene signatures associated with 
the disease and/or for all related protein targets implicated in the disease state. We use these 
disease related genes and proteins to query specialized databases to extract information about 
disease-protein (gene)-chemical connections.  For example, we use disease gene signatures to 
query the cmap for putative treatments, and we use related proteins to query ChemoText for 
related chemicals to establish new disease-protein (gene)-chemical connections. After a 
thorough analysis of all data, we select hit compounds that are expected to be novel 
treatments for the disease (cf. Fig. 5.1). 
Finally, we fuse hypotheses derived from the QSAR-based VS approach with those 
derived from text/network mining. Hypothesis fusion is based on structural identity between 
independently identified hits. The common structural hits are considered for further 
experimental validation. We assume that the level of confidence in structural hypotheses 
resulting from independent approaches to knowledge mining in chemocentric databases is 
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intrinsically higher than that in any computational hit generated in respective independent 
studies. 
Databases and Datasets 
The experimental data for Alzheimer‘s disease related target 5-HT6R were extracted 
from the PDSP Ki-DB available in the public domain. The complete 5-HT6R dataset included 
binding affinity data for 250 compounds. We used PubChem (PubChem 2009) to obtain all 
chemical structures for our datasets in SDF file format. After generating models we used the 
successful models for virtual screening of WDI and DrugBank.  
We also queried cmap database with disease Alzheimer‘s disease gene signature. 
Disease gene signatures were populated with Affymetrix U133A probe sets using NetAffx. 
All details about the databases and tools mentioned herein can be found in Chapter 2. 
Computational Methods 
(1) QSAR Modeling and QSAR-based Virtual Screening 
Preprocessing of the Dataset. We used a workflow for chemical data curation that 
was developed in our lab and published recently (Fourches et al. 2010) and discussed in 
details in Chapter 2.  Our analysis resulted in the detection and removal of 56 duplicate 
chemical entries leaving 194 unique normalized molecular structures. These 194 unique, 
organic compounds, including 102 binders and 94 non-binders (see Table S1 of Supporting 
Information) were used for binary QSAR studies.  We assigned the ‗activity‘ class for each 
compound based on its Ki value(s) obtained from the PDSP and according to PDSP 
specifications as reported at the PDSP website (http://pdsp.med.unc.edu/). Compounds with 
Ki values more than or equal to 10 µM were considered non-binders and assigned to class 0, 
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whereas compounds with Ki values less than 10 µM were considered binders and assigned to 
class 1.  
Dataset Division for Model Building and Validation. Following our predictive 
QSAR modeling workflow (Tropsha 2010), all QSAR models generated to classify 5-HT6R 
binders vs. non-binders were validated by predicting both test and external validation sets. 
The original dataset of 194 compounds (102 binders and 92 non-binders) was randomly split 
into 5 different subset of nearly equal size to allow for external 5-fold cross validation (CV) 
(Hawkins et al. 2003, Kohavi 1995). In this protocol, each subset including 20% of the 
original dataset was systematically employed as the external validations set while the 
remaining 80% of the compounds constituted the modeling set.  
Another level of internal validation was achieved by comparing model performance 
for training and test sets. This approach is always employed as a part of our predictive QSAR 
modeling workflow (Tropsha 2010, Tropsha & Golbraikh 2007) to emphasize the fact that 
training-set-only modeling is not sufficient to obtain reliable models that are externally 
predictive (Golbraikh & Tropsha 2002a). Thus, for each collection of descriptors, the 
modeling sets (each including 80% of the original dataset) were further partitioned into 
multiple chemically diverse training and test sets of different sizes using the Sphere 
Exclusion method implemented in our laboratory (Golbraikh & Tropsha 2002b). Only 
models that were highly predictive on the test sets were retained for the consensus prediction 
of the external validation sets. Finally, highly predictive models on both external sets were 
used in consensus fashion for virtual screening of external compound libraries.  The model 
building and validation approach is illustrated schematically in Figure 2. 
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QSAR Modeling. Two QSAR modeling approaches of different nature were used 
concurrently to generate classification models for 5-HT6R binders vs. non-binders (Fig. 5.2). 
The first approach relied on k-nearest neighbor (kNN) model optimization method combined 
with Dragon descriptors, and the second employed classification based on association (CBA) 
and subgraphs (SG) descriptors.  
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Figure 5.2. The workflow for QSAR model building, validation and virtual screening as 
applied to 5-HT6R dataset. 
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Molecular Descriptors. Both Dragon and SG descriptors were generated for dataset 
compounds. The final set of Dragon descriptors  used in this QSAR study included 331 descriptors. 
These descriptors were range-scaled so their values ranged from 0 to 1. For generating SG descriptors 
we used a support value of 15 %, and the defaults for the lower and upper size limits of the 
generated subgraphs were 2 and 1000 atoms consecutively. The average number of generated 
SG descriptors was about 400. These descriptors were then used for modeling 5-HT6R 
dataset with Classification Based on Association (CBA) method (Liu et al. 2001). All details 
about molecular decsriptors can be found in Chapter 2. 
Machine Learning Methods. In this study, we used variable selection classification 
kNN method with Dragon descriptors and the software implemented in our lab (Zheng & 
Tropsha 2000) to develop QSAR models for 5-HT6R binders vs. non-binders. We also used 
CBA with SG descriptors to build a classifier for 5-HT6R binders vs. non-binders. All 
computational details about these methods are discussed in Chapter 2. 
 Selection and Validation of QSAR Models 
As mentioned earlier, model validation is crucial for QSAR modeling. To evaluate the 
predictive power of a model, CCR (Eq. 1) values for the training, test, and external validation 
sets were calculated. We used sensitivity (SE) and specificity (SP) (refer to supplementary 
material) as well. SE and SP reflect the accuracy of predicting the compounds of binder 
(class 1) and non-binder (class 0) classes, respectively. We considered a QSAR model to have 
an acceptable predictive power, if both of the following conditions were satisfied:  
(i) CCR for the LOO cross-validation of the training and test sets 
(i.e., ) were at least 70% 
(ii) SE and SP for both training and test sets (i.e.,  ,  ,  , ) 
were at least 70%.  
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Applicability Domains. We applied AD in this study to avoid unreliable predictions. 
We defined the AD as a distance threshold DT between a compound under prediction and its 
nearest neighbors of the training set according to Equation 2.9. We set the default of Z at 0.5. 
We also defined a global AD in the entire descriptor space. In this case, the same formula 
(Eq. 2.9) was used, Z=0.5, k=1 and Euclidean distances were calculated using all descriptors. 
Thus, if the distances of the external compound from its k nearest neighbors (see above) in 
the training set within either the entire descriptor space or the selected descriptor space 
exceeded these thresholds, no prediction was made. In this study, applicability domain 
calculations were carried out using Dragon descriptors and kNN. 
 Robustness of QSAR Models. Y-randomization (randomization of response) is a 
widely used approach to validate the robustness of QSAR models (Wold & Eriksson 1995). It 
consists of rebuilding the models using randomized activities of the training set and 
subsequent assessment of model statistics. It is expected that models obtained for the training 
set with randomized activities should have significantly lower values of CCR for the training 
or the test set than the models built using training set with real activities, or at least these 
models should not satisfy some of the validation criteria mentioned above. If this condition is 
not satisfied, models built for this training set with real activities are not reliable and should 
be discarded.  
Consensus Prediction. Consensus prediction implies averaging the predictions for 
each compound by majority voting for classification QSAR models, using all models passing 
the validation criteria (e.g., CCRtrain and CCRtest above or equal to 0.70). Our experience 
suggests that consensus prediction provides the most stable and accurate solutions (Zhu et al. 
2008a).  In general, in order to determine the confidence in the obtained predictions we need 
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to define a consensus score. The consensus scores employed in this study take into account 
the total number of models used to predict a compound‘s activity, and the number of models 
that predicted the compound to belong to a specific class. In case of predicted binders 
(assigned to class 1), we accept predictions made with no less than half of the total 
acceptable models. Because we define two classes of compounds, i.e., class 1 (binders) and 
class 0 (non-binders), some models may predict a compound to belong to class 0 and others 
may predict it to belong to class 1. As a result, consensus scores (CS) between 0 and 1 will 
be obtained for each of the predicted compounds. As an additional measure of confidence 
(and an additional applicability domain criterion) we only accepted those predictions that had 
an average predicted value (consensus score) above 0.70 (for binders) or below 0.30 (for 
non-binders).  
Virtual Screening. To identify putative ligands, validated consensus kNN-Dragon 
models generated for 5-HT6R ligands were used for virtual screening of the 59000 molecules 
within both the WDI chemical library (Daylight 2004) and 1300 DrugBank compounds 
included in the cmap database. The identified hits (by consensus agreement between all 
accepted kNN-Dragon models) were then evaluated additionally using CBA-SG classifier 
when it was a need to reduce the size of the VS library generated with kNN-Dragon models.  
(2) Biological Network Mining 
Querying the cmap with Alzheimer’s Disease Gene Signatures. The cmap (Lamb 
et al. 2006) was used to discover unexpected connections between chemicals, genes and the 
Alzheimer‘s disease by generating a detailed map that links gene patterns associated with 
Alzheimer‘s to corresponding patterns produced by drug candidates and a variety of genetic 
perturbations included in the cmap database. The effects of different drugs and diseases are 
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described using ―genomic signatures" — the full complement of genes that are turned on and 
off by a particular drug or disease. We start by querying the online database (cmap: 
http://www.broadinstitute.org/cmap/) with Alzheimer‘s disease gene signatures. Then, a 
computer program, that uses sophisticated pattern-matching methods, matches the barcodes 
based on the patterns shared among Alzheimer‘s gene signature and drugs included in the 
cmap. 
Alzheimer’s Disease Gene Signatures. In order to query the cmap, a disease gene 
signature should exist. Two lists of genes are required to perform the query: a list of up-
regulated genes and a list of down-regulated genes characteristic of a disease. Query 
signatures can be obtained from two major sources: (1) biological literature: gene signatures 
of diseases can be extracted through the National Library of Medicine‘s PubMed system 
(http:// www.ncbi.nlm.nih.gov/pubmed), (2) GEO(Edgar et al. 2002, Barrett & Edgar 2006) 
database: a gene expression/molecular abundance repository supporting MIAME (Brazma et 
al. 2001) (Minimum Information About a Microarray Experiment) compliant data 
submissions, and a curated, online resource for gene expression data browsing, query and 
retrieval. For the purposes of this study, two independent reports of gene-expression changes 
in brain tissues from Alzheimer‘s patients were used to derive gene signatures (i.e., lists of 
genes up- and down- regulated in Alzheimer‘s disease) to query the cmap. Signature 1 (from 
hippocampus) consisted of 40 genes reported by Hata, R.  et al (Hata et al. 2001), and 
signature 2 (from cerebral cortex) consisted of 25 genes reported by Ricciarelli, R. et al 
(Ricciarelli et al. 2004). NetAffx was then used to map gene symbols and Unigene identifiers 
to populate gene signature lists with Affymetrix U133A probe sets to query the cmap. 
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(3) Hypothesis Fusion 
Data fusion is the process of combining multiple data in order to produce new 
information that improves the performance of the system (i.e., the in silico model or 
predictor). This fusion approach was first developed for applications in signal 
processing(Klien 1999) and later it was applied in VS efforts to enable better decisions as to 
which small number of molecules should go further for biological testing (Sukumar et al. 
2008, Whittle et al. 2006a, Whittle et al. 2006b). Herein, we cross-examined and fused 
structural hypotheses generated independently from both QSAR-based VS and biological 
network mining efforts to identify and accept common hits only. This step of merging 
hypotheses was based on structural identity comparisons. All chemical structures of cmap 
compounds were retrieved from DrugBank (Wishart et al. 2006, Wishart et al. 2008) using 
their DrugBank identifiers. Identical structures only were then accepted for further analysis. 
All chemical structures labeled as identical were also subjected to a manual curation step 
where structures and names of the chemical compounds were compared in different 
databases to make sure they both refer to the same chemical entity. Common hits were then 
considered for further experimental validation. 
Experimental Validation in Radiologand Binding Assays 
Final common hit compounds from QSAR-based VS and cmap negative connections 
with Alzheimer‘s were purchased and submitted to PDSP for experimental target validation. 
The experimental details are discussed in Chapter 2. 
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Results and Discussion 
QSAR Modeling of 5-HT6R Binders and Non-binders 
kNN with Dragon descriptors was employed to classify modeling set compounds into 
5-HT6R binders vs. non-binders. The five modeling sets derived from applying the external 
5-fold CV technique were divided into multiple training and test sets (28-40 divisions) using 
the Sphere Exclusion algorithm as described in Methods. Multiple QSAR models were 
generated independently for all training sets and applied to the test sets. Generally, we accept 
models with CCR values above or equal to 0.70 for both the training and test sets. However, 
because we were able to generate thousands of acceptable models, we used more 
conservative criteria (i.e., CCRtrain and CCRtest above or equal to 0.90) for model selection to 
predict external compounds. Results of Y-randomization tests confirmed that kNN-Dragon 
classification models with CCRtrain and CCRtest values above or equal to 0.90 were robust. 
None of the models with randomized class labels of the training set compounds had CCRtrain 
and CCRtest above 0.65 or CCRevs above 0.55 for any split.  
The CBA method was used to classify the dataset using SG descriptors. The dataset 
was initially divided, using external 5-fold cross validation technique, into modeling sets 
with about 155 compounds each and external validation sets containing about 39 compounds 
each. The modeling sets were then used to build the classifier in CBA(Liu et al. 2001) using 
an initial pool of about 400 SG descriptors. The classifier gave an average CCRtrain of 0.92 
(i.e., the average resulted from five different tests). Then, the external validation set 
consisting of 39 compounds was used to assess the robustness of the classifier. The average 
CCRtest was 0.78, which is not as high the CCR value for the training set, but is still 
statistically acceptable. 
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Clearly, kNN (mean CCRevs = 0.92) performed better than CBA (mean CCRevs 
equal to 0.78) on the external validation sets (see Fig. 5.3). Therefore, we chose to use 
kNN-Dragon models for VS of external drug libraries. Nevertheless, we maintained 
CBA-SG models as an additional filter to suggest smaller sets of compounds as 5-HT6R 
putative binders selected from the list of virtual hits obtained with kNN-Dragon models 
and therefore predicted by both models as putative binders. 
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Figure 5.3. Comparison of the QSAR approaches to classify 5-HT6R binders vs. non-binders 
based on CCRevs.  
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QSAR-Based Virtual Screening 
Since our models proved reasonably accurate based on external validation sets, we 
used the best models to mine two external databases of approved and potential drugs for 
putative 5-HT6R ligands. The use of AD assures reliable predictions by the models. Therefore, 
we used two types of ADs in the virtual screening of compound databases. First, we used a 
global AD that acted as a filter and ensured some level of global similarity between the 
predicted compounds and the compounds in the modeling set. Second, we defined a local AD 
for each of the individual classification models.  
We first screened the WDI database of about 59000 compounds (approved or 
investigational drugs) (Fig. 5.4). This original collection had many duplicates (i.e., many salt 
forms for the same chemical entity), and these duplicates were removed using MOE. We also 
removed all compounds included in our modeling and external validation sets. Dragon 
descriptors were generated for the remaining 46859 unique compounds in the database; of 
these, 9732 compounds were excluded because Dragon was unable to calculate at least one 
of the descriptors generated for the modeling set. The remaining 37127 compounds were then 
subjected to a global AD filter for the modeling set using a strict Z cutoff of 0.5 (which 
formally places the allowed pairwise distance threshold at the mean of all pairwise distance 
distribution for the training set plus one-half of the standard deviation). Then, all kNN-
Dragon models with CCRtrain and CCRtest above or equal to 0.70 were employed in consensus 
fashion to predict 1500 compounds remaining after several filtering steps, which resulted in 
the identification of the 600 predicted binders. In an effort to reduce the number of hits, we 
have generated SG descriptors for these 600 molecules and applied the CBA-SG classifier 
which filtered out half of these compounds, leaving 300 compounds as putative binders for 5-
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HT6R. None of these hits was tested in this manuscript since we explicitly focused on 
compounds from DrugBank that were employed in the cmap project.  These VS hits from 
WDI should be viewed as structural hypotheses awaiting the experimental confirmation; the 
report on these studies is reserved for separate future publication. 
Additionally, we screened 1300 DrugBank compounds included in the cmap database. 
Dragon descriptors were computed for 1273 unique compounds. These compounds were then 
subjected to a global AD filter for the modeling set using a strict Z cutoff of 0.5. 
Consequently, we placed the allowed pairwise distance threshold at the mean of all pairwise 
distance distribution for the training set plus one-half of the standard deviation which 
resulted in 577 predictions within the applicability domain. Next, validated consensus kNN-
Dragon models (i.e., all models with CCRtrain and CCRtest above or equal to 0.90) were used 
to predict these 577 compounds, resulting in the identification of 140 unique compounds 
predicted to be 5-HT6R binders. We did not apply the CBA-filter here because, for the 
subsequent integration with the cmap mining results, we wanted to explore a larger set of all 
140 compound hits (i.e., putative 5-HT6R binders) included in the cmap datasets predicted by 
kNN-Dragon models.  
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Figure  5.4. A representation for QSAR-based virtual screening steps of two chemical 
databases: the WDI and DrugBank compounds included in the cmap. 
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Searching the Connectivity Map for Potential Anti-Alzheimer’s Agents 
We used two gene signatures for the Alzheimer‘s disease (designated a S1 and S2) to 
query the cmap database in an attempt to link genes associated with the disease to potential 
therapeutic agents. These two signatures were based on two independent rank-ordered gene 
lists provided by two different Gene Set Enrichment Analysis (GSEA) studies (Hata et al. 
2001, Ricciarelli et al. 2004). The two disease signatures were compared with predefined 
signatures of therapeutic compounds included in the cmap and ranked according to a 
connectivity score (ranging from +1 to -1), representing relative similarity to the disease gene 
lists. The connectivity score itself is derived using a nonparametric, rank-based, pattern-
matching strategy based on the Kolmogorov-Smirnov statistic (Hollander & Wolfe 1999). 
Connectivity scores are calculated using the online tools available at the cmap 
(http://www.broadinstitute.org/cmap/).  All instances in the database are then ranked 
according to their connectivity scores; those at the top (+) are most strongly correlated to the 
query signature and looked at as disease causes, and those at the bottom (-) are most strongly 
anti-correlated and considered as possible therapeutics (see Fig. 4.5 for concept). 
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Figure 5.5. Querying the connectivity map with Alzheimer‘s disease gene signatures (S1 and 
S2).  
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The majority of chemicals included in the cmap database are represented by multiple 
independent replicates. Most compounds are profiled in three different cell lines, some at 
different concentrations.  These are called ‗instances‘ for the same chemical which are 
defined as ―a treatment and control pair and the list of probe sets ordered by their extent of 
differential expression between this treatment and control pair‖ (The connectivity map 2010). 
The instance is the basic unit of data and metadata in cmap. Instances of the same compound 
might have similar or dissimilar connectivity scores with the query signature. We have higher 
confidence in the derived connections when gene signatures are conserved across diverse cell 
types and experimental settings. However, Lamb and colleagues (Lamb et al. 2006, Lamb 
2007) indicated that the non-consistent scoring of different instances of the same chemical 
may represent either (1) a cellular-context dependent difference in activity, (2) a 
concentration-discriminated effect, or (3) poor reproducibility between replicates. Therefore, 
‗best‘ connections are those where multiple, autonomous instances of the same chemical 
have consistently high (or low) scores. However, inconsistently scoring compounds should 
not necessarily be dismissed since their significance as potential treatments for a disease can 
be boosted by additional evidence, such as predictions from QSAR models. 
In this study, we were interested in compounds whose chemogenomics profiles were 
negatively correlated with the Alzheimer‘s disease gene signatures. Hits with statistically 
significant, negative connectivity scores could be potential treatments for the Alzheimer‘s 
disease; however, the list of negatively correlated molecules might be long and must be 
analyzed carefully before suggesting hypotheses of possible mechanisms for controlling or 
mediating the disease. Examples of top negative connections with both signatures S1 and S2 
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are shown in Tables 5.1 and 5.2, respectively.  Although the two gene signatures (i.e., for the 
Alzheimer‘s disease) used to query the cmap shared no common genes, both queries resulted 
in a common list of negative connections which were given a higher confidence in our 
studies. All chemical structures for each chemical compound included in the cmap were 
obtained from the DrugBank and mapped based on the DrugBank identifiers provided by the 
cmap database.  
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Table 5.1. Top twenty negative connections from the cmap with S1. 
Compound Rank
a
 Cell Score Instance_ID 
Naproxen 6100 PC3 -1 7146 
Sulfacetamide 6099 MCF7 -0.990 1695 
Amprolium 6098 HL60 -0.930 1979 
Aminoglutethimide 6097 MCF7 -0.913 7463 
Ioxaglic acid 6096 HL60 -0.897 2966 
Dexpanthenol 6095 MCF7 -0.871 7455 
Suxibuzone 6094 MCF7 -0.870 7163 
Chlorphenesin 6093 HL60 -0.862 1432 
Metixene 6092 HL60 -0.853 2451 
Fulvestrant 6091 MCF7 -0.843 5565 
Seneciphylline 6090 MCF7 -0.841 2797 
Troglitazone 6089 MCF7 -0.839 6991 
Dicloxacillin 6088 HL60 -0.834 2445 
Phentolamine 6087 HL60 -0.831 2362 
Monocrotaline 6086 MCF7 -0.828 6771 
Lymecycline 6085 HL60 -0.823 2953 
Bezafibrate 6084 PC3 -0.815 6653 
6-Benzylaminopurine 6083 HL60 -0.812 2351 
Terbutaline 6082 MCF7 -0.811 3202 
Clorgiline 6081 MCF7 -0.805 3219 
a
The rank order is generated from estimating the connectivity scores 
of 6100 individual treatment instances with S1.  A rank order of 
6100 corresponds to the compound with the strongest negative 
connectivity S1, while a rank order of 1 corresponds to the 
compound with the strongest positive connectivity with S1. 
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Table 5.2. Top twenty negative connections from the cmap with S2 
Compound Rank
a
 Cell Score Instance_ID 
Trifluoperazine 6100 HL60 -1 2389 
Clomifene 6099 MCF7 -0.982 4994 
Ethotoin 6098 HL60 -0.977 2196 
Sulfafurazole 6097 HL60 -0.973 1603 
Quercetin 6096 MCF7 -0.964 4846 
Triflusal 6095 HL60 -0.925 1717 
Alfuzosin 6094 PC3 -0.903 4644 
Metitepine 6093 HL60 -0.890 1616 
Trioxysalen 6092 MCF7 -0.885 6216 
LY-294002 6091 MCF7 -0.883 258 
Tanespimycin 6090 HL60 -0.873 6184 
Spironolactone 6089 MCF7 -0.871 6255 
Nifurtimox 6088 MCF7 -0.859 4953 
Iobenguane 6087 HL60 -0.847 1729 
U0125 6086 PC3 -0.845 663 
Monorden 6085 MCF7 -0.841 5947 
Primidone 6084 PC3 -0.833 6723 
Calcium pantothenate 6083 MCF7 -0.828 4775 
Phthalylsulfathiazole 6082 HL60 -0.826 3033 
Ceforanide 6081 PC3 -0.824 6751 
a
The rank order is generated from estimating the connectivity scores 
of 6100 individual treatment instances with S2.  A rank order of 
6100 corresponds to the compound with the strongest negative 
connectivity S2, while a rank order of 1 corresponds to the 
compound with the strongest positive connectivity with S2.
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Hypothesis Generation: Integrating and Fusing Independent Hypotheses from QSAR-
Based VS and cmap Analysis 
We fused hypotheses produced from two different datasets and using two different 
computational methods (Fig. 5.1): (1) QSAR-based datamining of chemical databases in an 
effort to identify novel ligands for 5-HT6R, and (2) Network-mining using two signatures for 
Alzheimer‘s disease to query the cmap and identify possible anti-Alzheimer‘s therapeutics. 
Our procedure for hypothesis fusion was based on structural identity for chemical 
compounds derived from both approaches mentioned above. Compounds with negative 
connectivity scores, representing genes expressed in an opposite fashion to the imported 
Alzheimer‘s disease query—which implies their potential benefits to be candidate treatments, 
were compared with 5-HT6R hits predicted from QSAR-based VS.   
The primary goal for fusing hypotheses in this study was initially to overcome some 
of the inherent hit scoring problems in classification QSAR, and to achieve higher success 
rates in experimental testing of the VS hits. In other words; we often select for further 
experimental validation those QSAR hits with consensus scores above or equal to 0.90 (refer 
to consensus scores in methods). However, many novel scaffolds that are significantly 
different (i.e., structurally and therapeutically) from the training set compounds, might have 
lower consensus scores ranging from 0.50 to 0.90 despite the fact that they might be binders 
too. Thus, this process of fusing hypotheses derived independently from different types of 
data and using multiple prediction methods, allowed us to fish out these low-confidence 
QSAR hits (that yet could be highly important ligands) for further analysis. As a result, we 
posit that fusing independent hypotheses is likely to improve the overall success rates of in 
silico lead identification.  
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Additionally, our approach could be used to aid in the process of prioritizing 
connections from the cmap that might be difficult to call otherwise, especially as the size of 
the database continues to grow. In diseases like the Alzheimer‘s, with little knowledge about 
specific etiology, and the lack of drug gene signatures generated from neuronal cell lines, it is 
hard to decide a priori which negative connections are more important to be viewed as 
potential therapeutics. Thus, fusing hypotheses derived independently from cmap and QSAR 
should enable us to increase the confidence in recovered connections. 
Scoring and Fusing Structural Hypotheses to Identify Anti-Alzheimer’s Agents  
Our method for decision fusion was derived from a combination of voting and 
statistical metrics. In the first step, we used two different scoring functions to rank the 
computational hits generated independently from both QSAR and cmap. In the QSAR study, 
we used the kNN ‗consensus score‘ which takes into account the total number of models used 
to predict compound‘s activity, and the number of models that predicted the compound to 
belong to a specific class correctly. We considered all computational hits that had an average 
predicted value (i.e., consensus score) above or equal to 0.50 for further inspection. Our 
analysis resulted in 140 putative 5-HT6R binders among cmap compounds and with kNN 
consensus scores ranging from 0.50-1.00 (see Fig. 5.6). 
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Figure 5.6. The workflow for fusing hypotheses from QSAR modeling and cmap negative 
connections.   
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On the other hand, we used the connectivity scores (Lamb et al. 2006) to rank the hits 
resulted from querying the cmap with Alzheimer‘s disease gene signatures. Because we were 
interested in identifying novel treatments for Alzheimer‘s disease, we ranked hits with larger 
(-) connectivity scores at the top and gave them higher confidence. Such compounds were 
hypothesized to have higher chances to reverse the Alzheimer‘s gene signatures and therefore 
might have immense therapeutic value in Alzheimer‘s disease. We considered for further 
analysis all compounds that had at least one instance of negative connection with any of the 
two gene signatures used to query the cmap (S1 and S2) so that not to miss any important 
connections. Our analysis resulted in identifying 881 negative connectivity instances with S1 
and 861 instances with S2 (Fig. 5.6).   
Finally, we fused the hypotheses generated from both QSAR and cmap analyses and 
accepted common hits only. We identified 97 compounds that were both predicted to be 
active at 5-HT6R  and had at least one instance of negative connectivity with S1 and 106 
compounds that had at least one instance of negative connectivity with S2. Accepting only 
common hits among S1 and S2 resulted in 73 putative hits (see Fig. 5.6). At this stage we 
applied a manual curation where we inspected all available data for these 73 hits. Each of the 
73 common hits had three scores (kNN consensus score, cmap connectivity score with S1, 
and cmap connectivity score with S2) to be considered in the final decision to prioritize hits 
for further testing. Therefore, we estimated the average connectivity scores for all predicted 
hits across all treatment instances for each of the S1 and S2 hits. Then we excluded those 
compounds that had high positive connectivity scores in some treatment instances of the 
same compound. Finally, we retained 39 compounds that had acceptable negative average 
connectivity scores at least with one signature (see Fig. 5.6). We hypothesized that these 
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compounds could be looked at as putative 5-HT6R hits and potential cognitive enhancements. 
One of the final 39 hits, vinpocetine, worth special attention as there is new evidence that has 
just emerged indicating its potential role in the treatment of Parkinson's disease and 
Alzheimer‘s disease (Jeon et al. 2010, Medina 2010). Details on all these 39 VS hits are 
provided in Tables 5.3 and 5.4. 
Each of the 39 common hits had three scores (kNN consensus score, cmap 
connectivity score with S1, and cmap connectivity score with S2) to be considered in the 
final decision to prioritize hits for further experimental testing. We plotted the mean 
connectivity scores vs. kNN QSAR consensus scores generating separate plots for S1 and S2 
(see Fig. 5.7) to analyze these hits in further details.  
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Table 5.3. Final thirty nine computational hits from QSAR-based VS and cmap. 
cmap Name 
cmap 
Score 1 
cmap 
Score 2 
Num. kNN 
Models 
kNN 
CS 
kNN 
Pred 
CBA 
Pred 
Acepromazine -0.528 -0.496 441 0.93 B B 
Alimemazine -0.121 -0.117 438 1.00 B B 
Astemizole -0.349 -0.237 328 0.91 B B 
Bepridil -0.134 -0.409 393 0.89 B B 
Bromperidol -0.239 -0.213 428 0.83 B B 
Cetirizine -0.495 -0.327 421 0.92 B B 
Chlorprothixene -0.277 -0.298 442 0.90 B B 
Cinchocaine -0.004 -0.335 423 0.58 B B 
Cinnarizine -0.349 -0.149 414 0.98 B B 
Citalopram -0.003 -0.260 429 0.71 B NB 
1 (Clomiphene) -0.378 -0.265 409 0.91 B B 
2 (Clomipramine) -0.192 -0.310 437 0.96 B B 
Cloperastine -0.273 -0.353 443 0.88 B B 
3 (Clozpine) 0.093 -0.058 422 0.97 B B 
Diltiazem -0.128 -0.336 433 0.72 B NB 
4 (Doxepin) 0.027 -0.259 444 0.95 B B 
5 (Fendiline) -0.303 -0.228 393 0.84 B NB 
Flavoxate -0.127 -0.112 403 0.71 B NB 
6 (Fluspirilene) 0.055 -0.138 351 0.98 B B 
Imipramine -0.400 -0.214 427 0.96 B B 
Laudanosine -0.226 -0.174 411 0.78 B NB 
7 (LY-294002) -0.028 -0.078 428 0.71 B B 
Meclozine -0.365 -0.171 439 0.95 B B 
Mepacrine -0.236 -0.301 418 0.53 B B 
Methylergometrine -0.400 -0.509 441 0.98 B B 
Naftifine -0.198 -0.148 359 0.85 B B 
8 (Nortriptyline) 0.011 -0.354 433 0.93 B B 
Phenoxybenzamine -0.461 -0.309 444 0.79 B NB 
Piperidolate -0.168 -0.119 431 0.69 B NB 
9 (Prestwick-559) -0.247 -0.206 435 0.96 B B 
Prestwick-685 -0.086 -0.213 381 0.72 B B 
Promazine -0.210 -0.307 424 0.97 B B 
10 (Raloxifene) 0.047 -0.058 356 0.56 B NB 
11 (Tamoxifen) 0.300 -0.220 435 0.93 B B 
Telenzepine -0.419 -0.114 387 0.68 B B 
Terfenadine -0.183 -0.512 416 0.51 B NB 
Vanoxerine -0.450 -0.233 374 1.00 B NB 
Vinpocetine -0.177 -0.132 376 0.76 B B 
13 (Zuclopenthixol) -0.152 0.144 434 0.98 B B 
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Table 5.4. Therapeutic classes of the thirty nine final computational hits from QSAR-based 
VS and cmap. 
cmap Name Therapeutic Class/Use 
Acepromazine Antipsychotic 
Alimemazine Antipruritic, sedative, hypnotic and anti-emetic 
Astemizole Anti-Histamine 
Bepridil Calcium channel blocker once used to treat angina 
Bromperidol Neuroleptic, used as an antipsychotic in the treatment of 
schizophrenia 
Cetirizine Second-generation antihistamine 
Chlorprothixene Typical antipsychotic drug of the thioxanthene class 
Cinchocaine Local anesthetic 
Cinnarizine Antihistamine which is mainly used for the control of nausea and 
vomiting due to motion sickness 
Citalopram Antidepressant drug of the selective serotonin reuptake inhibitor 
(SSRI) class 
1 SERM 
2 Tricyclic antidepressant 
Cloperastine Cough suppressant. 
3 Atypical antipsychotics  
Diltiazem Calcium channel blocker 
4 Psychotropic agent with tricyclic antidepressant and anxiolytic 
properties 
5 Calcium channel blocker 
Flavoxate Anticholinergic with antimuscarinic effects 
6 Antipsychotic 
Imipramine Tricyclic antidepressant  
Laudanosine Benzyltetrahydroisoquinoline alkaloid. Interacts with GABA, 
opioid, and nicotinic acetylcholine receptors 
7 Morpholino derivative of quercetin. It is a potent inhibitor of 
phosphoinositide 3-kinase s (PI3Ks) 
Meclozine Antihistamine considered to be an antiemetic 
Mepacrine Antiprotozoal, antirheumatic and an intrapleural sclerosing agent. It 
is known to act as a histamine N-methyltransferase inhibitor 
Methylergometrine Psychedelic alkaloid 
Naftifine Allylamine antifungal drug 
8 Second-generation tricyclic antidepressant 
Phenoxybenzamine Non-specific, irreversible alpha antagonist 
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Piperidolate Antimuscarinic. 
9 Drug used in scientific research which acts as a moderately 
selective dopamine D3 receptor partial agonist. 
Prestwick-685 Not reported in the literature 
Promazine Antipsychotic 
10 SERM 
11  SERM 
Telenzepine Anticholinergic or sympatholytic 
Terfenadine Antihistamine formerly used for the treatment of allergic conditions 
Vanoxerine Piperazine derivative which is a potent and selective dopamine 
reuptake inhibitor (DRI) 
Vinpocetine Vinpocetine has been identified as a potent anti-inflammatory agent 
that might have a potential role in the treatment of Parkinson's 
disease and Alzheimer‘s disease (Jeon et al. 2010, Medina 2010) 
13 Typical antipsychotic drug 
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Figure 5.7.  Plots for kNN scores vs. cmap connectivity scores for 39 final common hits 
from QSAR-based VS and cmap for: (A) Alzheimer‘s disease signature S1, and (B) 
Alzheimer‘s disease signature S2. Squares: compounds predicted and validated as 5-HT6R 
binders having negative connectivity scores with Alzheimer‘s disease gene signatures; 
diamonds: compounds predicted and experimentally validated as 5-HT6R binders but having 
positive connectivity scores with one of the Alzheimer‘s disease gene signatures; triangles: 
compounds predicted as 5-HT6R binders having negative connectivity scores with 
Alzheimer‘s disease gene signatures but found non-binders in radioligand binding assays 
against 5-HT6R; circles: compounds predicted as 5-HT6R binders which have negative 
connectivity scores with Alzheimer‘s disease gene signatures but were not experimentally 
tested. 
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Additionally, another level of confidence was achieved (besides considering both 
kNN CS and cmap scores) by giving more emphasis to molecules that belonged to the same 
pharmacological or therapeutic group or had very high structural similarity to hits of higher 
confidence. This step permitted the retrieval of some compounds that had less significant 
negative connectivity scores with the disease (e.g., null connectivity or even low positive 
connectivity scores in few instances). We noticed that the 39 putative binders belonged to 
several major therapeutic groups (see Table 5.4): antipsychotics, antidepressants, anti-
histamines, selective estrogen receptor modulators (SERMs) and calcium channel blockers. 
Predicting antipsychotics, antidepressants and anti-histamines was not surprising as it is 
known that many of these compounds are active at 5-HT6R receptors (Roth et al. 1994) and 
because the modeling set of compounds in the QSAR study belonged to these classes of 
compounds. However, it was unexpected that SERMs are predicted to have activity at 5-
HT6R.  
Hypothesis Testing: Evaluation of Computational Hits at Human Cloned 5-HT6 
Receptors 
Common hits from QSAR-VS studies and cmap were taken forward for biological 
validation, in binding assays, for 5-HT6R.  As discussed above, we identified 39 chemicals, 
out of 59000 molecules included in the WDI (Daylight 2004), (and out of 1300 compounds 
included in the cmap),  as consensus hits and putative binders for 5-HT6R with higher 
chances of having potential therapeutic effects in Alzheimer‘s disease; none of these hits was 
included in the training set used to develop QSAR models. Then, we prioritized thirteen 
compounds for further experimental validation in 5-HT6R radioligand binding assays (Table 
5.5). Our final selection was based on different criteria: (1) we tested some compounds with 
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high consensus scores and stronger negative connectivity with Alzheimer‘s disease, (2) some 
compounds were selected because they belonged to the same therapeutic class as several 
other predicted hits and were not known before to bind to 5-HT6R such as selective estrogen 
receptor modulators (SERMs) (e.g., clomifene, tamoxifen and toremifene), (3) we tested 
some compounds with low kNN CS (e.g., raloxifene having kNN CS of 0.58) if other hits 
that belonged to the same therapeutic class had high consensus scores (e.g., tamoxifen and 
toremifene having kNN CS above to or equal 0.93 and clomiphene having a kNN CS of 
0.91), (4) we also tried to test predictions that had strong negative connectivity scores with 
one query signature but had much weaker negative connectivity with the second signature to 
see if there is one specific signature that was generating better results.  
We found that ten of these thirteen predicted actives were confirmed experimentally 
to inhibit 5-HT6R radioligand binding thereby achieving a success hit rate of 77 % in this 
proof-of-concept study (see Table 5.5).  
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Table 5.5. Experimental validation results for the thirteen computational hits predicted as 5-
HT6R ligands and had negative connections with Alzheimer‘s disease gene signatures. 
Cp. 
ID 
Compound 
PDSP ID 
CID
a
 
Score1
b
/Cell  
Score2
c
/Cell  
kNN 
CS
d
 
CBA 
Pred.
e
 
Ki 
(nM) 
1 
Clomifene  
13499 
1548953 
-0.602/ PC3 
-0.982/ 
MCF7 
 
0.91 B
f
 1,956.0 
2 
Clomipramine 
13494 
2801 
-0.768/PC3 
-0.814/MCF7 
 
0.96 B 112.0 
3 
Clozpine 
24842 
2818 
-0.590/PC3 
-0.652/MCF7 
 
0.97 B 17.0
g
 
4 
Doxepin  
13495 
667477 
 
-0.463/MCF7 
-0.777/HL60 
 
0.95 B 105.0 
5 
Fendiline 
14821 
3336 
-0.520/MCF7 
-0.683/HL60 
 
0.84 NB
h
 NB 
6  
Fluspirilene  
14815 
3396 
 
-0.493/MCF7 
-0.551/HL60 
 
0.98 B 1,188.0 
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7 
 
LY-294002  
13502 
3973 
 
-0.790/MCF7 
-0.883/MCF7 
 
0.69 B NB 
8 
Nortriptyline  
13503 
4543 
 
-0.555/PC3 
-0.586/MCF7 
 
0.96 B 214.0 
9 
Prestwick-559  
13498 
3038495 
-0.741/MCF7 
-0.619/HL60 
 
0.79 B NB 
10 
Raloxifene  
13505 
5035 
-0.626/HL60 
-0.619/HL60 
 
0.56 NB 750.0 
11 
Tamoxifen  
13506 
2733526 
0/MCF7 
-0.531/MCF7 
 
0.93 B 1,041.0 
12 
Toremifene
i
  
16514 
3005573 
N/A 
N/A 
0.93 B 4,125.0 
13 
 
 
Zuclopenthixol 
13510 
5311507 
-0.609/PC3 
-0.746/HL60 
 
0.98 B 169.0 
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Success Rate  
77 % for predictions  
with kNN CS ≥ 0.5 
Success Rate  
100% for predictions  
with kNN CS ≥ 0.9 
a
CID, PubChem compound ID;
 b
cmap score1, the highest negative connectivity score for 
this compound with S1 (or the smallest positive in case all other scores are positive); 
c
cmap score2, the highest negative connectivity score for this compound with S2 (or the 
smallest positive in case all other scores are positive); 
d
CS, consensus score; 
e
CBA pred., 
predicted binding to 5-HT6 receptors by CBA; 
f
B, binder; 
g
PDSP certified data; 
h
NB, non-
binder; 
i
Toremifene was not included in the cmap but was prioritized because 3 other 
related SERMs were hits from both cmap and QSAR-based VS. 
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One of these ten confirmed hits was clozapine, which is known to bind 5-HT6R but 
was not included in our training set. Binding affinity (Ki) values for the nine predicted hits 
were in the range 17 - 4125 nM, with six compounds having Ki values < 1 µM. These six 
highest affinity compounds were: clozapine (Ki=17 nM), doxepin (Ki=105 nM, Fig. 5.8 (A)), 
clomipramine (Ki=112 nM, Fig. 5.8 (B)), zuclopenthixol (Ki=169 nM, Fig. 5.8 (C)), 
nortriptyline (Ki=214 nM, Fig. 5.8 (D)) and raloxifene (Ki=750 nM, Fig. 5.8 (E)).  Of these, 
raloxifene was the most surprising. 
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Figure 5.8. Competition binding isotherms at 5-HT6R for several predicted actives: (A) 
clomipramine (2, red triangle) and chlorpromazine (square), and doxepin (4, blue triangle) 
and chlorpromazine (square); (B) nortiptyline (8, red triangle) and chlorpromazine (square), 
and raloxifene (10, blue triangle) and chlorpromazine (square); (C) zuclopenthixol (13, 
triangle) and chlorpromazine (square), versus [3H]LSD.  
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Among the tested compounds, we found that compounds having negative 
connectivity scores and kNN CS above 0.90 were all true actives at 5-HT6R achieving a 
success rate of 100%. We also found that lowering the threshold to 0.50 resulted in 3 false 
positives which decreased the success rate down to 77 %. It was strikingly important that we 
were able to prioritize a VS hit (i.e., raloxifene) with very low kNN CS of 0.56 and 
insignificant negative connectivity scores with Alzheimer‘s (see Table 5.5) and validate that 
this compound was a true binder of 5-HT6R and a potential therapeutic for Alzheimer‘s 
disease. This is a clear example on the importance of integrating and fusing independent 
hypotheses to increase the confidence of otherwise ‗desperate‘ computational hits. 
Mining of the biomedical literature using ChemoText identified possible 
neuroprotective, in addition to cognitive- and memory-enhancing effects for most of the 
computational hits (see Table 5.6), although there is no evidence that 5-HT6R –active 
compounds are neuroprotective. The list of all 39 compounds predicted by our integrative 
approach as putative 5-HT6R binders with possible anti-Alzheimer‘s effects is shown in 
Table 5. In addition, the top 100 VS hits (i.e., putative 5-HT6R ligands) from the WDI 
identified by the QSAR/VS approach are provided in the Supporting Information.  
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Table 5.6. The significance of the tested hits in relation to cognition, neuroprotection and 
anti-Alzheimer‘s effects. 
Compound Predicted Ki 
Significance to Alzheimer’s disease 
prevention/treatment 
1 Active 1956.0 Unknown 
2 Active 112.0 Neuroprotective (Hwang et al. 2008) 
3 Active 17.0 
Used in combination therapy for Alzheimer‘s (PFEIFER 
et al. 2009) 
4 Active 105.0 Unknown 
5 Active NB GABA receptor modulator (Ong & Kerr 2005, Ong et 
al. 2005) and may inhibit amyloid-beta protein 
oligomerization as other related antihypertensives (Zhao 
et al. 2009) 
6 Active 1188.0 Possible anti-Alzheimer‘s effects (Zhang et al. 2007) 
7 Active NB 
Can inhibit central sensitization and neuroinflammation 
(Horwood et al. 2006, Pezet et al. 2008) 
8 Active 214.0 
Possible anti-Alzheimer‘s effects (Doraiswamy et al. 
2003) 
9 Active NB Unknown 
10 Active 750.0 Possible anti-Alzheimer‘s effects (Yaffe et al. 2005) 
11 Active 1041.0 Neuroprotective (O'Neill et al. 2004) 
12 Active 4125.0 Unknown 
13 Active 169.0 Facilitates memory in rats (Khalifa 2003) 
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SERMs Identified as 5-HT6R Ligands 
 Several selective estrogen receptor modulators (SERMs) were predicted as 5-HT6R 
ligands and also had negative connections with the Alzheimer‘s disease gene signatures.  
Clomifene, raloxifene and tamoxifen had negative connections with Alzheimer‘s disease 
gene signatures in the cmap database (Lamb et al. 2006). Toremifene was not included in the 
cmap but was predicted as 5-HT6R binder by QSAR-based VS. Although anti-Alzheimer‘s 
effects of these drugs were observed previously and attributed to their modulation of estrogen 
receptors (ERs), the evidence about ER modulators or hormone replacement therapy in 
postmenopausal women to prevent or treat the Alzheimer‘s disease has been inconclusive 
and sometimes even contradictory (Asthana et al. 2009, Henderson 2009, Shumaker et al. 
2003). Although postmenopausal estrogen depletion is a known risk factor for Alzheimer‘s 
disease, estrogen-containing hormone therapy initiated during late postmenopausal period 
does not improve episodic memory (an important early symptom of Alzheimer's disease), 
leads to no improvement or adverse effect on overall cognitive performance and Alzheimer‘s 
disease in postmenopausal women (Pinkerton & Henderson 2005, Rapp et al. 2003, 
Shumaker et al. 2003), and it increases the risk of dementia (Henderson 2009, Shumaker et 
al. 2003). Be that as it may, there is still substantial evidence from both pre-clinical and 
human studies that ovarian steroids have significant effects on neuroregulatory pathways 
(Schmidt & Rubinow 2009, Benmansour et al. 2009, Frye 2009, Ledoux et al. 2009, Woolley 
2007b, Hart et al. 2007, Woolley 2007a, Woolley & Schwartzkroin 1998). However, critical 
gaps exist in our knowledge of both the effects on brain function of declining ovarian steroid 
secretion during reproductive aging, and the role of ovarian steroid hormone therapy in the 
prevention or treatment of brain diseases (Asthana et al. 2009). 
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Raloxifene Identified as a 5-HT6R Ligand and Agent with Potential Utility in 
Alzheimer’s Disease 
Raloxifene is a selective estrogen receptor modulator used to prevent or treat 
osteoporosis; recently it was also approved by the FDA as an anti-cancer drug for reducing 
the risk of invasive breast cancer in postmenopausal women (FDA 2007).  It was one of the 
low confidence QSAR-based VS hits because of the low structural similarity with modeling 
set compounds. Therefore, we would have avoided testing this compound if it had not been 
predicted from the cmap to have a decent negative connection with Alzheimer‘s disease. 
Another level of confidence was obtained from having other compounds that belonged to the 
same pharmacological group (SERMs) which were predicted as 5-HT6R actives with high 
confidence (i.e., consensus scores above 0.90) and had negative connections with 
Alzheimer‘s disease. This example highlights the value of the integrated informatics 
approach in increasing the hit rates of QSAR-based VS. Experimental testing had indeed 
confirmed that raloxifene binds to 5-HT6R with a Ki of 750 nM (Table 5.5, Fig. 5.8 (E)).  
Yaffe and coworkers examined the data from the Multiple Outcomes of Raloxifene 
Evaluation (MORE) trial and indicated that raloxifene given at a dose of 120 mg/day, but not 
60 mg/day, led to reduced risk of cognitive impairment in postmenopausal women. The 
maximum plasma concentration (Cmax) at such high doses indicated that administration of a 
single dose of 185 mg of raloxifene hydrochloride to four healthy volunteers resulted in a 
maximum plasma concentration (Cmax) of 12.5 μg/L (~26 nM) (Morello et al. 2003). 
We hypothesize that our studies identified raloxifene‘s putative cognition enhancing 
effects by suing QSAR-assisted analysis of cmap connectivity scores. In the same time cmap 
analysis helped in prioritizing  raloxifene, despite its very low kNN CS,  as 5-HT6R binder 
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which turned out to have a decent binding to a very important potential target for cognition 
enhancement. Although raloxifene was not considered before as an attractive CNS drug due 
to its pharmacodynamic profile, the current findings of the MORE study, and others 
(Littleton-Kearney et al. 2002) pointed out that raloxifene enters the brain in relevant 
quantities and exerts a measurable effects in humans. 
However, it is very possible that raloxifene‘s anticipated anti-Alzheimer‘s effects 
could be due to complex polypharmacological profile effecting several protein targets and 
signaling pathways involved in memory, cognition, inflammation, oxidative control and 
other important biological processes to Alzheimer‘s disease etiology, and not limited to its 
canonical targets (i.e. estrogen receptors). Future animal studies are required to validate the 
mechanism(s) of action for raloxifene‘s anti-Alzheimer‘s effects.  Currently,  raloxifene is in 
phase II clinical trials for Alzheimer‘s disease (NIA.NIH 2010).  
Predict and Validate Polypharmacology of SERMs 
 Our receptor family models suggested ploypharmacological effects for SERMs 
through their predicted activities against 5-HT, adrenergic alpha, dopaminergic, histamine, 
muscarinic, and Sigma receptors (see Table 5.7). However, a closer look at the chemical 
structures of these compounds revealed some level of chemical dissimilarity between 
raloxifene and the three other SERMs studied here (i.e., clomiphene ,tamoxifen and 
toremifene).  
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Table 5.7. Predicting polypharmacology of SERMs using receptor family-based QSAR 
models described in Chapter 3. 
Compound 
Serotonin Alpha Dopamine Muscarinic Histamine Sigma 
Pred
a
 Exp
b
 Pred Exp Pred Exp Pred Exp Pred Exp Pred Exp 
Clomiphene B
c
 B B B B B B B B B B B 
Raloxifene B B B B B B B B B B B B 
Tamoxifen B B B B B B B NB
d
 B B B B 
Toremifene B B B B B B B NB B B B B 
Success 
Rate 
100% 100% 100% 50% 100% 100% 
a
Pred, predicted binding using QSAR models; 
b
Exp, experimental result using secondary 
radioligand binding assays; 
c
B, binder; 
d
NB, non-binder. 
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Structural similarity evaluation based on MACCS structural keys and Tanimoto 
coefficients indicated that raloxifene‘s similarity to the other SERMs (clomiphene, tamoxifen 
and toremifene) is < 30%. This suggests this molecule might have some distict 
pharmacological profile and might interact with different molecular targets in a distinct 
manner (at least with some of these molecular targets). However, the structural similarity 
between the three other SERMs studied here is > 78% (see Table 5.8). Additionally, analysis 
of SERMs-protein interaction networks using STITCH (Kuhn et al. 2008) indicated that 
raloxifene has a different set of nearest neighbor proteins than the other SERMs (see Fig. 
5.9). This chemical and biological dissimilarity suggests that raloxifene might have a 
different polypharmacological profile that‘s not limited to its action on estrogen receptors. 
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Table 5.8.  Tanimoto similarities between SERMs based on MACCS structural keys. 
SERMs Clomiphene Tamoxifen Toremifene Raloxifene 
Clomiphene 
100.0 78.6 81.0 29.4 
Tamoxifen 
78.6 100.0 87.5 27.9 
Toremifene 
81.0 87.5 100.0 27.5 
Raloxifene 
29.4 27.9 27.5 100.0 
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Figure 5.9. Chemical protein interaction networks for SERMs. (A) Network centered at 
clomiphene, (B) Network centered at raloxifene, (C) Network centered at tamoxifen, and (D) 
Network centered at toremifene. 
A 
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Additionally, we undertook a large screen of potential targets using the receptorome 
profiling approach (Armbruster and Roth, 2005). All tests were performed by our 
collaborators at PDSP. Secondary screening results indicated that raloxifene has nanomolar 
binding affinities to several GPCRs, ion channels and protein transporters. The highest 
binding affinities were towards adrenergic alpha2C receptors with a Ki of 61 nM, 5-HT2B 
receptors with Ki of 69 nM, kappa opioid receptors (KOR) with Ki of 186, and sigma 1 
receptors with Ki of 247 nM.  All binding affinity results are shown in Table 5.9.   
Clustering binding affinities of SERMs across a panel of molecular targets confirmed 
both QSAR and STITCH predictions that raloxifene‘s biological profile might more different 
that that for other SERMs. In figure 5.9 we can see that centering the STITCH network on 
clomiphene, will pull the rest of the three other SERMs but tamoxifen is closer to clomiphene 
than to raloxifene. Additionally, in figure 5.9 D, we can see that centering the network on 
toremifene identified tamoxifen as the nearest neighbor SERM. Binding profiles of SERMs 
to a panel of GPCRs and other related molecular targets (cf. Fig. 5.10) confirmed that 
clomiphene, tamoxifen and toremifene indeed cluster together, while raloxifene‘s binding 
affinity profile seemed a bit more different. Form this example we can foresee the great 
potential for combining the knowledge derived from both genomic and protein binding 
profiles with the knowledge derived from QSAR-based VS to identify unexpected 
connections between molecular targets and chemical compounds. 
  
209 
 
Table 5.9. Ki estimates for SERMs (i.e., clomiphene, raloxifene, tamoxifen and toremifene) 
at a large panel of cloned receptors. 
Receptor 
Ki for 
Clomiphene 
(PDSP 13499) 
Ki for 
Raloxifene 
(PDSP 13505) 
Ki for 
Tamoxifen 
(PDSP 678) 
Ki for 
Tamoxifen 
(PDSP 10572) 
Ki for 
Toremifene 
(PDSP 16514) 
5ht1a >10000 2330 3477 >10000 >10000 
5ht1b Primary < 50% 624 1618 7857 
Primary < 
50% 
5ht1d 2171 1222 N/A Primary < 50% 4431 
5ht1e Primary < 50% 1868 Primary < 50% Primary < 50% 
Primary < 
50% 
5ht2a 2281 1049 2596 2720 4520 
5ht2b 1210 69 N/A 1952 1916 
5ht2c Primary < 50% 1642 4282 5787 >10000 
5ht4 N/A 5050 N/A N/A N/A 
5ht5a 506 1219 2123 7821 1283 
5ht6 1956 750 931.1 1698 4125 
5ht7 6615 1220 1077 >10000 5428 
Alpha1A 4085 247.7 N/A N/A 
Primary < 
50% 
Alpha1B Primary < 50% 534.6 N/A N/A 
Primary < 
50% 
Alpha1D 1625 478.2 N/A Primary < 50% 1633 
Alpha2A 1440 1288.2 N/A 1211 622.8 
Alpha2B Primary < 50% 7556 N/A N/A 1105 
Alpha2C 1255 61 N/A Primary < 50% 1004 
D1 1252 1626 1508 657 1138 
D2 3543.0(AVE) 683 1682 5517 5122 
D3 1302 >10000 498 1740 514 
D4 6191 (AVE) 3023 7817 >10000 6209 
D5 2298 3803 >10000 >10000 4550 
DAT N/A 928 4328 2820 263 
H1 5853 5356 N/A Primary < 50% 
Primary < 
50% 
H2 1403 1436 N/A 1980 3067 
H3 550.1 3847 N/A N/A 1520 
H4 Primary < 50% 7072 N/A Primary < 50% 
Primary < 
50% 
M1 Primary < 50% >10,000 N/A Primary < 50% 
Primary < 
50% 
M2 Primary < 50% 2037 N/A Primary < 50% 
Primary < 
50% 
M3 4476 Primary < 50% N/A Primary < 50% Primary < 
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50% 
M4 N/A 1229 N/A Primary < 50% 
Primary < 
50% 
M5 6816 8127 N/A Primary < 50% 
Primary < 
50% 
Sigma 1 128 247.8 N/A 481 183 
Sigma 2 19 Primary < 50% N/A 331 377 
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Figure 5.10. The heatmap of binding affinities (Ki) for several SERMs (clomiphene, raloxifene, 
tamoxifen and toremifene), across a panel of GPCRs and other transmembrane molecular targets, 
analyzed by hierarchical clustering of the pairwise similarities in binding affinities using Euclidean 
distances. The bar-view is a key for coloring according to normalized descriptor frequency based on 
binding affinities where blue color indicates most potent binding affinities while red color denotes 
least potent binding affinities.  
 
 
  
Conclusions  
We have developed a novel integrative chemocentric informatics approach that could be 
used as a tool for generating and cross-validating drug discovery hypotheses. Our approach 
integrates different in silico strategies and different data types and sources to increase the 
confidence in the final hypotheses. The study design was composed of three major parts: (1) 
QSAR-based datamining of chemical libraries to identify new ligands for target proteins, (2) 
Network-mining to identify chemicals that could treat specific diseases; and (3) Hypothesis 
fusion between (1) and (3).  
This approach has been applied to study the 5-HT6R system in relation to cognition 
enhancement strategies which may be useful for Alzheimer‘s and similar diseases with 
impaired cognition (e.g., schizophrenia). Disease gene signatures for Alzheimer‘s disease 
have been used to query the cmap database to formulate testable hypotheses about potential 
treatments. Common compound hits from QSAR/VS studies against 5-HT6R and the cmap 
were tested in at 5-HT6R.  Our approach identified 39 drugs, as potential 5-HT6R antagonists, 
out of 59000 molecules included in the WDI. Thirteen hits with higher confidence level were 
tested in binding assays and ten compounds were confirmed as 5-HT6R ligands achieving a 
success rate of 77%. We noticed that this study design can be applied to many other protein 
targets and families of targets involved in the etiology of Alzheimer‘s disease.  
Herein, we hypothesized and proved that integrating results generated from the cmap 
with predictions generated from QSAR-based VS increased the confidence level in the 
computational hits generated from QSAR-based VS. It also increased our confidence in some 
cmap negative connections with Alzheimer‘s (i.e., raloxifene) that would have been 
neglected based on either their cmap weak scores or lower confidence predictions from 
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QSAR models. Therefore, we foresee this design as a promising tool to identify molecule-
molecular target-disease (phenotype) associations.  
  
  
CHAPTER 6 
FUTURE DIRECTIONS 
Summary 
In order to pursue a rational approach for the discovery of ‗magic shotguns‘ and to 
end our reliance on serendipity as the major driving force for discovering such compounds, 
both genomics-based physical screening and in silico receptoromics should come together in 
the interplay. Herein, we attempted for the first time to establish a compendium of 
computational predictors, completely based on 2D QSAR methods, could be used 
simultaneously for the identification of potential leads. Once leads are discovered, potential 
toxicities could be also predicted in a similar manner by virtually screening such compounds 
against anti-targets (e.g., 5-HT2B agonists) (Setola & Roth 2005). Later, after confirming 
activities against the predicted molecular targets, structure activity effects can be tweaked by 
medicinal chemists. 
In this study, we succeeded in accumulating a large number of computational 
predictors for several receptor families (5-HT, adrenergic, dopamine, histamine, muscarinic 
and sigma receptors) and subtypes (5-HT2A, 5-HT2B, 5-HT6, 5-HT7, adrenergic Alpha2A, 
adrenergic Alpha2B, adrenergic Alpha2C, D1, D2, D3, D4, and D5). Our classification models 
had high accuracies (CCRevs in the range 0.74 to 0.97) estimated on 
  
external validation sets. Continuous models using actual binding affinity data had lower 
accuracies however, with R
2
 ranging from 0.59-0.67. This might be partially due to some 
inconsistencies in binding data extracted from different sources and generated by different 
groups. It might be also indicative that binding data per se might not be as effective as 
activity data to generate highly predictive structure activity models. In other words, our 
experience with testing actives indicated that many compounds that have very good 
nanomolar binding affinities are totally inactive in functional assays. Therefore, using high-
quality functional data instead of binding data might be more appropriate to achieve our 
goals in predicting highly active compounds across several receptors of interest. 
Consequently, this might lead to a new era of successful QSAR modeling of 
polypharmacological effects. So far, we are still very short in high-quality activity data 
deposited in public repositories. 
One of the most important predictors generated in our studies was based on QSAR 
models of 5-HT2B receptor ligands that can be used for virtual screening to identify potential 
valvulopathic compounds. Our results indicated the reliability of our computational models 
as efficient predictors of compounds‘ affinity towards 5-HT2B receptors. We suggest that the 
computational models developed in this study could be used as drug liability predictors 
similar to commonly used predictors of other undesired side effects such as carcinogenicity, 
mutagenicity, PGP binding, or hERG binding. Our models can be used to flag compounds 
that are expected to bind to 5-HT2B receptors but they cannot distinguish agonists from 
antagonists.  Nevertheless, as demonstrated in this study, these putative 5-HT2B binders can 
be tested in functional assays for their potential to activate 5-HT2B receptors to further assess 
their valvulopathic potential.   
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We have also developed a novel integrative chemocentric informatics approach that 
could be used as a tool for generating and cross-validating drug discovery hypotheses. Our 
approach integrates different in silico strategies and different data types and sources to 
increase the confidence in the final hypotheses. The study design was composed of three 
major parts: (1) QSAR-based datamining of chemical libraries to identify new ligands for 
target proteins, (2) Network-mining to identify chemicals that could treat specific diseases; 
and (3) Hypothesis fusion between (1) and (3).  
This approach has been applied to study the 5-HT6R system in relation to cognition 
enhancement strategies which may be useful for Alzheimer‘s and similar diseases with 
impaired cognition (e.g., schizophrenia). Herein, we hypothesized and proved that integrating 
results generated from the cmap with predictions generated from QSAR-based VS increased 
the confidence level in the computational hits generated from QSAR-based VS. It also 
increased our confidence in some cmap negative connections with Alzheimer‘s (i.e., 
raloxifene) that would have been neglected based on either their cmap weak scores or lower 
confidence predictions from QSAR models. Therefore, we foresee this design as a promising 
tool to identify molecule-molecular target-disease (phenotype) associations. We also believe 
that our recent and future studies into integrated chemocentric informatics will provide new 
successful avenues for the development of novel multi-targeted therapeutics capable of 
treating and/or preventing complex diseases such as neurodegenerative diseases, cancer and 
diabetes. This approach could be extended to many similar receptor systems and many 
different diseases serving as a cost-effective in silico tool for the discovery of novel 
biologically active compounds acting via clinically relevant targets. 
In silico Receptoromics 
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All methods discussed above share potential pitfalls of any QSAR methodology such 
as over-fitting and potential danger associated with extrapolation.  However, with the 
continuing advancements in this field, on the level of machine learning methods and 
descriptor types, there is a great room for improving the expected outcome. Future work in 
this field will include experimenting with various types of descriptors as well as consider 
additional combinations of classification techniques in the context of combinatorial QSAR 
modeling.  
Experimental validation procedures should be designed carefully to study the 
possibilities and the limitations of family-based models, especially because we are dealing 
with closely related proteins (i.e., GPCRs). For example, common hits predicted to bind 
several families of GPCRs should be experimentally validated. We should be cautioned 
however, that even though the binding profile might look promising but the real therapeutic 
effects are related to the actual functional activities of these ligands on specific receptor 
subtypes within these families. At the same time, the higher is the predicted promiscuity 
level, the higher is the risk for having adverse effects in vivo and the higher possibility for 
complications in drug design efforts in general; trying to optimize a lead‘s activity on several 
molecular targets at the same time would be highly difficult. 
Additionally, to be able to make the best use of family-based models we should 
design the proper tools for: (1) calculation of the appropriate consensus scores across family-
based models, (2) estimating the hit rates in actual binding assays. Currently, we are 
calculating consensus scores separately from models generated for each family. Then we 
select for further experimental testing those hits that possess acceptable consensus scores in 
each case. It might be useful to find new ways to calculate one consensus score across all 
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families which will make it easier for us to perform activity profiling across families and to 
calculate corresponding hit rates. However, calculating hit rates for hits predicted to bind 
several families of GPCRs could be highly complicated. It should be kept in mind that 
although we predict a compound to be a ligand for a specific receptor family, but this 
prediction does not imply in any way that this compound will bind to several or all receptor 
subtypes in that specific family. This result is dictated by the nature of the datasets used for 
model building. We will find that some chemicals will bind one specific subtype and does 
not bind to any other subtypes in the same family and vice versa. 
Additionally, as more data becomes available where we have full matrices for large 
number of compounds tested in binding and functional assays against a panel of receptors, it 
will be highly useful to experiment with Multi-Task learning (MTL) methods; unlike the case 
with conventional QSAR calculations using Single Task Learning (STL), where the models 
are developed for a single property, Multi-task Learning (MTL) approaches train the models 
simultaneously for several related properties (i.e., binding profiles against several receptor 
families or subtypes). Such approach has the potential to predict polypharmacology against a 
multitude of receptor families and subtypes and/or subtype selectivity. MTL is expected to 
increase the predictive power of the QSAR models in comparison to STL models (Varnek et 
al. 2009), because ―what is learned for each task can help the other tasks learned better‖ 
(Caruana 1997). 
GPCRs are highly promiscuous targets, and the majority of GPCR ligands hit 
multiple GPCRs at the same time, therefore, it makes more sense to use modeling methods 
that could analyze the ligand binding profile to families and subtypes of GPCRs at once. This 
process will allow the model to take into account all the commonalities and differences that 
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exist between families of receptors and specific receptor subtypes. We foresee MTL as a 
promising approach to study both polypharmacology and selectivity of GPCR ligands; single 
task models are surely missing an important layer on information embedded in the ligands 
affinity to all other families of receptors or receptor subtypes. In MTL, the modeled property 
consists of all the binding affinities of compounds across different families of receptors. Such 
property can be coded in a bit string of zeros and ones (i.e., binding is encoded by 1 and non-
binding is encoded by 0). 
 One can use Associative Neural Networks (ASNN) (ASNN 2010, Tetko 2002) as a 
machine learning method to conduct MTL on polypharmacological datasets. This method 
represents a combination of an ensemble of feed-forward neural networks and the k-nearest 
neighbor technique. ASNN uses the correlation between ensemble binding responses as a 
measure of distance among the analyzed cases for the nearest neighbor technique. Using this 
method provides an improved prediction by the bias correction of the neural network 
ensemble. An associative neural network has a memory that can coincide with the training 
set. If new data becomes available, the network further improves its predictive ability and 
provides a reasonable approximation of the unknown function without a need to retrain the 
neural network ensemble. This feature of the method dramatically improves its predictive 
ability over traditional neural networks and k-nearest neighbor techniques. Another important 
feature of ASNN is the possibility to interpret neural network results by analysis of 
correlations between data cases in the space of models. 
Chemocentric Informatics Approach 
One of the major limitations of using our integrative approach effectively is the 
relatively small number of compounds contained in the cmap. Consequently, this will limit 
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our ability to identify novel hits; novel hits are better identified from larger libraries with a 
multitude of diverse compounds. But this resource is constantly growing, and it aims to cover 
all FDA approved drugs and other chemicals of clinical potential. However, we might be able 
to tackle this problem computationally; where the negative connections (with a disease state) 
having the highest confidence can be used a similarity probes to search chemical databases.  
There are also limitations that originate from the disease gene-signatures. It is 
common that patients having certain diseases or who are older than 50, are already taking 
some medications for different reasons. These medications might affect the quality of 
generated disease gene signatures so that changes in gene signatures might be more 
correlated to drugs rather than disease states (i.e. it might mask disease signatures in 
postmortem signatures from human brain) and consequently could affect the result we obtain 
from querying the cmap.  However, the amount of information contained in these genomic 
signatures is enormous. Therefore, the earnest analysis of all predicted negative and positive 
connections with a disease state and considering the wide range of connectivity scores (i.e. 
negative, positive and null) should be considered and studied carefully. Experiments should 
be also designed to test both positive and negative hypotheses. 
Another kind of analysis for cmap predictions depends on the specific scores for gene 
signature similarities (with the disease gene signature) in each of the cell lines used to 
generate the chemical‘s gene expression profiles. Herein, we raise the question whether 
specific cell types are more reliable than others in a disease state of interest? Do we have to 
analyze scores obtained from each cell line separately to derive hypotheses based on the 
differences between cell lines and what protein targets are over-expressed in which cell 
lines? Or shall we consider inconsistencies in connectivity scores among cell lines as an 
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evidence for non-reliable gene expression profiles and therefore should be neglected? So 
these are all important issues to keep in mind for further improvements on the way we 
analyze data from this important chemogenomic resource. It would be wise though to 
consider all possibilities, derive hypotheses, design appropriate tests and validate predictions 
and methods. Finally, fusing all generated hypotheses is expected to provide us with the most 
optimal solutions. 
Conclusion 
In conclusion, it is likely that our computational efforts described herein and other 
efforts by different groups to study polypharmacology in silico will eventually result in 
useful and reliable tools aimed at enriching chemical libraries in compounds that have 
affinities for more than a single desired molecular target. We also think that a combination of 
in silico methods will be more powerful than a single method alone as our expertise in the 
computational field has indicated time after time. 
  
Appendix I: 
Final VS Hits as 5-HT2B Actives 
WDI Compound Name 
No. of kNN 
Models 
Consensus 
Score 
VEIUTAMINE 104 1.00 
DROMIA 112 1.00 
BRL-56905 121 1.00 
CLAUSINE-E 123 0.99 
ARAPROFEN 112 0.99 
FURPROFEN 104 0.99 
ADRENOGLOMERULOTROPIN 122 0.98 
6-FLUOROMELATONIN 115 0.98 
HYDROXYTRYPTAMINE-
GLUTAMYL 
111 0.98 
LIQUIRITIGENIN 110 0.98 
PIDOBENZONE 123 0.98 
GALANGIN 103 0.97 
EMD-47020 102 0.97 
SYRIACUSIN-C 119 0.97 
MICROMINUTIN 117 0.97 
NPC-14692 113 0.96 
SALSALIC-ACID 124 0.96 
CP-123800 116 0.96 
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METHYLDOPA-RACEMIC 115 0.96 
SR-4452 114 0.96 
CEAROIN 111 0.95 
CL-08-A 109 0.95 
MNA-279 102 0.95 
2-HYDROXYESTRONE 102 0.95 
5-METHOXYTRYPTOLINE 115 0.95 
EMD-57283 111 0.95 
SALICYL-TYROSINE 110 0.95 
HYDROXYMESOCARB-BETA 108 0.94 
RHAPONTIGENIN 114 0.94 
AFFININE 108 0.94 
6-METHOXYMELLEIN 122 0.93 
R-53309 105 0.93 
BARCELONEIC-ACID-B 103 0.93 
17-ALPHA-ESTRADIOL-ACETATE 116 0.93 
RH-34 112 0.93 
LEK-8827 109 0.93 
PAXAMATE 122 0.93 
ACETYLCARANINE 106 0.92 
METHYLERGOMETRINE 118 0.92 
FEBRIFUGINE 117 0.92 
K-182 116 0.92 
224 
 
2-METHOXYESTRONE 113 0.92 
METHYLDOPA 107 0.92 
CGP-13698 114 0.91 
BW-826-C 101 0.91 
BE-6143 110 0.91 
AM-40 112 0.90 
BUTOLAME 110 0.90 
L-TYROSINE 104 0.89 
LAPACHONE-BETA 107 0.89 
TOFETRIDINE 124 0.89 
FUSAROCHROMANONE 103 0.88 
DOISYNESTROL 119 0.88 
METBUFEN 108 0.88 
H-195-60 122 0.88 
AMINOHIPPURATE-SODIUM 102 0.87 
SR-4895 100 0.87 
XANTHANOIC-ACID 123 0.87 
HEXACYPRONE 115 0.87 
BENZALBUTYRATE-SODIUM 115 0.87 
LY-248510 121 0.87 
BENZOYLNORECGONINE 110 0.86 
PYRIDAZOMYCIN 102 0.86 
VALLDEMOSSINE 115 0.86 
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CARFIMATE 107 0.86 
TL-404 121 0.86 
RO-03-9024 115 0.85 
4-BENZYLOXYPHENYLACETATE 121 0.85 
NB-355 119 0.85 
MENADIONE 102 0.84 
PIM-35 101 0.84 
TRANS-2-HYDROXYLOMUSTINE 106 0.84 
FLUTIMIDE 111 0.84 
661-U-88 117 0.84 
SENKYUNOLIDE-J 104 0.84 
ERYTHRININ-B 103 0.83 
LY-193326 120 0.83 
YM-992 120 0.83 
CARBESTROL 123 0.83 
RETICULATINE-A 103 0.83 
CLAVIROLIDE-D 102 0.82 
3-HYDROXYPRAZEPAM 110 0.82 
NSC-350102 114 0.82 
POLYMONINE 114 0.82 
C-883901 102 0.81 
PISIFERIC-ACID 107 0.81 
IMIDOCARB 100 0.81 
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NPC-15199 115 0.81 
ISO-BUTYLNAPHTHYLACETATE 121 0.80 
PROPIONYLPHENETIDINE 123 0.80 
RALGIN 121 0.79 
NPC-15667 119 0.79 
HYDROXYPHENYLGLYCINE 104 0.79 
BUTYLPHENAMIDE 112 0.79 
ARPHAMENINE-B 111 0.78 
METAMIVANE 123 0.78 
RICCARDIPHENOL-C 120 0.77 
WAY-122331 120 0.77 
TROXIPIDE 114 0.77 
BW-306-U 117 0.77 
MELINONINE-F 105 0.76 
GLYCOCITRINE-II 109 0.76 
AMICLENOMYCIN 104 0.76 
METHYLSALICYLATE 103 0.75 
L-4035 118 0.75 
BUTACETIN 113 0.74 
O-ACETYLPROPRANOLOL 116 0.74 
L-372460 114 0.74 
ETERSALATE 113 0.73 
FUCHSIN 100 0.73 
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4-HYDROXYDERRICIN 111 0.73 
FPL-13950 124 0.73 
KWD-2131 116 0.72 
K-7731 118 0.72 
CD-417 117 0.72 
MC-207110 106 0.72 
ENALAPRIL 109 0.72 
PHENOXYACETATE-METHYL-ESTER 107 0.71 
BENZASTATIN-B 114 0.70 
NSC-319848 107 0.70 
NSC-645306 100 0.70 
ASPERGILLAMIDE-A 100 0.70 
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Appendix II 
146 5-HT2B Actives Used in the Modeling Studies 
Cp. 
ID 
PubChe 
CID 
SMILES 
1 1001 NCCc1ccccc1 
2 1065 O(C)c1cc2c(nccc2C(O)C2N3CC(C(C2)CC3)C=C)cc1 
3 1150 [nH]1cc(c2c1cccc2)CCN 
4 1224 OC1(CC2N(CC1)CC1c3c2cccc3CCc2c1cccc2)C(C)(C)C 
5 1229 Ic1cc(OC)c(cc1OC)CC(N)C 
6 1243 Brc1cc2c(cc1O)C(CN(CC2)C)c1ccccc1 
7 1250 Oc1cc2c(N(C3N(CCC23C)C)C)cc1 
8 1355 Clc1cc(N2CCNCC2)ccc1 
9 1614 O1c2cc(ccc2OC1)CC(N)C 
10 1615 O1c2cc(ccc2OC1)CC(NC)C 
11 1832 O(C)c1cc2c([nH]cc2CCN(C)C)cc1 
12 2099 O=C1N(CCc2n(c3c(c12)cccc3)C)Cc1nc[nH]c1C 
13 2159 S(=O)(=O)(CC)c1cc(C(=O)NCC2N(CCC2)CC)c(OC)cc1N 
14 2160 N(CCC=C1c2c(CCc3c1cccc3)cccc2)(C)C 
15 2170 Clc1cc2c(Oc3c(N=C2N2CCNCC2)cccc3)cc1 
16 2196 O(C)c1ccc(cc1)C(=O)N1CCCC1=O 
17 2247 Fc1ccc(cc1)Cn1c2c(nc1NC1CCN(CC1)CCc1ccc(OC)cc1)cccc2 
18 2267 Clc1ccc(cc1)CC1=NN(C2CCCN(CC2)C)C(=O)c2c1cccc2 
19 2308 ClC12C(C3CC(C)C(O)(C(=O)CO)C3(CC1O)C)CCC1=CC(=O)C=CC12C 
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20 2318 FC(F)(F)c1cc(ccc1)CC(NCCOC(=O)c1ccccc1)C 
21 2326 O(CC(N1CCCCC1)C)c1ccccc1Cc1ccccc1 
22 2344 O(C(c1ccccc1)c1ccccc1)C1CC2N(C(C1)CC2)C 
23 2377 O(CCCCNC)c1ccccc1Cc1ccccc1 
24 2443 Brc1[nH]c2c3c1CC1N(CC(C=C1c3ccc2)C(=O)NC1(OC2(O)N(C(CC(C)C
)C(=O)N3C2CCC3)C1=O)C(C)C)C 
25 2477 O=C1N(CCCCN2CCN(CC2)c2ncccn2)C(=O)CC2(C1)CCCC2 
26 2512 O=C(N(CCCN(C)C)C(=O)NCC)C1CC2C(N(C1)CC=C)Cc1c3c2cccc3[nH
]c1 
27 2520 O(C)c1cc(ccc1OC)C(C(C)C)(CCCN(CCc1cc(OC)c(OC)cc1)C)C#N 
28 2585 O(CCNCC(O)COc1c2c3c([nH]c2ccc1)cccc3)c1ccccc1OC 
29 2726 Clc1cc2N(c3c(Sc2cc1)cccc3)CCCN(C)C 
30 2769 Clc1cc(C(=O)NC2CCN(CC2OC)CCCOc2ccc(F)cc2)c(OC)cc1N 
31 2771 Fc1ccc(cc1)C1(OCc2c1ccc(c2)C#N)CCCN(C)C 
32 2780 Clc1cc(C(=O)NC2CCN(CC2)Cc2ccccc2)c(OC)cc1N 
33 2781 Clc1ccc(cc1)C(OCCC1N(CCC1)C)(C)c1ccccc1 
34 2782 Clc1ccc(cc1)Cn1c2c(nc1CN1CCCC1)cccc2 
35 2801 Clc1cc2N(c3c(CCc2cc1)cccc3)CCCN(C)C 
36 2818 Clc1cc2NC(N3CCN(CC3)C)=C3C(=Nc2cc1)C=CC=C3 
37 2820 Clc1cc2NC(N3CCNCC3)=C3C(=Nc2cc1)C=CC=C3 
38 2866 OC1CCC2C(CC3N(C2)CCc2c3[nH]c3c2cccc3)C1C(OC)=O 
39 2895 N(CCC=C1c2c(C=Cc3c1cccc3)cccc2)(C)C 
40 2913 N1(CCC(CC1)=C1c2c(C=Cc3c1cccc3)cccc2)C 
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41 3065 O1C(NC(=O)C2CC3C(N(C2)C)Cc2c4c3cccc4[nH]c2)(C(C)C)C(=O)N2C(
Cc3ccccc3)C(=O)N3C(CCC3)C12O 
42 3066 O1C(NC(=O)C2CC3C(N(C2)C)Cc2c4c3cccc4[nH]c2)(C)C(=O)N2C(Cc3c
cccc3)C(=O)N3C(CCC3)C12O 
43 3117 S(SC(=S)N(CC)CC)C(=S)N(CC)CC 
44 3250 OCC(NC(=O)C1C=C2C(N(C1)C)Cc1c3c2cccc3[nH]c1)C 
45 3251 O1C(NC(=O)C2C=C3C(N(C2)C)Cc2c4c3cccc4[nH]c2)(C)C(=O)N2C(Cc
3ccccc3)C(=O)N3C(CCC3)C12O 
46 3341 Clc1c2c(cc(O)c1O)C(CNCC2)c1ccc(O)cc1 
47 3372 S1c2c(N(c3c1cccc3)CCCN1CCN(CC1)CCO)cc(cc2)C(F)(F)F 
48 3386 FC(F)(F)c1ccc(OC(CCNC)c2ccccc2)cc1 
49 3463 O(CCCC(C(O)=O)(C)C)c1cc(ccc1C)C 
50 3519 Clc1cccc(Cl)c1CC(=O)N=C(N)N 
51 3646 O1c2c(OC1)cc1c(CN(CC1)C)c2OC 
52 3675 N(N)CCc1ccccc1 
53 3689 Oc1ccc(cc1)C(O)C(N1CCC(CC1)Cc1ccccc1)C 
54 3827 s1c2c(cc1)C(c1c(CC2=O)cccc1)=C1CCN(CC1)C 
55 3878 Clc1c(cccc1Cl)-c1nnc(nc1N)N 
56 3938 O=C(NC1C=C2C(N(C1)C)Cc1c3c2cccc3[nH]c1)N(CC)CC 
57 3964 Clc1cc2c(Oc3c(N=C2N2CCN(CC2)C)cccc3)cc1 
58 4090 O(Cc1ccccc1)C(=O)NCC1CC2C(N(C1)C)Cc1c3c2cccc3n(c1)C 
59 4106 S1c2c(cc(SC)cc2)C(N2CCN(CC2)C)Cc2c1cccc2 
60 4140 OCC(NC(=O)C1C=C2C(N(C1)C)Cc1c3c2cccc3[nH]c1)CC 
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61 4184 N12C(c3c(Cc4c1cccc4)cccc3)CN(CC2)C 
62 4205 n1c2N3C(c4c(Cc2ccc1)cccc4)CN(CC3)C 
63 4296 FC(F)(F)c1cc(N2CCNCC2)ccc1 
64 4418 O(C)c1ccccc1N1CCN(CC1)CC(O)COc1c2c(ccc1)cccc2 
65 4449 Clc1cc(N2CCN(CC2)CCCN2N=C(N(CCOc3ccccc3)C2=O)CC)ccc1 
66 4475 Brc1cc(cnc1)C(OCC1CC2(OC)C(N(C1)C)Cc1c3c2cccc3n(c1)C)=O 
67 4543 N(CCC=C1c2c(CCc3c1cccc3)cccc2)C 
68 4585 S1C2=Nc3c(NC(N4CCN(CC4)C)=C2C=C1C)cccc3 
69 4595 O=C1c2c(n(c3c2cccc3)C)CCC1Cn1ccnc1C 
70 4636 Oc1c(C)c(CC=2NCCN=2)c(cc1C(C)(C)C)C 
71 4658 Ic1ccc(cc1)C(=O)N(CCN1CCN(CC1)c1ccccc1OC)c1ncccc1 
72 4691 Fc1ccc(cc1)C1CCNCC1COc1cc2OCOc2cc1 
73 4745 S(CC1CC2C(N(C1)CCC)Cc1c3c2cccc3[nH]c1)C 
74 4748 Clc1cc2N(c3c(Sc2cc1)cccc3)CCCN1CCN(CC1)CCO 
75 4847 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCC=1C(=O)N2C(=NC=1C)C=CC=C2 
76 4893 o1cccc1C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 
77 4917 Clc1cc2N(c3c(Sc2cc1)cccc3)CCCN1CCN(CC1)C 
78 4927 S1c2c(N(c3c1cccc3)CC(N(C)C)C)cccc2 
79 5002 S1c2c(cccc2)C(=Nc2c1cccc2)N1CCN(CC1)CCOCCO 
80 5011 n1c2c(ccc1N1CCNCC1)cccc2 
81 5018 Clc1cc2c(cc1O)C(CN(CC2)C)c1ccccc1 
82 5073 Fc1cc2onc(c2cc1)C1CCN(CC1)CCC=1C(=O)N2C(=NC=1C)CCCC2 
83 5074 S1C=CN2C1=NC(C)=C(CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1)C
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2=O 
84 5095 O=C1Nc2c(C1)c(ccc2)CCN(CCC)CCC 
85 5163 O=C(Nc1cccnc1)N1CCc2c1cc1c(n(cc1)C)c2 
86 5202 Oc1cc2c([nH]cc2CCN)cc1 
87 5406 O=C(NC1CC2C(N(C1)C)Cc1c3c2cccc3[nH]c1)N(CC)CC 
88 5452 S1c2c(N(c3c1cccc3)CCC1N(CCCC1)C)cc(SC)cc2 
89 5533 Clc1cc(N2CCN(CC2)CCCN2N=C3N(C=CC=C3)C2=O)ccc1 
90 5566 S1c2c(N(c3c1cccc3)CCCN1CCN(CC1)C)cc(cc2)C(F)(F)F 
91 5684 O(C)c1ccccc1N1CCN(CC1)CCN(C(=O)C1CCCCC1)c1ncccc1 
92 5709 N1CCN=C1Cc1c(cc(cc1C)C(C)(C)C)C 
93 5736 Clc1cc2c(Sc3c(C=C2OCCN(C)C)cccc3)cc1 
94 6018 O(C)c1cc2C3N(CC(CC(C)C)C(=O)C3)CCc2cc1OC 
95 7638 O(Cc1ccccc1)c1ccc(O)cc1 
96 8794 N#CCc1ccccc1 
97 15443 Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ncccc1 
98 15641 P(OCCCCCCCC)(OCCCCCCCC)(=O)c1ccccc1 
99 15897 FC(F)(F)c1cc(ccc1)CC(N)C 
100 16106 N=1c2c(Cc3c(cccc3)C=1N1CCN(CC1)C)cccc2 
101 16118 S(=O)(=[NH])(CCC(N)C(O)=O)C 
102 16414 Clc1cc2N(c3c(Sc2cc1)cc(O)cc3)CCCN(C)C 
103 21722 n1(c2CCCCCCc2c2c1cccc2)CCCN(C)C 
104 23897 O1CCN(CC1)CC1CCc2[nH]c(C)c(c2C1=O)CC 
105 27400 s1c2c(cc1)C(c1c(CC2)cccc1)=C1CCN(CC1)C 
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106 37586 Clc1[nH]c2c3c1CC1N(CC(CC1c3ccc2)CC#N)C 
107 49381 Fc1cc2N=C(N3CCN(CC3)C)c3c(Cc2cc1)cccc3 
108 54940 Brc1ccc(OC)c(C(=O)NCC2N(CCC2)CC)c1OC 
109 60149 Clc1cc2c(n(cc2C2CCN(CC2)CCN2CCNC2=O)-c2ccc(F)cc2)cc1 
110 60795 Clc1c(N2CCN(CC2)CCCCOc2cc3NC(=O)CCc3cc2)cccc1Cl 
111 60809 s1nc(C=2CN(CCC=2)C)c(OCCCCCC)n1 
112 65489 Clc1cc2NC(=O)N(c2cc1)CCCN1CCC(CC1)C(=O)c1ccc(F)cc1 
113 73333 Fc1ccc(cc1)C(CCCN1CCN(CC1)C(=O)NCC)c1ccc(F)cc1 
114 91613 [nH]1c(cnc1C)CCN 
115 99049 O1C(NC(=O)C2C=C3C(N(C2)C)Cc2c4c3cccc4[nH]c2)(C(C)C)C(=O)N2
C(CC(C)C)C(=O)N3C(CCC3)C12O 
116 107992 Clc1nc(N2CCNCC2)cnc1 
117 108029 O(C)c1cc2c([nH]cc2C=2CCNCC=2)cc1 
118 123932 S(Oc1ccc(cc1O)CCN)(O)(=O)=O 
119 125085 Fc1ccc(cc1)C(=O)CCCN1CCC2(N(CN(CCc3ccc(N)cc3)C2=O)c2ccccc2)
CC1 
120 131747 Clc1nc(N2CCC(N)CC2)ccc1 
121 132564 O1CCCc2c3c(n(cc3CCN)C)ccc12 
122 146224 Clc1cc(Cl)ccc1CNN\C=N/C(=O)c1nc(Cl)c(nc1N)N 
123 291264 O1C2C(CCC(=C3C2C(=CC3=O)C)C)C(C)C1=O 
124 589768 Oc1c2c([nH]cc2CC(N)C(O)=O)ccc1 
125 592735 O1C(NC(=O)C2CC3C(N(C2)C)Cc2c4c3cccc4[nH]c2)(C(C)C)C(=O)N2C(
C(CC)(C)C)C(=O)N3C(CCC3)C12O 
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126 627310 Brc1[nH]c2c3c1CC1N(CC(C=C1c3ccc2)C(=O)N(CC)CC)C 
127 667466 Clc1cc\2c(Sc3c(cccc3)/C/2=C\CCN(C)C)cc1 
128 667468 O1Cc2c(cccc2)\C(\c2c1cccc2)=C\CCN(C)C 
129 1548943 O(C)c1cc(ccc1O)CNC(=O)CCCC\C=C\C(C)C 
130 3065828 O(C)c1c(cccc1OC)C(=O)NC1CC2N(C(C1)CC2)Cc1ccccc1 
131 3408722 O(C)c1c2c(cccc2)c(cc1C(=O)NCC1N(CCC1)CCCC)C#N 
132 3906894 Clc1cc2NC(=O)C3N(CCNC3)c2cc1Cl 
133 4284720 s1cccc1COc1cc2c([nH]cc2CC(N)C)cc1 
134 5251926 S(=O)(=O)(NC1CC2C(N(C1)C)Cc1c3c2cccc3n(c1)C)N(C)C 
135 5281881 S1c2c(cc(cc2)C(F)(F)F)\C(\c2c1cccc2)=C/CCN1CCN(CC1)CCO 
136 5474706 O(C)C=1C=CC2=NC=3C(=C2C=1)CCNC=3C 
137 5487301 OCc1cc\2c(N=C/C/2=C\NN\C(=N\CCCCC)\N)cc1 
138 6422124 O(CCCc1[nH]cnc1)c1ccc(cc1)C(=O)C1CC1 
139 6446980 Clc1cc2C=C(N3CCN(CC3)C)c3c(cccc3)\C(\c2cc1)=C\C#N 
140 6510284 s1cc2c(c1)\C(\c1c(N=C2N2CCN(CC2)C)csc1)=C\C#N 
141 6713986 Clc1cc(CC)c(O)c(C(=O)NCC2N(CCC2)CC)c1OC 
142 9908697 OC1CCCC1NC(=O)C1CC2C(N(C1)C)Cc1c3c2cccc3n(c1)C(C)C 
143 13995788 O(C(=O)C1CC2C(N(C1)C)Cc1c3c2cccc3n(c1)C(C)C)C1CCC(OC)CC1 
144 14096625 s1nc(N2CCN(CC2)CCCCN2C(=O)C3C(CCCC3)C2=O)c2c1cccc2 
145 14665495 Ic1cc(C(=O)NCC2N(CCC2)CC)c(OC)c(OC)c1 
146 21982952 O=C(NC1CCCCC1)C1CC2C(N(C1)C)Cc1c3c2cccc3n(c1)C(C)C 
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Appendix III 
608 5-HT2B Inactives Used in the Modeling Studies 
Cp. 
ID 
PubChe 
CID 
SMILES 
147 89 Oc1cccc(C(=O)CC(N)C(O)=O)c1N 
148 143 O=C1N=C(NC=2NCC(N(C1=2)C=O)CNc1ccc(cc1)C(=O)NC(CCC(
O)=O)C(O)=O)N 
149 191 O1C(CO)C(O)C(O)C1n1c2ncnc(N)c2nc1 
150 199 N(CCCCN)=C(N)N 
151 204 O=C1NC(=O)NC1NC(=O)N 
152 225 OC1CC2CCC3C4CCC(=O)C4(CCC3C2(CC1)C)C 
153 235 O1C(C(O)CO)C(=O)C(O)=C1O 
154 253 S1CC2NC(=O)NC2C1CCCCC(O)=O 
155 275 O(N=C(N)N)CCC(N)C(O)=O 
156 288 OC(CC(=O)[O-])C[N+](C)(C)C 
157 298 ClC(Cl)C(=O)NC(C(O)c1ccc([N+](=O)[O-])cc1)CO 
158 408 O=C1N(C)C(CC1)c1cccnc1 
159 450 OC1CCC2C3C(CCC12C)c1c(cc(O)cc1)CC3 
160 554 O=C([O-])C1[N+](CCC1)(C)C 
161 653 O1c2c(cccc2)C(=O)C(CC=2C(=O)c3c(OC=2O)cccc3)=C1O 
162 815 O1C(CN)C(O)C(O)C(O)C1OC1C(O)C(OC2OC(CO)C(O)C(N)C2O)
C(N)CC1N 
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163 853 Ic1cc(cc(I)c1Oc1cc(I)c(O)c(I)c1)CC(N)C(O)=O 
164 861 Ic1cc(cc(I)c1Oc1cc(I)c(O)cc1)CC(N)C(O)=O 
165 925 P(OCC1OC([n+]2cc(ccc2)C(=O)N)C(O)C1O)(OP(OCC1OC(n2c3ncn
c(N)c3nc2)C(O)C1O)(O)=O)(=O)[O-] 
166 932 O1c2c(C(=O)CC1c1ccc(O)cc1)c(O)cc(O)c2 
167 1027 OC1CC2=CCC3C4CCC(C(=O)C)C4(CCC3C2(CC1)C)C 
168 1046 O=C(N)c1nccnc1 
169 1054 Oc1c(CO)c(cnc1C)CO 
170 1072 O=C1NC(=O)N=C2N(c3cc(C)c(cc3N=C12)C)CC(O)C(O)C(O)CO 
171 1130 s1c[n+](Cc2cnc(nc2N)C)c(C)c1CCO 
172 1203 O1c2c(CC(O)C1c1cc(O)c(O)cc1)c(O)cc(O)c2 
173 1207 N1C2Cc3c(cccc3)C1(c1c2cccc1)C 
174 1211 O1c2cc3C(N(CCc3cc2OC)C)Cc2ccc(Oc3c4C([N+](CCc4cc(OC)c3O
)(C)C)Cc3cc1c(O)cc3)cc2 
175 1258 O1C2C3[N+]([O-])(C(CC(OC(=O)C(CO)c4ccccc4)C3)C12)C 
176 1302 O(C)c1cc2c(cc(cc2)C(C(O)=O)C)cc1 
177 1691 O1C(C)C(O)C(N)CC1OC1CC(O)(Cc2c1c(O)c1c(C(=O)c3c(C1=O)c(
OC)ccc3)c2O)C(=O)CO 
178 1805 O1C(CO)C(O)C(O)C1N1C=NC(=NC1=O)N 
179 1892 O=C1N(C)C(=O)N(c2ncn(c12)CCO)C 
180 1978 O(CC(O)CNC(C)C)c1ccc(NC(=O)CCC)cc1C(=O)C 
181 1981 Clc1ccc(cc1)C(=O)n1c2c(cc(OC)cc2)c(CC(OCC(O)=O)=O)c1C 
182 1983 Oc1ccc(NC(=O)C)cc1 
237 
 
183 1986 s1c(nnc1S(=O)(=O)N)NC(=O)C 
184 1989 S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(cc1)C(=O)C 
185 1990 O=C(NO)C 
186 1993 O(C(C[N+](C)(C)C)C)C(=O)C 
187 2012 O(C)C1C2(O)CC3C(C(OC(=O)C)(C4C5N(CC6(C(C35C(OC)CC6O)
C4OC)COC)CC)C1O)C2OC(=O)c1ccccc1 
188 2022 O=C1N=C(Nc2n(cnc12)COCCO)N 
189 2073 OC1N2C3C4C(CC2C2N(c5c(C2(C3)C4O)cccc5)C)C1CC 
190 2082 S(CCC)c1cc2[nH]c(nc2cc1)NC(OC)=O 
191 2083 Oc1ccc(cc1CO)C(O)CNC(C)(C)C 
192 2094 O=C1N=CN=C2NNC=C12 
193 2116 O1c2c(CCC1(CCCC(CCCC(CCCC(C)C)C)C)C)c(C)c(O)c(C)c2C 
194 2130 NC12CC3CC(C1)CC(C2)C3 
195 2142 O1C(CN)C(O)C(O)C(O)C1OC1C(O)C(OC2OC(CO)C(O)C(N)C2O)
C(NC(=O)C(O)CCN)CC1N 
196 2151 O=C1N(N(C)C(C)=C1N)c1ccccc1 
197 2153 O=C1N(C)C(=O)N(c2nc[nH]c12)C 
198 2157 Ic1cc(cc(I)c1OCCN(CC)CC)C(=O)c1c2c(oc1CCCC)cccc2 
199 2158 O1C2OC(OC2C(OCCCN(C)C)C1C(O)CO)(C)C 
200 2173 S1C2N(C(C(=O)[O-])C1(C)C)C(=O)C2NC(=O)C(N)c1ccccc1 
201 2178 [n+]1(ccccc1C)Cc1cnc(nc1N)CCC 
202 2199 O(C(=O)C)C1C(NCC1O)Cc1ccc(OC)cc1 
203 2202 Oc1c2c(Cc3c(C2=O)c(O)ccc3)ccc1 
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204 2206 O=C1N(N(C)C(=C1)C)c1ccccc1 
205 2227 N(CCCCN=C(N)N)=C(N)N 
206 2230 O(C(=O)C=1CN(CCC=1)C)C 
207 2240 O1C2OC3(OOC24C(CCC(C4CC3)C)C(C)C1=O)C 
208 2255 S(OC1C(OS(O)(=O)=O)C(OC(OC2CC3(C(CCC45C3CCC(C4)C(=C
)C5O)C(C2)C(O)=O)C)C1OC(=O)CC(C)C)CO)(O)(=O)=O 
209 2265 S(c1n(cnc1[N+](=O)[O-])C)c1ncnc2nc[nH]c12 
210 2271 S1C2N(C(C(O)=O)C1(C)C)C(=O)C2NC(=O)C(NC(=O)N1CCNC1=
O)c1ccccc1 
211 2282 S1C2N(C(C(OC(OC(OCC)=O)C)=O)C1(C)C)C(=O)C2NC(=O)C(N)
c1ccccc1 
212 2284 Clc1ccc(cc1)C(CC(O)=O)CN 
213 2315 S(=O)(=O)(N)c1cc2S(=O)(=O)NC(Nc2cc1C(F)(F)F)Cc1ccccc1 
214 2333 Brc1cc(cc(Br)c1O)C(=O)c1c2c(oc1CC)cccc2 
215 2337 O(C(=O)c1ccc(N)cc1)CC 
216 2343 Clc1cc2NC(=NS(=O)(=O)c2cc1S(=O)(=O)N)CSCc1ccccc1 
217 2353 O1c2c(OC1)cc-1c(CC[n+]3c-1cc1c(c3)c(OC)c(OC)cc1)c2 
218 2356 O1C2C(OC(=O)c3c2c(O)c(OC)c(O)c3)C(O)C(O)C1CO 
219 2366 n1ccccc1CCNC 
220 2371 OC1CCC2(C(CCC3(C2CCC2C4C(CCC23C)(CCC4C(C)=C)C(O)=O
)C)C1(C)C)C 
221 2376 O1C(c2c(c3OCOc3cc2)C1=O)C1N(CCc2c1cc1OCOc1c2)C 
222 2391 O(C(=O)C)c1ccc(cc1)C(c1ccc(OC(=O)C)cc1)c1ncccc1 
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223 2448 Brc1ccc(cc1)C1(O)CCN(CC1)CCCC(=O)c1ccc(F)cc1 
224 2462 O1C2(C(OC1CCC)CC1C3C(C4(C(=CC(=O)C=C4)CC3)C)C(O)CC1
2C)C(=O)CO 
225 2466 O(CCCC)c1ccc(cc1)CC(=O)NO 
226 2471 S(=O)(=O)(N)c1cc(cc(NCCCC)c1Oc1ccccc1)C(O)=O 
227 2478 S(OCCCCOS(=O)(=O)C)(=O)(=O)C 
228 2482 O(C(=O)c1ccc(N)cc1)CCCC 
229 2485 O1C(CN)C(O)C(O)C(N)C1OC1C(OC2OC(CO)C(O)C2O)C(O)C(NC
(=O)C(O)CCN)CC1N 
230 2550 SCC(C(=O)N1CCCC1C(O)=O)C 
231 2551 O(CC[N+](C)(C)C)C(=O)N 
232 2554 O=C(N)N1c2c(C=Cc3c1cccc3)cccc2 
233 2560 S1C2N(C(C(O)=O)C1(C)C)C(=O)C2NC(=O)C(C(O)=O)c1ccccc1 
234 2561 O(C(=O)CCC(O)=O)C1CCC2(C3C(CCC2C1(C)C)(C)C1(C(C2CC(C
CC2(CC1)C)(C(O)=O)C)=CC3=O)C)C 
235 2562 O(C(=O)C1(CCCC1)c1ccccc1)CCOCCN(CC)CC 
236 2564 Clc1ccc(cc1)C(OCCN(C)C)c1ncccc1 
237 2574 O=C(NCCc1[nH]cnc1)CCN 
238 2576 O(CC(CCC)(COC(=O)N)C)C(=O)NC(C)C 
239 2578 ClCCN(N=O)C(=O)NCCCl 
240 2609 ClC=1CSC2N(C(=O)C2NC(=O)C(N)c2ccccc2)C=1C(O)=O 
241 2610 S1C2N(C(=O)C2NC(=O)C(N)c2ccc(O)cc2)C(C(O)=O)=C(C1)C 
242 2615 S1C2N(C(=O)C2NC(=O)C(OC=O)c2ccccc2)C(C(O)=O)=C(C1)CSc1
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nnnn1C 
243 2617 s1c(nnc1SCC=1CSC2N(C(=O)C2NC(=O)Cn2nnnc2)C=1C(=O)[O-
])C 
244 2625 S1C2N(C(=O)C2(OC)NC(=O)CSCC#N)C(C(=O)[O-
])=C(C1)CSc1nnnn1C 
245 2630 S1C2N(C(=O)C2NC(=O)C(NC(=O)N2CCN(CC)C(=O)C2=O)c2ccc(
O)cc2)C(C(O)=O)=C(C1)CSc1nnnn1C 
246 2637 s1cccc1CC(=O)NC1(OC)C2SCC(COC(=O)N)=C(N2C1=O)C(=O)[O
-] 
247 2665 O(C)c1cc2C3N(CC(CC)C(C3)CC3NCCc4c3cc(OC)c(O)c4)CCc2cc1
OC 
248 2666 S1C2N(C(=O)C2NC(=O)C(N)c2ccccc2)C(C(O)=O)=C(C1)C 
249 2670 s1cccc1CC(=O)NC1C2SCC(COC(=O)C)=C(N2C1=O)C(=O)[O-] 
250 2672 S1C2N(C(=O)C2NC(=O)CSc2ccncc2)C(C(=O)[O-
])=C(C1)COC(=O)C 
251 2678 Clc1ccc(cc1)C(N1CCN(CC1)CCOCC(O)=O)c1ccccc1 
252 2717 Clc1ccc(cc1)C1S(=O)(=O)CCC(=O)N1C 
253 2719 Clc1cc2nccc(NC(CCCN(CC)CC)C)c2cc1 
254 2720 Clc1cc2NC=NS(=O)(=O)c2cc1S(=O)(=O)N 
255 2724 Clc1ccc(OCC(O)COC(=O)N)cc1 
256 2727 Clc1ccc(S(=O)(=O)NC(=O)NCCC)cc1 
257 2732 Clc1ccc(cc1S(=O)(=O)N)C1(O)NC(=O)c2c1cccc2 
258 2733 Clc1cc2NC(Oc2cc1)=O 
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259 2749 O=C1N(O)C(=CC(=C1)C)C1CCCCC1 
260 2757 OC(C1N2CC(C(C1)CC2)C=C)c1c2c(ncc1)cccc2 
261 2762 O1c2c(OC1)cc1N(N=C(C(O)=O)C(=O)c1c2)CC 
262 2764 Fc1cc2c(N(C=C(C(O)=O)C2=O)C2CC2)cc1N1CCNCC1 
263 2784 O(C(=O)C(O)(c1ccccc1)c1ccccc1)C1C2CC[N+](C1)(CC2)C 
264 2786 ClC(C(NC(=O)C1N(CC(C1)CCC)C)C1OC(SC)C(O)C(O)C1O)C 
265 2791 ClCC(=O)C1(OC(=O)CC)C2(CC(O)C3(F)C(C2CC1C)CCC1=CC(=
O)C=CC13C)C 
266 2794 Clc1ccc(N2C3=C\C(=N/C(C)C)\C(Nc4ccc(Cl)cc4)=CC3=Nc3c2cccc
3)cc1 
267 2797 Clc1ccc(OC(C(O)=O)(C)C)cc1 
268 2798 Clc1ccc(cc1)CCCC[N+](CCCCCCC)(CC)CC 
269 2812 Clc1ccccc1C(n1ccnc1)(c1ccccc1)c1ccccc1 
270 2813 Clc1ccccc1-c1noc(C)c1C(=O)NC1C2SC(C)(C)C(N2C1=O)C(=O)[O-
] 
271 2833 O(C)C1=CC=C2C(=CC1=O)C(NC(=O)C)CCc1c2c(OC)c(OC)c(OC)
c1 
272 2860 N(C)(C)C1CC2=CCC3C(CCC45C(CCC34)C(N(C5)C)C)C2(CC1)C 
273 2882 O1c2c(C(=O)C=C1C(O)=O)c(OCC(O)COc1c3c(OC(=CC3=O)C(O)=
O)ccc1)ccc2 
274 2900 O=C1C(CC(CC1C)C)C(O)CC1CC(=O)NC(=O)C1 
275 2907 ClCCN(P1(OCCCN1)=O)CCCl 
276 2949 o1ncc2CC3(C4C(C5CCC(O)(C#C)C5(CC4)C)CCC3=Cc12)C 
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277 2955 S(=O)(=O)(c1ccc(N)cc1)c1ccc(N)cc1 
278 2958 O1C(C)C(O)C(N)CC1OC1CC(O)(Cc2c1c(O)c1c(C(=O)c3c(C1=O)c(
OC)ccc3)c2O)C(=O)C 
279 2966 NC(=N)N1CCc2c(C1)cccc2 
280 2973 O=C(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCC
CCN(O)C(=O)C 
281 2975 O=C1CC2C(C3CCC(C(CCC(O)=O)C)C13C)C(=O)CC1CC(=O)CCC
12C 
282 2993 [n+]1(c2c(cccc2)c(N)cc1C)CCCCCCCCCC[n+]1c2c(cccc2)c(N)cc1C 
283 2995 N(CCCN1c2c(CCc3c1cccc3)cccc2)C 
284 3003 FC12C(C3CC(C)C(O)(C(=O)CO)C3(CC1O)C)CCC1=CC(=O)C=CC
12C 
285 3008 O(C)c1cc2C34C(C(N(CC3)C)Cc2cc1)CCCC4 
286 3019 Clc1cc2S(=O)(=O)N=C(Nc2cc1)C 
287 3025 O(CCCC)c1nc2c(cccc2)c(c1)C(=O)NCCN(CC)CC 
288 3038 Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N)cc1Cl 
289 3040 Clc1cccc(Cl)c1-
c1noc(C)c1C(=O)NC1C2SC(C)(C)C(N2C1=O)C(=O)[O-] 
290 3052 O=C(N(CC)CC)N1CCN(CC1)C 
291 3059 Fc1cc(F)ccc1-c1cc(C(O)=O)c(O)cc1 
292 3062 O1C(C)C(OC2OC(C)C(O)C(O)C2)C(O)CC1OC1C(OC(OC2CC3CC
C4C(CC(O)C5(C)C(CCC45O)C4=CC(OC4)=O)C3(CC2)C)CC1O)C 
293 3069 O1C(CO)C(O)C(O)C(NC)C1OC1C(O)(CO)C(OC1OC1C(N=C(N)N)
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C(O)C(N=C(N)N)C(O)C1O)C 
294 3076 S1c2c(N(CCN(C)C)C(=O)C(OC(=O)C)C1c1ccc(OC)cc1)cccc2 
295 3081 O1C(C)(C)C(=O)NC1=O 
296 3108 OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)
CCO 
297 3110 S(=O)(=O)([O-])CN(C)C=1C(=O)N(N(C)C=1C)c1ccccc1 
298 3114 O=C(N)C(CCN(C(C)C)C(C)C)(c1ccccc1)c1ncccc1 
299 3132 SCC(Cc1ccccc1)C(=O)NCC(O)=O 
300 3162 O(C(C)(c1ccccc1)c1ncccc1)CCN(C)C 
301 3168 Fc1ccc(cc1)C(=O)CCCN1CCC(N2c3c(NC2=O)cccc3)=CC1 
302 3169 OC(CN1CCN(CC1)c1ccccc1)CO 
303 3180 O(CCCC)c1ccc(cc1)C(=O)CCN1CCCCC1 
304 3182 O=C1N(C)C(=O)N(c2ncn(c12)CC(O)CO)C 
305 3195 O=C1n2c3C4N(CCCC4(C1)CC)CCc3c1c2cccc1 
306 3198 Clc1cc(Cl)ccc1C(OCc1ccc(Cl)cc1)Cn1ccnc1 
307 3202 Oc1cc([N+](CC)(C)C)ccc1 
308 3222 O(C(=O)C(NC(C(=O)N1CCCC1C(O)=O)C)CCc1ccccc1)CC 
309 3242 O(C)c1n(nc(c1)C)-c1nc(cc(OC)n1)C 
310 3247 Oc1cc2CC=C3C4CCC(=O)C4(CCC3c2cc1)C 
311 3255 O1C(CC)C(O)(C)C(O)C(C)C(=O)C(CC(O)(C)C(OC2OC(CC(N(C)C)
C2O)C)C(C)C(OC2OC(C)C(O)C(OC)(C2)C)C(C)C1=O)C 
312 3276 OCCNC(=O)Cn1ccnc1[N+](=O)[O-] 
313 3279 OCC(NCCNC(CC)CO)CC 
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314 3280 O(CC)c1cc(ccc1OCC)Cc1nccc2c1cc(OCC)c(OCC)c2 
315 3288 OC1(CCC2C3C(CCC12C)C1(C(=CC(=O)CC1)CC3)C)C#C 
316 3291 O=C1NC(=O)CC1(CC)C 
317 3308 O1CCc2c([nH]c3c2cccc3CC)C1(CC(O)=O)CC 
318 3310 O1C2C(OC(OC2)C)C(O)C(O)C1OC1C2C(C(c3c1cc1OCOc1c3)c1cc
(OC)c(O)c(OC)c1)C(OC2)=O 
319 3333 Clc1c(cccc1Cl)C1C(C(OCC)=O)=C(NC(C)=C1C(OC)=O)C 
320 3335 OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1 
321 3342 O(c1cc(ccc1)C(C(O)=O)C)c1ccccc1 
322 3343 Oc1cc(cc(O)c1)C(O)CNC(Cc1ccc(O)cc1)C 
323 3351 Clc1ccc(OCC(=O)N2CCN(CC2)Cc2cc3OCOc3cc2)cc1 
324 3354 O1c2c(cccc2C(OCCN2CCCCC2)=O)C(=O)C(C)=C1c1ccccc1 
325 3371 FC(F)(F)c1cc(Nc2ccccc2C(O)=O)ccc1 
326 3374 Fc1cc2c3N(C=C(C(O)=O)C2=O)C(CCc3c1)C 
327 3375 FC12C(C3CC(C)C(O)(C(=O)CO)C3(CC1O)C)CC(F)C1=CC(=O)C=
CC12C 
328 3379 FC1C2=CC(=O)C=CC2(C2C(C3CC4OC(OC4(C(=O)CO)C3(CC2O)
C)(C)C)C1)C 
329 3382 FC12C(C3CC4OC(OC4(C(=O)COC(=O)C)C3(CC1O)C)(C)C)CC(F)
C1=CC(=O)C=CC12C 
330 3384 FC12C(C3CCC(O)(C(=O)C)C3(CC1O)C)CC(C1=CC(=O)C=CC12C
)C 
331 3392 FC1C2=CC(=O)CCC2(C2C(C3CC4OC(OC4(C(=O)CO)C3(CC2O)C
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)(C)C)C1)C 
332 3405 O=C1N=C(Nc2ncc(nc12)CNc1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=
O)N 
333 3414 P(=O)([O-])([O-])C(=O)[O-] 
334 3418 P(Oc1ccccc1C(O)=O)(O)(O)=O 
335 3442 OC(=O)c1ncc(cc1)CCCC 
336 3446 OC(=O)CC1(CCCCC1)CN 
337 3449 O1c2c3C4(C1CC(O)C=C4)CCN(Cc3ccc2OC)C 
338 3454 O=C1N=C(Nc2n(cnc12)COC(CO)CO)N 
339 3467 O1C(OC2C(O)C(OC3OCC(O)(C)C(NC)C3O)C(N)CC2N)C(N)CCC1
C(NC)C 
340 3475 S(=O)(=O)(NC(=O)NN1CC2C(CCC2)C1)c1ccc(cc1)C 
341 3478 S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(cc1)CCNC(=O)c1ncc(nc1)C 
342 3488 Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)c(OC
)cc1 
343 3503 Oc1c(O)c(c2c(cc(C)c(-
c3c(cc4c(c(C=O)c(O)c(O)c4C(C)C)c3O)C)c2O)c1C(C)C)C=O 
344 3516 O(CC(O)CO)c1ccccc1OC 
345 3553 ClCC(=O)C12OC(OC1CC1C3CCC4=CC(=O)CCC4(C)C3(F)C(O)C
C12C)(C)C 
346 3561 IC#CCOc1cc(Cl)c(Cl)cc1Cl 
347 3573 O1CC(CCC12OC1C(C3(C(C4C(CC3=O)C3(C(CC(O)CC3)CC4)C)C
1)C)C2C)C 
246 
 
348 3590 OC(CCCC(N)C)(C)C 
349 3604 [N+](CCCCCC[N+](C)(C)C)(C)(C)C 
350 3606 Oc1ccc(cc1)C(C(CC)c1ccc(O)cc1)CC 
351 3607 NC1(CN(CN(C1)CC(CCCC)CC)CC(CCCC)CC)C 
352 3623 O(C(=O)C(O)c1ccccc1)C1CC2N(C(C1)CC2)C 
353 3637 n1ncc2c(cccc2)c1NN 
354 3639 Clc1cc2NCNS(=O)(=O)c2cc1S(=O)(=O)N 
355 3640 OC1(CCC2C3C(C4(C(=CC(=O)CC4)CC3)C)C(O)CC12C)C(=O)CO 
356 3647 S(=O)(=O)(N)c1cc2S(=O)(=O)NCNc2cc1C(F)(F)F 
357 3649 O(C)c1cc2c(nccc2C(O)C2N3CC(C(C2)CC3)CC)cc1 
358 3661 O(C(=O)C(CO)c1ccccc1)C1CC2N(C(C1)CC2)C 
359 3676 O=C(Nc1c(cccc1C)C)CN(CC)CC 
360 3677 N(C(Cc1ccccc1)(C)C)C 
361 3687 IC1=CN(C2OC(CO)C(O)C2)C(=O)NC1=O 
362 3698 O=C1NC=C(C=C1N)c1ccncc1 
363 3718 O=C1N(Cc2c1cccc2)c1ccc(cc1)C(C(O)=O)C 
364 3730 Ic1c(C(=O)NCC(O)CO)c(I)c(N(C(=O)C)CC(O)CO)c(I)c1C(=O)NCC
(O)CO 
365 3746 O(C(=O)C(CO)c1ccccc1)C1CC2[N+](C(C1)CC2)(C(C)C)C 
366 3748 O=C(NNC(C)C)c1ccncc1 
367 3760 Clc1cccc(Cl)c1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl 
368 3762 Oc1cc(ccc1O)C(O)C(NC(C)C)CC 
369 3767 O=C(NN)c1ccncc1 
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370 3775 O=C(N)C(CC[N+](C(C)C)(C(C)C)C)(c1ccccc1)c1ccccc1 
371 3780 O1C2C(OCC2O[N+](=O)[O-])C(O[N+](=O)[O-])C1 
372 3783 O(CC(NC(C(O)c1ccc(O)cc1)C)C)c1ccccc1 
373 3823 Clc1cc(Cl)ccc1C1(OC(CO1)COc1ccc(N2CCN(CC2)C(=O)C)cc1)Cn
1ccnc1 
374 3825 OC(=O)C(C)c1cc(ccc1)C(=O)c1ccccc1 
375 3830 o1cccc1CNc1ncnc2nc[nH]c12 
376 3879 O1C(CO)C(O)C(O)C(O)C1OC1C(OC(OC2C(OC(OC3C(OC(OC4CC
5CCC6C(CC(O)C7(C)C(CCC67O)C6=CC(OC6)=O)C5(CC4)C)CC3
O)C)CC2O)C)CC1OC(=O)C)C 
377 3888 O1C(CC(C)C1C(C(=O)C(C(O)C(CCc1ccc(C)c(O)c1C(O)=O)C)C)C
C)(CC)C1OC(C)C(O)(CC1)CC 
378 3913 S1CCN2CC(N=C12)c1ccccc1 
379 3917 Oc1cc(ccc1O)C(O)C(N)C 
380 3928 S(C)C1OC(C(NC(=O)C2N(CC(C2)CCC)C)C(O)C)C(O)C(O)C1O 
381 3937 OC(=O)C1N(CCC1)C(=O)C(NC(CCc1ccccc1)C(O)=O)CCCCN 
382 3945 OC(CC1N(C)C(CCC1)CC(=O)c1ccccc1)c1ccccc1 
383 3948 Fc1c2N(C=C(C(O)=O)C(=O)c2cc(F)c1N1CC(NCC1)C)CC 
384 3955 Clc1ccc(cc1)C1(O)CCN(CC1)CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc
1 
385 3962 O1C(CC(O)CC1=O)CCC1C2C(=CC(CC2OC(=O)C(CC)C)C)C=CC1
C 
386 3966 N12C(C3CC(C4N(C3)CCCC4)C1)CCCC2 
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387 3978 O1c2c(OC1)cc1c(C3C4N(CCC4=CC(O)C3O)C1)c2 
388 3998 S(=O)(=O)(N)c1ccc(cc1)CN 
389 4030 O(C(=O)Nc1[nH]c2cc(ccc2n1)C(=O)c1ccccc1)C 
390 4034 Clc1ccc(cc1)C(N1CCN(CC1)Cc1cc(ccc1)C)c1ccccc1 
391 4036 Clc1c(Nc2ccccc2C(=O)[O-])c(Cl)ccc1C 
392 4039 Clc1ccc(OCC(OCCN(C)C)=O)cc1 
393 4043 OC1C2C(C3CCC(C(=O)C)C3(C1)C)CC(C1=CC(=O)CCC12C)C 
394 4045 O(CC(=O)NCCN(CC)CC)c1ccc(OC)cc1 
395 4046 FC(F)(F)c1c2nc(cc(c2ccc1)C(O)C1NCCCC1)C(F)(F)F 
396 4053 ClCCN(CCCl)c1ccc(cc1)CC(N)C(O)=O 
397 4055 O=C1c2c(cccc2)C(=O)C=C1C 
398 4057 O(C(=O)C(O)(c1ccccc1)c1ccccc1)C1CCC[N+](C1)(C)C 
399 4059 O(CC(O)CO)c1ccccc1C 
400 4077 S(=O)(=O)([O-])CCS 
401 4078 S1c2c(N(c3c1cccc3)CCC1N(CCCC1)C)cc(S(=O)C)cc2 
402 4080 O(C)c1cc2CCC3C4CCC(O)(C#C)C4(CCC3c2cc1)C 
403 4086 Oc1cc(cc(O)c1)C(O)CNC(C)C 
404 4087 Oc1cc(ccc1)C(O)C(N)C 
405 4091 N(C(N=C(N)N)=N)(C)C 
406 4098 s1cccc1CN(CCN(C)C)c1ncccc1 
407 4100 S1\C(=N/C(=O)C)\N(N=C1S(=O)(=O)N)C 
408 4101 N12CN3CN(C1)CN(C2)C3 
409 4107 O(CC(O)COC(=O)N)c1ccccc1OC 
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410 4112 OC(=O)C(NC(=O)c1ccc(N(Cc2nc3c(nc(nc3N)N)nc2)C)cc1)CCC(O)
=O 
411 4114 O1c2c(C=CC1=O)cc1c(occ1)c2OC 
412 4122 s1cccc1C(=O)c1cc2[nH]c(nc2cc1)NC(OC)=O 
413 4138 Oc1cc(ccc1O)CC(N)(C(O)=O)C 
414 4139 S1C2=CC(=[N+](C)C)C=CC2=Nc2c1cc(N(C)C)cc2 
415 4140 OCC(NC(=O)C1C=C2C(N(C1)C)Cc1c3c2cccc3[nH]c1)CC 
416 4159 OC1(CCC2C3C(C4(C(=CC(=O)C=C4)C(C3)C)C)C(O)CC12C)C(=O
)CO 
417 4165 S(=O)(=O)(N)c1cc2S(=O)(=O)CCCc2cc1C 
418 4170 Clc1cc2NC(N(c3ccccc3C)C(=O)c2cc1S(=O)(=O)N)C 
419 4171 O(CC(O)CNC(C)C)c1ccc(cc1)CCOC 
420 4189 Clc1cc(Cl)ccc1C(OCc1ccc(Cl)cc1Cl)Cn1ccnc1 
421 4195 O(C)c1ccc(OC)cc1C(O)CNC(=O)CN 
422 4196 OC1(CCC2C3C(=C4C(=CC(=O)CC4)CC3)C(CC12C)c1ccc(N(C)C)c
c1)C#CC 
423 4201 ON1C(N)=CC(=NC1=N)N1CCCCC1 
424 4211 Clc1ccccc1C(C(Cl)Cl)c1ccc(Cl)cc1 
425 4212 Oc1c2c(C(=O)c3c(C2=O)c(NCCNCCO)ccc3NCCNCCO)c(O)cc1 
426 4240 ClC12C(C3CC(C)C(OC(=O)c4occc4)(C(=O)CCl)C3(CC1O)C)CCC1
=CC(=O)C=CC12C 
427 4243 O1C(C(CC(C)C1(O)CO)C)C1OC(C2(OC(CC2)C2(OC3(OC(C(C(OC
)C(C(O)=O)C)C)C(C)C(O)C3)CC2)C)CC)C(C1)C 
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428 4246 O1C2C3N(CC2)CC=C3COC(=O)C(O)(C)C(O)(C)C(C)C1=O 
429 4260 O(C(=O)C)c1cc(C(C)C)c(OCCN(C)C)cc1C 
430 4411 O(CC(O)CNC(C)(C)C)c1c2CC(O)C(O)Cc2ccc1 
431 4419 O1C2C34CCN(C(Cc5c3c1c(O)cc5)C4(O)CCC2O)CC1CCC1 
432 4425 O1C2C34CCN(C(Cc5c3c1c(O)cc5)C4(O)CCC2=O)CC=C 
433 4428 O1C2C34CCN(C(Cc5c3c1c(O)cc5)C4(O)CCC2=O)CC1CC1 
434 4436 N1CCN=C1Cc1c2c(ccc1)cccc2 
435 4441 O1C(CO)C(O)C(O)C(OC2OC(C)C(O)C(O)C2O)C1Oc1cc(O)c2c(OC
(CC2=O)c2ccc(O)cc2)c1 
436 4454 O1C(CN)C(O)C(O)C(N)C1OC1C(O)C(OC1CO)OC1C(OC2OC(CN)
C(O)C(O)C2N)C(N)CC(N)C1O 
437 4456 O(C(=O)N(C)C)c1cc([N+](C)(C)C)ccc1 
438 4474 O(C(=O)C=1C(C(C(OC)=O)=C(NC=1C)C)c1cc([N+](=O)[O-
])ccc1)CCN(Cc1ccccc1)C 
439 4477 Clc1cc([N+](=O)[O-])ccc1NC(=O)c1cc(Cl)ccc1O 
440 4487 O=C1N(N(C)C(C)=C1NC(=O)c1cccnc1)c1ccccc1 
441 4488 FC(F)(F)c1cc(Nc2ncccc2C(O)=O)ccc1 
442 4495 S(=O)(=O)(Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1)C 
443 4528 Nc1c2c(ccc1)C(CN(C2)C)c1ccccc1 
444 4536 OC1(CCC2C3C(C4C(=CC(=O)CC4)CC3)CCC12C)C#C 
445 4537 OC1(CCC2C3C(C4=C(CC(=O)CC4)CC3)CCC12C)C#C 
446 4539 Fc1cc2c(N(C=C(C(O)=O)C2=O)CC)cc1N1CCNCC1 
447 4542 OC1(CCC2C3C(C4C(=CC(=O)CC4)CC3)CCC12CC)C#C 
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448 4544 O1C(c2c(c(OC)c(OC)cc2)C1=O)C1N(CCc2c1c(OC)c1OCOc1c2)C 
449 4583 Fc1cc2c3N(C=C(C(O)=O)C2=O)C(COc3c1N1CCN(CC1)C)C 
450 4587 O1C(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2OC(CC(N(C)C)C
2O)C)C(C)C(OC2OC(C)C(O)C(OC)C2)C(C)C1=O 
451 4594 S(=O)(Cc1ncc(C)c(OC)c1C)c1[nH]c2cc(OC)ccc2n1 
452 4605 O1C(C)C(O)C(O)C(O)C1OC1CC2(O)CCC3C(C2(CO)C(O)C1)C(O)
CC1(C)C(CCC13O)C1=CC(OC1)=O 
453 4621 OCCN(CC(=O)N(C(Cc1ccccc1)(C)C)C)CC(=O)N(C(Cc1ccccc1)(C)
C)C 
454 4628 O1c2c(OC1)cc1N(C=C(C(O)=O)C(=O)c1c2)CC 
455 4666 O1C2CC(O)C3(C(C(OC(=O)c4ccccc4)C4(O)CC(OC(=O)C(O)C(NC(
=O)c5ccccc5)c5ccccc5)C(=C(C4(C)C)C(OC(=O)C)C3=O)C)C2(OC(
=O)C)C1)C 
456 4678 OC(C(CO)(C)C)C(=O)NCCCO 
457 4680 O(C)c1cc(ccc1OC)Cc1nccc2c1cc(OC)c(OC)c2 
458 4688 N(Cc1ccccc1)(CC#C)C 
459 4689 O1C(CN)C(O)C(O)C(N)C1OC1C(O)C(OC1CO)OC1C(OC2OC(CO)
C(O)C(O)C2N)C(N)CC(N)C1O 
460 4735 O(CCCCCOc1ccc(cc1)C(N)=N)c1ccc(cc1)C(N)=N 
461 4740 O=C1N(CCCCC(=O)C)C(=O)N(c2ncn(c12)C)C 
462 4742 OC(C(NC(=O)C(NC(=O)C(NC(=O)CC(C)C)C(C)C)C(C)C)CC(C)C)
CC(=O)NC(C(=O)NC(C(O)CC(O)=O)CC(C)C)C 
463 4746 N1CCCCC1CC(C1CCCCC1)C1CCCCC1 
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464 4754 O(CC)c1ccc(NC(=O)C)cc1 
465 4758 S1C2N(C(C(=O)[O-])C1(C)C)C(=O)C2NC(=O)C(Oc1ccccc1)C 
466 4760 O=C1c2c(cccc2)C(=O)C1c1ccccc1 
467 4761 n1ccccc1C(CCN(C)C)c1ccccc1 
468 4806 s1ccnc1NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1 
469 4811 O(C(=O)NC)c1cc2c(N(C3N(CCC23C)C)C)cc1 
470 4814 O(C)c1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1 
471 4816 O1C2C3OC(=O)C45OC4CC(O)(C(C2C(C)=C)C1=O)C35C 
472 4819 O1CC(Cc2n(cnc2)C)C(CC)C1=O 
473 4828 O(CC(O)CNC(C)C)c1c2c([nH]cc2)ccc1 
474 4832 O(C(=O)C(O)(c1ccccc1)c1ccccc1)C1CCC[N+](C1)(CC)C 
475 4843 O=C1N(CCC1)CC(=O)N 
476 4848 O=C1Nc2cccnc2N(c2c1cccc2)C(=O)CN1CCN(CC1)C 
477 4855 O=C1c2c(nc(nc2)N2CCCC2)N(C=C1C(O)=O)CC 
478 4865 O1CC2C(C(c3c(cc4OCOc4c3)C2O)c2cc(OC)c(OC)c(OC)c2)C1=O 
479 4883 O(CC(O)CNC(C)C)c1ccc(NC(=O)C)cc1 
480 4886 O1CCN(CC1)CCCOc1ccc(OCCCC)cc1 
481 4894 OC1(CCC2C3C(C4(C(=CC(=O)C=C4)CC3)C)C(O)CC12C)C(=O)C
O 
482 4900 OC1(CCC2C3C(C4(C(=CC(=O)C=C4)CC3)C)C(=O)CC12C)C(=O)
CO 
483 4904 OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1 
484 4906 O=C(Nc1ccccc1C)C(NCCC)C 
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485 4908 O(C)c1cc(NC(CCCN)C)c2ncccc2c1 
486 4911 S(=O)(=O)(N(CCC)CCC)c1ccc(cc1)C(O)=O 
487 4919 OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1 
488 4920 O=C1CCC2(C3C(C4CCC(C(=O)C)C4(CC3)C)CCC2=C1)C 
489 4922 OC(=O)CCC(NC(=O)c1ccccc1)C(=O)N(CCC)CCC 
490 4934 O1c2c(cccc2)C(c2c1cccc2)C(OCC[N+](C(C)C)(C(C)C)C)=O 
491 4974 O1C23C(C4(O)C(C5C(C(O)C4OC(=O)C(CC)C)C(O)(C4N(CC(CC4)
C)C5)C)C2)C(OC(=O)C)C(OC(=O)C)C2C1(O)C(OC(=O)C(O)(CC)
C)CCC23C 
492 4984 O1C(CO)C(NC(=O)C(N)Cc2ccc(OC)cc2)C(O)C1n1c2ncnc(N(C)C)c
2nc1 
493 4993 Clc1ccc(cc1)-c1c(nc(nc1N)N)CC 
494 4994 O=C1C=CNC(=O)C1(CC)CC 
495 5037 O=C1N(N(C)C(C)=C1NC(C)C)c1ccccc1 
496 5052 O(C)C1C(C2C(CC1OC(=O)c1cc(OC)c(OC)c(OC)c1)CN1C(C2)c2[n
H]c3cc(OC)ccc3c2CC1)C(OC)=O 
497 5066 O1C(CN)C(O)C(O)C(N)C1OC1C(OC2OC(CO)C(O)C2O)C(O)C(N)
CC1N 
498 5070 s1c2cc(OC(F)(F)F)ccc2nc1N 
499 5102 O1c2c(CC1C(C)=C)c1OC3C(c4cc(OC)c(OC)cc4OC3)C(=O)c1cc2 
500 5184 O1C2C3N(C(CC(OC(=O)C(CO)c4ccccc4)C3)C12)C 
501 5195 N(C(Cc1ccccc1)C)(CC#C)C 
502 5198 ClCCN(N=O)C(=O)NC1CCC(CC1)C 
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503 5215 S(=O)(=O)(Nc1ncccn1)c1ccc(N)cc1 
504 5224 O1C(OC2C(O)C(OC3OCC(O)(C)C(NC)C3O)C(N)CC2N)C(N)CC=C
1CN 
505 5250 O1C2C(C(C)C13NCC(CC3)C)C1(C(C3C(CC1)C1(C(CC(O)CC1)=C
C3)C)C2)C 
506 5267 S(C(=O)C)C1C2C3CCC4(OC(=O)CC4)C3(CCC2C2(C(C1)=CC(=O)
CC2)C)C 
507 5275 O(C)c1ccc(cc1)-c1n[n+](CCCC(O)=O)c(N)cc1 
508 5297 O1C(CO)C(O)C(O)C(NC)C1OC1C(O)(C=O)C(OC1OC1C(N=C(N)N
)C(O)C(N=C(N)N)C(O)C1O)C 
509 5299 OC(C(NC(=O)N(N=O)C)C=O)C(O)C(O)CO 
510 5303 O1CC(=CC1=O)C1CCC2(O)C3C(CCC12C)C1(CCC(O)CC1(O)CC3
)C=O 
511 5315 s1ccnc1NS(=O)(=O)c1ccc(NC(=O)CCC(O)=O)cc1 
512 5318 Clc1cc(Cl)ccc1C(SCc1ccc(Cl)cc1)Cn1ccnc1 
513 5319 S(=O)(=O)(NC(=O)c1ccccc1)c1ccc(N)cc1 
514 5323 S(=O)(=O)(Nc1nc(OC)nc(OC)c1)c1ccc(N)cc1 
515 5324 S(=O)(=O)(N=C(N)N)c1ccc(N)cc1 
516 5325 S(=O)(=O)(Nc1nc(ccn1)C)c1ccc(N)cc1 
517 5326 S(=O)(=O)(Nc1ncc(OC)cn1)c1ccc(N)cc1 
518 5328 s1c(nnc1NS(=O)(=O)c1ccc(N)cc1)C 
519 5329 S(=O)(=O)(Nc1noc(c1)C)c1ccc(N)cc1 
520 5330 S(=O)(=O)(Nc1nnc(OC)cc1)c1ccc(N)cc1 
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521 5332 S(=O)(=O)(Nc1ncnc(OC)c1)c1ccc(N)cc1 
522 5333 S(=O)(=O)(N)c1ccc(N)cc1 
523 5335 S(=O)(=O)(Nc1n(ncc1)-c1ccccc1)c1ccc(N)cc1 
524 5336 S(=O)(=O)(Nc1ncccc1)c1ccc(N)cc1 
525 5340 s1ccnc1NS(=O)(=O)c1ccc(N)cc1 
526 5342 S(=O)(CCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1)c1ccccc1 
527 5353 S(=O)(C)c1cc(OC)c(cc1)-c1[nH]c2cccnc2n1 
528 5354 S(C(C)C)c1ccc(cc1)C(O)C(NCCCCCCCC)C 
529 5355 S(=O)(=O)(N)c1cc(C(=O)NCC2N(CCC2)CC)c(OC)cc1 
530 5359 s1cccc1C(=O)c1ccc(cc1)C(C(O)=O)C 
531 5362 O=C1N(N(C(=O)C1(CCCC)COC(=O)CCC(O)=O)c1ccccc1)c1ccccc
1 
532 5367 O(C)C1C(C2C(CC1OC(=O)c1cc(OC)c(OC(OCC)=O)c(OC)c1)CN1C
(C2)c2[nH]c3cc(OC)ccc3c2CC1)C(OC)=O 
533 5387 s1cc2c(N(c3c(NC2=O)cccc3)C(=O)CN2CCN(CC2)C)c1C 
534 5401 O1CCCC1C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 
535 5403 Oc1cc(cc(O)c1)C(O)CNC(C)(C)C 
536 5404 Clc1cc(Cl)ccc1C1(OC(CO1)COc1ccc(N2CCN(CC2)C(C)C)cc1)Cn1n
cnc1 
537 5410 O(C(=O)CC)C1CCC2C3C(CCC12C)C1(C(=CC(=O)CC1)CC3)C 
538 5419 N1CCN=C1C1CCCc2c1cccc2 
539 5424 OC=1C(=O)C(O)=C(O)C(=O)C=1O 
540 5426 O=C1NC(=O)CCC1N1C(=O)c2c(cccc2)C1=O 
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541 5429 O=C1NC(=O)N(c2ncn(c12)C)C 
542 5430 s1cc(nc1)-c1[nH]c2c(n1)cccc2 
543 5433 ClC(Cl)C(=O)NC(C(O)c1ccc(S(=O)(=O)C)cc1)CO 
544 5468 s1c(ccc1C(C(O)=O)C)C(=O)c1ccccc1 
545 5472 Clc1ccccc1CN1CCc2sccc2C1 
546 5479 S(=O)(=O)(CCn1c(ncc1[N+](=O)[O-])C)CC 
547 5496 O1C(CO)C(O)C(N)C(O)C1OC1C(O)C(OC2OC(CN)C(O)CC2N)C(N
)CC1N 
548 5501 O(CC)C(=O)NNc1nncc2c1cccc2 
549 5503 S(=O)(=O)(NC(=O)NN1CCCCCC1)c1ccc(cc1)C 
550 5504 N1CCN=C1Cc1ccccc1 
551 5505 S(=O)(=O)(NC(=O)NCCCC)c1ccc(cc1)C 
552 5507 Clc1ccc(Nc2ccccc2C(O)=O)cc1C 
553 5508 O=C(c1ccc(cc1)C)c1n(C)c(cc1)CC(=O)[O-] 
554 5510 S=C(Oc1cc2c(cc1)cccc2)N(C)c1cc(ccc1)C 
555 5526 OC(=O)C1CCC(CC1)CN 
556 5530 NC1CC1c1ccccc1 
557 5534 N1(CCCC1)CC#CCN1CCCC1 
558 5544 FC12C(C3CC(O)C(O)(C(=O)CO)C3(CC1O)C)CCC1=CC(=O)C=CC
12C 
559 5546 n1c(N)c2nc(-c3ccccc3)c(nc2nc1N)N 
560 5560 Clc1cc2NC(NS(=O)(=O)c2cc1S(=O)(=O)N)C(Cl)Cl 
561 5571 OC(=O)c1ccc[n+](c1)C 
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562 5572 OC(CCN1CCCCC1)(C1CCCCC1)c1ccccc1 
563 5576 O1C(C)(C)C(=O)N(C)C1=O 
564 5577 O(C)c1c(OC)cc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1 
565 5585 O1c2c(cc3c(oc(c3)C)c2C)C(=CC1=O)C 
566 5593 OCC(C(=O)N(Cc1ccncc1)CC)c1ccccc1 
567 5635 O1C2C(C3N(CCC3=CC2OC)C)c2c(cc3OCOc3c2)C1=O 
568 5645 OC1C2C3CCC(C(CCC(O)=O)C)C3(CCC2C2(C(C1)CC(O)CC2)C)C 
569 5651 Clc1c2Oc3cc4C(NC(=O)C(NC(=O)C(NC(=O)C(NC)CC(C)C)C(O)c(
c1)cc2)CC(=O)N)C(=O)NC1c2cc(-
c5c(cc(O)cc5O)C(NC(=O)C(NC1=O)C(O)c1cc(Cl)c(Oc(c4)c3OC3O
C(CO)C(O)C(O)C3OC3OC(C)C(O)C(N)(C3)C)cc1)C(O)=O)c(O)cc2 
570 5665 OC(=O)CCC(N)C=C 
571 5666 O1CCNCC1COc1ccccc1OCC 
572 5668 OC1(n2c3C4N(CCCC4(C1)CC)CCc3c1c2cccc1)C(OC)=O 
573 5673 O(C(=O)C=1n2c3C4N(CCCC4(C=1)CC)CCc3c1c2cccc1)CC 
574 5707 S1CCCN=C1Nc1c(cccc1C)C 
575 5803 Ic1cc(cc(I)c1Oc1cc(I)c(O)cc1)CC(O)=O 
576 5850 [N+]1(CCCC1)(CCCCC[N+]1(CCCC1)C)C 
577 5853 ClC(Cl)(Cl)C(P(OC)(OC)=O)O 
578 5917 n12nnnc1CCCCC2 
579 6077 S1c2c(N(c3c1cccc3)CCCN(C)C)cc(cc2)C(=O)C 
580 6082 O(C)c1ccc(OC)cc1C(O)C(N)C 
581 6093 s1c([N+](=O)[O-])cnc1N1CCNC1=O 
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582 6103 Clc1cc2nc(oc2cc1)N 
583 6127 [N+]1(CCC(CC1)=C(c1ccccc1)c1ccccc1)(C)C 
584 6603 N1(C)C(CCCC1(C)C)(C)C 
585 6634 Clc1nnc(NS(=O)(=O)c2ccc(N)cc2)cc1 
586 6726 N1(CCN(CC1)C)C(c1ccccc1)c1ccccc1 
587 6834 Brc1ccc(cc1)C(CCN(C)C)c1ncccc1 
588 6890 [nH]1cc(c2c1cccc2)CN(C)C 
589 7534 O(C(=O)C(O)c1ccccc1)C1CC(N(C)C(C1)C)(C)C 
590 8249 N(=C(\N=C(N)N)/N)/CCc1ccccc1 
591 8513 O=C1c2c(cccc2N)C(=O)c2c1cccc2N 
592 8646 O=C1N=C(N=C2NNN=C12)N 
593 9052 O1c2c(cccc2)C(=O)C(C(CC(=O)C)c2ccc([N+](=O)[O-])cc2)=C1O 
594 9341 OC1C2N(CC1)CC=C2COC(=O)C(O)(C(C)C)C(OC)C 
595 9363 O(C)c1cc(ccc1O)C(=O)N(CC)CC 
596 9429 S1c2c(N(c3c1cccc3)CCCN1CCN(CC1)C)cc(S(=O)(=O)N(C)C)cc2 
597 9458 FC(F)(F)c1cc(OC(=O)C)c(cc1)C(O)=O 
598 9801 N(C(Cc1ccccc1)C)CCC(c1ccccc1)c1ccccc1 
599 9985 N1CCCCC1CCC 
600 10147 O1c2c3c(C4C(N(C3)C)c3c(CC4O)cc4OCOc4c3)ccc2OC1 
601 10302 O(C)c1cc2c(cc1OC)CCNC2C 
602 10428 O1CCC(O)(CC1=O)C 
603 10666 O(C)C=1C=CN(C)C(=O)C=1C#N 
604 10745 O(C(=O)c1ccccc1OC(=O)C)c1ccccc1C(O)=O 
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605 10767 O(C(=O)c1ccccc1)C(CC)(CN(C)C)C 
606 11066 O1c2c(OC1)cc1C=3N(CCc1c2)C(=O)c1c(C=3)ccc(OC)c1OC 
607 11096 O=C1CC2N(C(C1)CCC2)C 
608 11289 ClC(=C(c1ccc(OC)cc1)c1ccc(OC)cc1)c1ccc(OC)cc1 
609 12550 O1C(C)C(NC(=O)c2cccc(NC=O)c2O)C(OC(C)C(OC(=O)CC(C)C)C
(CCCCCC)C1=O)=O 
610 13729 S1C2N(C(=O)C2N)C(C(O)=O)=C(C1)COC(=O)C 
611 13738 o1nc(nc1CCN(CC)CC)-c1ccccc1 
612 14520 S1CCC(NC(=O)C)C1=O 
613 15548 O(C)c1cc(ccc1OC)CC1N(CCc2c1cc(OC)c(OC)c2)C 
614 16231 Clc1nc(C(=O)N=C(N)N)c(nc1N)N 
615 16363 Fc1ccc(cc1)C(=O)CCCN1CCC(N2c3c(NC2=O)cccc3)CC1 
616 18999 O(C)c1c(OC)c2C=3C(=CC(=O)C(O)=CC=3)C(N)CCc2cc1OC 
617 19009 O(C)c1c2c(ccc1OC)cc-1[n+](CCc3cc(OC)c(OC)cc-13)c2 
618 19659 S=C1N([O-])C=CC=C1 
619 20710 O(C(=O)C(CO)c1ccccc1)C1CC2[N+]([O-])(C(C1)CC2)C 
620 21100 O(C)c1cc(ccc1O)C(O)CNC 
621 21109 O(C)c1c(OC)c(OC)ccc1CN1CCNCC1 
622 22407 O=C1N2C(C3CC(C2)CNC3)=CC=C1 
623 22955 O(C)c1ccc2c(CN3C(C2)c2cc(O)c(OC)cc2CC3)c1O 
624 23307 O(C)c1cc2c(cc1OC)cc1[n+](ccc3cc(OC)c(OC)cc13)c2C 
625 23831 S(O)(=O)(=O)CCN1CCN(CC1)CCO 
626 28061 ClCC(O)Cn1c(ncc1[N+](=O)[O-])C 
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627 31072 S=C1N(C=CN1C)C(OCC)=O 
628 31729 Oc1ccc(cc1)C(O)C(NCCc1ccc(O)cc1)C 
629 37338 [N+](CCCc1[n+](c2cc(N)ccc2c2c1cc(N)cc2)-c1ccccc1)(CC)(CC)C 
630 40634 O1c2c(CCC1(C(O)=O)C)c(C)c(O)c(C)c2C 
631 42616 O=C1C(N2CC2)=C(NC(OCC)=O)C(=O)C(N2CC2)=C1NC(OCC)=O 
632 44097 S1C2N(C(=O)C2NC(=O)C(S(O)(=O)=O)c2ccccc2)C(C(=O)[O-
])=C(C1)C[n+]1ccc(cc1)C(=O)N 
633 48704 O(C)c1c2-c3c(CC4N(CCc(cc1OC)c24)C)ccc(OC)c3O 
634 54456 Oc1cc2c(cc1O)CCNC2C 
635 60793 O1C(CO)C(O)C(O)C(O)C1OC(C(O)C(O)C(O)=O)C(O)CO 
636 62389 [nH]1c2c(ncnc2NCc2ccccc2)nc1 
637 64961 [nH]1c2c(c3c1cncc3)cccc2 
638 67425 O(CCN(CC)CC)c1c(OCCN(CC)CC)cccc1OCCN(CC)CC 
639 68094 O=C1C=C2NC=3C(=C2C=C1)C=CNC=3C 
640 68843 N1C(CCCC1C)C 
641 69216 O=C1NC(=O)NC1C 
642 71655 O1CCN(CC1)C(N=C(N)N)=N 
643 71771 Clc1cccc(Cl)c1Nc1ccccc1CC(OCC(O)=O)=O 
644 91522 [nH]1c2c(CCNC2C)c2c1cccc2 
645 92118 O(C)C1C2C34C(N(CC2(CCC3O)COC)CC)C1(O)C1(O)C2C4CC(C2
OC)C(OC)C1 
646 96946 OC(CC1N(C)C(CCC1)CC(O)c1ccccc1)c1ccccc1 
647 97508 OC(=O)C(NC(=O)C)CC(O)=O 
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648 98889 OC=1C(=O)N(N(C)C=1C)c1ccccc1 
649 99114 O1C2C(C(C)C1=O)C(O)CC(=C1C2C(=CC1=O)C)C 
650 107751 S(C(=O)C)CC(Cc1ccccc1)C(=O)NCC(OCc1ccccc1)=O 
651 122642 P(OC1C(O)C(OC1n1c2ncnc(N)c2nc1)CO)(OCC1OC(n2c3ncnc(N)c3
nc2)C(OP(OCC2OC(n3c4ncnc(N)c4nc3)C(O)C2O)(O)=O)C1O)(O)=
O 
652 161120 O1C2C(O)(C34OC5OC(=O)C(O)C56C3(C(OC4=O)C(O)C6C(C)(C)
C)C2O)C(C)C1=O 
653 165537 O1C23C4(OC1)C1C(O)(C56C(C(CCC5OC)(CN(C26)CC)C)C3OC(=
O)C)CC(C1OC)C(OC)C4 
654 170157 O(C)C1C2CC3C(C(O)(C1)C1C4N(CC5(C(C34C(O)CC5)C1)C)CC)
C2O 
655 170344 OC(=O)CN(CC(=O)Nc1c(cccc1CC)CC)CC(O)=O 
656 179850 OC1CCCc2c1nc1c(cccc1)c2N 
657 180933 O=C1C=CC(=O)c2c1c1c(c3c(cc1)cccc3)cc2 
658 195165 O1CCN(CC1)CCNc1nnc-2c(c1)CCCc1c-2cccc1 
659 201400 O(C(=O)C1(CCC(c2c1cccc2)C(OC1CC2[N+](C(C1)CC2)(CC)C)=O)
c1ccccc1)C1CC2[N+](C(C1)CC2)(CC)C 
660 220774 OC1CCC2(C(CCC3(C2CC=C2C4C(C)C(CCC4(CCC23C)C(O)=O)C
)C)C1(C)C)C 
661 248507 O(C)c1c2-c3cc(OC)c(O)cc3CC3N(CCc(cc1O)c23)C 
662 251561 O1C=C(C2C(CN3C(C2)c2[nH]c4c(c2CC3)cccc4)C1C)C(OC)=O 
663 260807 O(Cc1ccccc1)c1c2[nH]cc(c2ccc1)CN(C)C 
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664 264115 N1C2N(CCC3(C24CCN(C3Nc2c4cccc2)C)c2c1cccc2)C 
665 267769 O1C23C(=CC1=O)C=CC(N1C2CCCC1)C3 
666 271325 Brc1cc(OC)c(OC)cc1CC1N(CCc2c1cc(OC)c(OC)c2)C 
667 274159 O1CC(=CC1=O)C1CCC2(O)C3C(CCC12C)C1(C(CC(O)CC1)CC3)
C 
668 279057 O1C2CC3C(C4N(CC3(C4C23c2c(NC3=O)cccc2)C=C)C)C1 
669 287691 S(C)C1=CC=C2C(=CC1=O)C(NC(=O)C)CCc1c2c(OC)c(OC)c(OC2
OC(CO)C(O)C(O)C2O)c1 
670 312827 O1C2C(C(C)C13NCC(CC3)C)C1(C(C3C(CC1)C1(C(CC(O)CC1)CC
3)C)C2)C 
671 342467 Ic1c(C(=O)NC2C(O)C(O)C(OC2O)CO)c(I)c(NC(=O)C)c(I)c1N(C(=
O)C)C 
672 413349 O1C(CN)C(O)C(O)C(N)C1OC1C(O)C(O)C(N)CC1N 
673 418931 O1C(C)C(C)C(OC(=O)C)C(C)C(=O)C2(OC2)CC(C)C(OC2OC(CC(
N(C)C)C2OC(=O)C)C)C(C)C(OC2OC(C)C(OC(=O)C)C(OC)C2)C(
C)C1=O 
674 420422 O(C)c1cc(ccc1OC)C(OC1CC2N(C(C1)CC2)C)=O 
675 439739 OC1C2C(C3CCC(C(=O)CO)C3(C1)C)CCC1=CC(=O)CCC12C 
676 442649 n1cc(ccc1)C1=NCCC1 
677 443007 O(C)c1cc(ccc1O)C(OC1CC2N(C(C1)CC2)C)=O 
678 446541 O1Cc2c(c(O)c(C\C=C(\CCC(O)=O)/C)c(OC)c2C)C1=O 
679 457906 OC1CC([N+](C1)(C)C)C(=O)[O-] 
680 500165 OC1CC2CCC3C4CCC(C(CCC(O)=O)C)C4(CCC3C2(CC1)C)C 
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681 521440 OC1(CCC2C3C(C4(C(=CC(=O)CC4)CC3)C)C(=O)CC12C)C(=O)C
O 
682 523975 O=C1N2C(=Nc3c1cccc3)CCCC2 
683 542212 O1C(CO)C(O)C(OC(C(O)=O)C)C(NC(=O)C)C1O 
684 580552 O1C2C(C3N(CCC3=CC2O)C)c2c(cc3OCOc3c2)C1=O 
685 630532 O1C2CC(=O)N3C4C5(C6[N+]([O-
])(CC(C(C24)C6)=CC1)CC5)c1c3cccc1 
686 630921 OC1CCC2C(CC3N(C2)CCc2c3[nH]c3c2cccc3)C1C(O)=O 
687 643764 O(C)c1c(OC)cc(cc1OC)\C=C/C(=O)N1CCC=CC1=O 
688 657298 S=C1NC(=CC(=O)N1)CCC 
689 657345 S(Cc1oc(cc1)CN(C)C)CCN\C(\NC)=C/[N+](=O)[O-] 
690 667493 S=C1NC(=CC(=O)N1)C 
691 688585 n1ccccc1/C(=C\CN1CCCC1)/c1ccc(cc1)C 
692 719408 s1ccnc1NC(=S)Nc1ccccc1 
693 1349907 S=C1NC=CN1C 
694 1548885 S(=O)(C)c1ccc(cc1)\C=C/1\c2c(cc(F)cc2)C(CC(O)=O)=C\1C 
695 1548912 O1c2cc(ccc2OC1)\C=C/C=C\C(=O)N1CCCCC1 
696 1548942 O(C)c1cc(ccc1O)CNC(=O)CCCC\C=C/C(C)C 
697 1548955 Cl\C(=C(\c1ccc(OCCN(CC)CC)cc1)/c1ccccc1)\c1ccccc1 
698 2761171 S=C(N)c1cc(ncc1)CC 
699 3032771 S(\C(=C(/N(Cc1cnc(nc1N)C)C=O)\C)\CCOP(O)(O)=O)C(=O)c1cccc
c1 
700 3133561 OC1C23C(C45C6CC2C4N(CC6(CCC5O)C)CC)CC(O)C(C3)C1=C 
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701 3634067 O=CC=1C2CC3[N+](CC2=CC)(CCC23C=1Nc1c2cccc1)C 
702 3649142 O=C1NC(CC(C)C)C(=O)NC(CCN)C(=O)NC(CCN)C(=O)NC(C(O)
C)C(=O)NCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CCCCC(CC
)C)CCN)C(O)C)CCN)C(=O)NC(CCN)C(=O)NC1CC(C)C 
703 3672427 [nH]1c2C3N(C4C5C(NCCC5)C3CC4)CCc2c2c1cccc2 
704 3787925 OC1(CCC2C3C(C4C(CC3)=CCCC4)CCC12C)C#C 
705 3851247 O=C1NC(CCCN)C(=O)NC(CC(C)C)C(=O)NC(Cc2ccccc2)C(=O)N2
C(CCC2)C(=O)NC(C(C)C)C(=O)NC(CCCN)C(=O)NC(CC(C)C)C(=
O)NC(Cc2ccccc2)C(=O)N2C(CCC2)C(=O)NC1C(C)C 
706 3915039 O1C2C(OC3OC(CC(=O)C13O)C)C(O)C([NH2+]C)C(O)C2[NH2+]C 
707 3996620 O=C1c2ccc(nc2N(C=C1C(=O)[O-])CC)C 
708 4320774 O(CCCC)c1cc(ccc1N)C(OCC[NH+](CC)CC)=O 
709 4359763 O1C23C4(OC1)C1C(C56C(C(CCC5OC)(CN(C26)CC)COC)C3O)CC
(C1OC)C(OC)C4 
710 4479096 O(CC(O)C[NH2+]C(C)(C)C)c1c2c(ccc1)C(=O)CCC2 
711 4486617 O1C2C3N(C(CC(OC(=O)C(=C)c4ccccc4)C3)C12)C 
712 4580358 O1C(CC)C(O)(C2OC(NC(C2C)C(CC(O)(C)C(OC2OC(CC(N(C)C)C
2O)C)C(C)C(OC2OC(C)C(O)C(OC)(C2)C)C(C)C1=O)C)COCCOC)
C 
713 4636599 S1C2N(C(C(=O)[O-
])C1(C)C)C(=O)C2NC(=O)c1c2c(ccc1OCC)cccc2 
714 4677798 O1C(CC(O)CC1=O)CCC1C2C(=CC(CC2OC(=O)C(CC)(C)C)C)C=
CC1C 
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715 4739621 S(=O)([O-])(=Nc1nc(cc(n1)C)C)c1ccc(N)cc1 
716 5053503 P(O)(=O)([O-])C(P(O)(=O)[O-])(O)C 
717 5171637 O1C23C(CCC4C1(O)C(OC(=O)c1cc(OC)c(OC)cc1)CCC24C)C1(O)
C(C2C(C(O)C1O)C(O)(C1N(CC(CC1)C)C2)C)C3 
718 5191579 OC(C(CO)(C)C)C(=O)NCCC(=O)[O-] 
719 5231296 Clc1cc(cc(Cl)c1N)C(O)C[NH2+]C(C)(C)C 
720 5280442 O1c2c(C(=O)C=C1c1ccc(OC)cc1)c(O)cc(O)c2 
721 5280443 O1c2c(C(=O)C=C1c1ccc(O)cc1)c(O)cc(O)c2 
722 5280445 O1c2c(C(=O)C=C1c1cc(O)c(O)cc1)c(O)cc(O)c2 
723 5280953 O(C)c1cc2[nH]c3c(c2cc1)ccnc3C 
724 5281404 [nH]1c2c(c3c1cccc3)ccnc2C 
725 5281672 O1c2c(C(=O)C(O)=C1c1cc(O)c(O)c(O)c1)c(O)cc(O)c2 
726 5312135 S1(=O)(=O)N(C)\C(=C(/O)\Nc2ncccc2)\C(=O)c2c1cccc2 
727 5312154 s1c2c(S(=O)(=O)N(C)\C(=C(/O)\Nc3ncccc3)\C2=O)cc1 
728 5351819 OC12C(CC3C(C1=O)=C(O)c1c(cccc1O)C3(O)C)C(N(C)C)C(=O)/C(
=C(\O)/NCN1CCCC1)/C2=O 
729 5353527 OC1C\C(=C/C=C\2/C3CCC(C(CCCC(C)C)C)C3(CCC/2)C)\C(CC1)
=C 
730 5353656 O=C1C=C2NC=3C(=C2C=C1)CCNC=3C 
731 5353779 OC12C(CC3C(C1=O)=C(O)c1c(C3)c(N(C)C)ccc1O)C(N(C)C)C(=O)
/C(=C(\O)/N)/C2=O 
732 5353864 O1C2C(CC\C(=C/CCC3(OC23)C)\C)C(=C)C1=O 
733 5353990 OC12C(CC3C(C1=O)=C(O)c1c(cccc1O)C3(O)C)C(N(C)C)C(=O)/C(
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=C(\O)/N)/C2=O 
734 5360959 S1(=O)(=O)N(C)\C(=C(/O)\Nc2noc(c2)C)\C(=O)c2c1cccc2 
735 5367858 Clc1c2c(C(O)=C3C(CC4C(O)(C(=O)\C(=C(/O)\N)\C(=O)C4N(C)C)
C3=O)C2O)c(O)cc1 
736 5367871 Clc1c2c(C(O)=C3C(CC4C(O)(C(=O)\C(=C(/O)\N)\C(=O)C4N(C)C)
C3=O)C2(O)C)c(O)cc1 
737 5368888 O1CC=2C3N(CCC3OC(=O)/C(/CC(=C)C(O)(C)C1=O)=C/C)CC=2 
738 5378180 O1C(C(O)C(O)C(O)C1CO)c1c2OC(=CC(=O)c2c(O)cc1O)c1ccc(O)c
c1 
739 5458656 Brc1ccc(cc1)\C(=C/CN(C)C)\c1cccnc1 
740 5462906 O1CC=2C3N(CCC3OC(=O)/C(/CC(C)C(O)(CO)C1=O)=C/C)CC=2 
741 5473483 O1c2c(N=C3C1=CC(N(CC)CC)C=C3)c(cc(O)c2O)C(=O)N 
742 5474986 O1C(C)C(OC2OC(C)C(OC(=O)CC(C)C)C(O)(C2)C)C(N(C)C)C(O)
C1OC1C(OC)C(OC(=O)C)CC(OC(C\C=C\C=C/C(O)C(CC1CC=O)C
)C)=O 
743 5791942 Fc1ccc(cc1)-c1c2c(n(C(C)C)c1\C=C\C(O)CC(O)CC(=O)[O-])cccc2 
744 5820787 O(C(=O)C)C/1CC2(C(CC(O)C3C2(CCC2C(C)C(O)CCC23C)C)\C\1
=C(\CCC=C(C)C)/C(=O)[O-])C 
745 6420076 N12C(=Nc3c(C1)cccc3)CCCC2 
746 6914279 s1ccc(C)c1\C=C/C1=NCCCN1C 
747 6914280 s1cccc1\C=C/C1=NCCCN1C 
748 6914283 Oc1cc(ccc1)\C=C/C1=NCCCN1C 
749 6921821 Clc1ccc(cc1)C(=O)c1n(C)c(cc1C)CC(=O)[O-] 
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750 9604989 S(=O)(=O)([O-])c1cc(S(=O)(=O)[O-
])c2c(c1N)C(=O)/C(=N/Nc1ccc(cc1OC)-
c1cc(OC)c(N\N=C\3/C=Cc4c(c(N)c(S(=O)(=O)[O-
])cc4S(=O)(=O)[O-])C/3=O)cc1)/C=C2 
751 10099444 O1C(=O)C(=CC1C)CCCCCCCCCCCCC(O)C1OC(CC1)C(O)CCCC
CCCCCCCC 
752 14506494 FC12C(C3CC(C)C(OC(=O)C)(C(=O)CO)C3(CC1O)C)CCC1=CC(=
O)C=CC12C 
753 16219826 OC1CC(=O)C(C\C=C/CCCC(O)=O)C1\C=C\C(O)CCCCC 
754 24848418 O(C)c1cc2[NH2+]C3=C(CCN=C3C)c2cc1 
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Appendix IV: 
5-HT2B External Set Compounds 
Cp. 
ID 
PubChem_
CID 
SMILES 
755 896 O(C)c1cc2c([nH]cc2CCNC(=O)C)cc1 
756 3194 [Se]1N(C(=O)c2c1cccc2)c1ccccc1 
757 3410 O(C)c1ccc(cc1)CC(NCC(O)c1cc(NC=O)c(O)cc1)C 
758 4452 Clc1cc(C(=O)NC2CCN(Cc3ccccc3)C2C)c(OC)cc1NC 
759 5454 S1c2c(cc(S(=O)(=O)N(C)C)cc2)C(c2c1cccc2)=CCCN1CCN(CC1)C 
760 5574 S1c2c(N(c3c1cccc3)CC(CN(C)C)C)cccc2 
761 12454 Clc1cc2c(Sc3c(cccc3)C2=CCCN2CCN(CC2)CCO)cc1 
762 60854 Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2c1cccc2 
763 62875 Clc1cc2N(c3c(Sc2cc1)cccc3)CCCNC 
764 122295 Clc1c2c(CCN(CC2)C)c(OCC=C(C)C)cc1 
765 123836 O(C)c1cc2C3N(CC(CC(C)C)C(O)C3)CCc2cc1OC 
766 152151 S(Oc1cc2c([nH]cc2CCN)cc1)(O)(=O)=O 
767 5361110 Clc1cc(ccc1)C1=NCCN=C2N(NC(=C12)C)C 
768 9543513 O=C(N1CCC(CC1)CCCCNC(=O)CCc1cccnc1)c1ccccc1 
769 9952054 Ic1ccc(cc1)C1CC2N(C(CC2)C1C(OC)=O)C 
770 24901748 O(C)c1ccc(cc1)C(n1ccnc1)COCCCc1ccc(OC)cc1 
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Appendix V: 
Predictions on 5-HT2B Test Set Compounds for a Simple Model Generated Using the 
Number of Nitrogen Atoms, Number of Hydrophobic Groups, And LogP. 
Cp. ID Model Actual Class Predicted Class 
1 Simple Active Inactive 
5 Simple Active Active 
11 Simple Active Inactive 
15 Simple Active Inactive 
18 Simple Active Inactive 
21 Simple Active Inactive 
26 Simple Active Inactive 
27 Simple Active Inactive 
28 Simple Active Active 
33 Simple Active Inactive 
37 Simple Active Active 
44 Simple Active Active 
49 Simple Active Inactive 
59 Simple Active Inactive 
60 Simple Active Inactive 
64 Simple Active Active 
65 Simple Active Inactive 
72 Simple Active Inactive 
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73 Simple Active Active 
74 Simple Active Inactive 
82 Simple Active Active 
84 Simple Active Inactive 
85 Simple Active Inactive 
86 Simple Active Inactive 
106 Simple Active Inactive 
107 Simple Active Active 
124 Simple Active Inactive 
129 Simple Active Inactive 
134 Simple Active Active 
136 Simple Active Inactive 
151 Simple Inactive Inactive 
158 Simple Inactive Inactive 
163 Simple Inactive Inactive 
168 Simple Inactive Inactive 
170 Simple Inactive Inactive 
179 Simple Inactive Inactive 
188 Simple Inactive Active 
193 Simple Inactive Inactive 
195 Simple Inactive Inactive 
201 Simple Inactive Inactive 
203 Simple Inactive Inactive 
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208 Simple Inactive Active 
210 Simple Inactive Active 
218 Simple Inactive Inactive 
221 Simple Inactive Active 
223 Simple Inactive Inactive 
232 Simple Inactive Inactive 
233 Simple Inactive Inactive 
238 Simple Inactive Inactive 
250 Simple Inactive Inactive 
251 Simple Inactive Inactive 
254 Simple Inactive Inactive 
261 Simple Inactive Inactive 
266 Simple Inactive Inactive 
267 Simple Inactive Inactive 
268 Simple Inactive Inactive 
270 Simple Inactive Inactive 
274 Simple Inactive Inactive 
283 Simple Inactive Active 
287 Simple Inactive Active 
292 Simple Inactive Inactive 
293 Simple Inactive Inactive 
296 Simple Inactive Inactive 
300 Simple Inactive Inactive 
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304 Simple Inactive Active 
311 Simple Inactive No Prediction 
327 Simple Inactive Inactive 
345 Simple Inactive Inactive 
346 Simple Inactive Active 
354 Simple Inactive Inactive 
359 Simple Inactive Inactive 
364 Simple Inactive No Prediction 
369 Simple Inactive Inactive 
370 Simple Inactive Active 
374 Simple Inactive Inactive 
375 Simple Inactive Inactive 
380 Simple Inactive Inactive 
381 Simple Inactive Inactive 
385 Simple Inactive Inactive 
399 Simple Inactive Inactive 
408 Simple Inactive Inactive 
413 Simple Inactive Inactive 
414 Simple Inactive Active 
427 Simple Inactive Inactive 
431 Simple Inactive Inactive 
432 Simple Inactive Inactive 
440 Simple Inactive Inactive 
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441 Simple Inactive Inactive 
442 Simple Inactive Inactive 
443 Simple Inactive Inactive 
450 Simple Inactive No Prediction 
455 Simple Inactive Active 
457 Simple Inactive Active 
473 Simple Inactive Inactive 
478 Simple Inactive Inactive 
480 Simple Inactive Inactive 
488 Simple Inactive Inactive 
513 Simple Inactive Inactive 
520 Simple Inactive Inactive 
523 Simple Inactive Active 
526 Simple Inactive Inactive 
532 Simple Inactive Inactive 
538 Simple Inactive Inactive 
548 Simple Inactive Inactive 
555 Simple Inactive Inactive 
556 Simple Inactive Inactive 
562 Simple Inactive Inactive 
566 Simple Inactive Inactive 
568 Simple Inactive Inactive 
571 Simple Inactive Active 
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576 Simple Inactive Inactive 
577 Simple Inactive Inactive 
583 Simple Inactive Inactive 
584 Simple Inactive Inactive 
604 Simple Inactive Inactive 
605 Simple Inactive Inactive 
606 Simple Inactive Inactive 
610 Simple Inactive Inactive 
611 Simple Inactive Inactive 
618 Simple Inactive Inactive 
621 Simple Inactive Active 
626 Simple Inactive Inactive 
628 Simple Inactive Inactive 
629 Simple Inactive Inactive 
630 Simple Inactive Inactive 
638 Simple Inactive Inactive 
639 Simple Inactive Inactive 
654 Simple Inactive Inactive 
655 Simple Inactive Inactive 
657 Simple Inactive Inactive 
659 Simple Inactive Active 
672 Simple Inactive Inactive 
681 Simple Inactive Inactive 
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688 Simple Inactive Inactive 
698 Simple Inactive Inactive 
702 Simple Inactive Inactive 
703 Simple Inactive Active 
711 Simple Inactive Inactive 
717 Simple Inactive Active 
721 Simple Inactive Inactive 
723 Simple Inactive Inactive 
725 Simple Inactive Active 
733 Simple Inactive Inactive 
736 Simple Inactive Inactive 
737 Simple Inactive No Prediction 
741 Simple Inactive Active 
742 Simple Inactive Inactive 
751 Simple Inactive Inactive 
753 Simple Inactive Inactive 
754 Simple Inactive Inactive 
TP=9; FP= 20; TN=96; FN=21; CCRevs = 0.55 
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Appendix VI: 
The Purity Data for Ten Virtual Screening Compounds Tested In 5-HT2B Study 
Compd.* 
ID 
PDSP ID 
PubChem 
CID 
Purity 
% 
Method 
1 14809 43922 99% LC/MS Spectra 
2 14807 71928 96% LC/MS Spectra 
3 14806 114709 98% LC/MS Spectra 
4 14814 3038495 100% LC/MS Spectra 
5 14821 3336 96% LC/MS Spectra 
6 14815 1715104 100% LC/MS Spectra 
7 27769 4140 98% LC/MS Spectra 
8 14805 195658 99% LC/MS Spectra 
9 13513 9909648 70% LC/MS Spectra 
10 13505 15940170 98% LC/MS Spectra 
  *Compound IDs as reported in chapter 4. 
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Appendix VII: 
LC/MS Purity Spectra for Tested Virtual Screening Hits 
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LC/MS purity spectra for compound 1. 
 
 
 
279 
 
 
280 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
281 
 
LC/MS purity spectra for compound 2.
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LC/MS purity spectra for compound 3. 
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LC/MS purity spectra for compound 4. 
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LC/MS purity spectra for compound 5. 
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LC/MS purity spectra for compound 6.
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LC/MS purity spectra for compound 8.
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LC/MS purity spectra for compound 9.
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LC/MS purity spectra for compound 10.
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